

Effective: January 1, 2025\*

<b>Prior Authorization Required</b> If <u>REQUIRED</u> , submit supporting clinical documentation pertinent to service request to the FAX numbers below	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>
<b>Notification Required</b> IF <u>REQUIRED</u> , concurrent review may apply	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>
<p><b>Applies to:</b></p> <p><b>Commercial Products</b></p> <p><input checked="" type="checkbox"/> Harvard Pilgrim Health Care Commercial products; 800-232-0816  <input checked="" type="checkbox"/> Tufts Health Plan Commercial products; 617-972-9409                  CareLink<sup>SM</sup> – Refer to <a href="#">CareLink Procedures, Services and Items Requiring Prior Authorization</a></p> <p><b>Public Plans Products</b></p> <p><input checked="" type="checkbox"/> Tufts Health Direct – A Massachusetts Qualified Health Plan (QHP) (a commercial product); 888-415-9055  <input checked="" type="checkbox"/> Tufts Health Together – MassHealth MCO Plan and Accountable Care Partnership Plans; 888-415-9055  <input checked="" type="checkbox"/> Tufts Health RItogether – A Rhode Island Medicaid Plan; 857-304-6404  <input checked="" type="checkbox"/> Tufts Health One Care – A dual-eligible product; 857-304-6304</p> <p><b>Senior Products</b></p> <p><input type="checkbox"/> Harvard Pilgrim Health Care Stride Medicare Advantage; 866-874-0857  <input type="checkbox"/> Tufts Health Plan Senior Care Options (SCO), (a dual-eligible product); 617-673-0965  <input type="checkbox"/> Tufts Medicare Preferred HMO, (a Medicare Advantage product); 617-673-0965  <input type="checkbox"/> Tufts Medicare Preferred PPO, (a Medicare Advantage product); 617-673-0965</p>	

\*For the purposes of this document, this date refers to the date when the list was updated with the addition or deletion of items/services. Please see specific item to determine when that item was placed on noncovered status.

According to the The Plan Evidence of Coverage (EOC), a treatment or procedure is considered investigative or unproven if reliable evidence shows that the treatment is “under study to determine its safety, efficacy, toxicity, maximum tolerated dose, or its efficacy as compared with a standard means of treatment or diagnosis”. The Plan restricts coverage to those devices, treatments, or procedures for which the safety and efficacy have been proven, or where the clinical evidence is such that the treatment is at least as beneficial as any established evidence-based alternatives. Any device, medical treatment, supply or procedure for which safety and efficacy has not been established and proven is considered investigational (unproven) and therefore not medically necessary and is excluded from coverage.

To determine whether a device, medical treatment, supply or procedure is proven safe and effective the following hierarchy of reliable evidence is used:

1. Published formal technology assessments and/or high quality meta analyses
2. Well-designed randomized studies published in credible, peer-reviewed literature
3. High quality case-control or cohort studies
4. Historical control studies, or case reports and/or case series
5. Reports of expert opinion from national professional medical societies or national medical policy organizations

With respect to clinical studies, only those reports and articles containing scientifically valid data and published in the referred medical and scientific literature shall be considered reliable evidence. Specifically, not included in the meaning of reliable evidence are reports, articles, or statements by providers or groups of providers containing only abstracts, anecdotal evidence or personal professional opinions. Also not included is the fact that a provider or a number of providers have elected to adopt a device, medical treatment, or procedure as their personal treatment or procedure of choice or standard of practice.

**Policy and Coverage Criteria:**

The plan considers the following services and technology as experimental/investigational, and therefore not covered (this is not an all-inclusive list):

- Abiliti Gastric Stimulation
- ABRx Antibiotic Resistance Panel (Diatherix Laboratories)
- AccuBoost for breast cancer (Non-invasive image-guided breast brachytherapy)
- Acoustic heart sound recording, computer analysis only
- Acoustic heart sound recording, computer analysis with interpretation and report
- Acoustic heart sound recording, interpretation and report only
- Active Specific Immunotherapy with Therapeutic Melanoma Vaccines
- Agile Patency Capsule (except when used for 'patency capsule' trial before a planned video capsule when the request is suspected Crohn's disease)
- AlloSure (CareDX Inc.)
- Alpha-Stim for Treatment of Chronic Pain
- AlzoSure Predict- Alzheimer's Early Prediction Bloodtest
- Amniotic Allografts for Tendon and Ligament Injuries
- Amniotic fluid epidural injections in the management of patients with LBP
- Amniotic membrane tissue (e.g. tissue graft, injection) for treatment of orthopedic conditions (e.g. spinal, tendon/ligament injury/inflammation, osteoarthritis, cartilage restoration)
- Amplatzer Cardiac Plug (ACP) and Amplatzer Amulet devices in left atrial appendage closure to reduce risk of stroke in adult patients with NVAf
- AmpliChip™ Cytochrome P450 (CYP450) Test for pharmacogenetic assay of medication sensitivity
- Ancillary Hyaluronic-Hyaluronidase testing for bladder cancer screening and detection
- Angiotensin Receptor 1 (AGTR1) c.\*86A>C (1166A>C, A1166C) Polymorphism Testing for Essential Hypertension
- Anora Miscarriage Test for Miscarriage, (Natera)
- Anoscopy, with delivery of thermal energy to the muscle of the anal canal (eg, for fecal incontinence)
- Anser VDZ® Test (Prometheus Laboratories) for monitoring vedolizumab treatment of Crohn's disease
- Anterior Scoliosis Correction (ASC)
- Antiprothrombin (phospholipid cofactor) antibody, each Ig class
- Apollo Overstitch™ Endoscopic Suturing System for bariatric applications
- Apple Watch Irregular Rhythm Notification Feature (Apple Inc.) for Detection of Atrial Fibrillation
- AQUACEL Ag Advantage (ConvaTec) for Wound Care
- ARISK™ Autism Risk Assessment Test
- ArthroFLEX Decellularized Dermal Allograft
- Arthrographic Hydrodilatation for Adhesive Capsulitis
- Arthroscopic Microdiscectomy (AMD)
- Aspire Assist Aspire Bariatrics
- Asynchronous texting including but not limited to depression and anxiety.
- ATI Neurostimulation System (Autonomic Technologies Inc.) for Electrical Stimulation of the Sphenopalatine Ganglion (SPG) for Headache
- Autism and Intellectual Disability NGS Panel
- Autism NGS Panel (Fulgent Diagnostics)
- AutismNext
- Autologous micro-fragmented adipose tissue (MFAT) injection for treatment of degenerative joint disease
- Autologous Serum Eye Drops
- Autologous Stem Cell Transplantation (ASCT) for Crohn's Disease (CD)
- Autosomal Dominant Hereditary Spastic Paraplegia (AD-HSP)
- Autosomal Dominant Thrombocytopenia (Prevention Genetics)
- Axone Sequencing Genome Testing
- BBDRisk Dx (Silbiotech Inc.)
- Bilateral Frontoparietal Polymicrogyria (BFPP)
- BioCartilage for orthopedic indications
- BioDDryFlex® human amniotic allograft
- BioDFence® G3 human amniotic allograft
- Bioidentical Hormone Replacement Therapy for Menopause (BHRT)
- Bioimpedance Spectroscopy
- Bioness H200 Wireless Hand Rehabilitation System (Bioness) in Patients with Traumatic Brain Injury
- BioZorb 3D Bioabsorbable Marker (Focal Therapeutics)
- Bleeding Disorders NextGen Sequencing (NGS) Panel (Prevention Genetics)
- Blood-Based Genetic Testing for Colorectal Cancer Screening
- BluePrint Molecular Subtyping Profile for Breast Cancer
- Bone Marrow Failure Region of Interest (Claritis Genomics)

- Bone substitute injection for subchondral bone cysts
- BostonSight Prosthetic - C466Replacement of the Ocular Surface Ecosystem (PROSE) Treatment for Dry Eye Disease
- Bovine Collagen Implants for the Treatment of Rotator Cuff Injuries (REGENETEN bioinductive implant)
- BRCAVantage Plus (BRCA1, BRCA2, TP53, STK11, PTEN, CDH1, PALB2)
- Breast Cancer Focus Panel (Fulgent Genetics)
- Breast Ovarian Cancer NGS Panel (Fulgent Diagnostics)
- Breast/GYN Cancer Panel (GeneDx)
- BreastTrue High Risk Panel for Hereditary Breast Cancer, (Pathway Genomics Corp.)
- BROCA Cancer Risk Prenatal Test
- Burst -frequency spinal cord stimulation
- CancerIntercept Detect
- CancerIntercept Monitor
- CancerNext Next-Gen Cancer Panel (Ambry Genetics Corp.)
- CancerPlex (KEW Inc.)
- Capillary Malformation-Arteriovenous Malformation Syndrome (CMAVM)
- Carbon monoxide, expired gas analysis (e.g., ETCOc/hemolysis breath test)
- CardioMag MCG System (MagnetoCardioGraphy; CardioMag Imaging Inc.)
- Cartilage transfer surgery (OATS and mosaicplasty) for joints other than knee and ankle
- Cartiva synthetic cartilage implant
- CASR DNA Sequencing Test (Athena Diagnostics)
- Catheter based thrombectomy procedure- The JETi system
- Catheter lavage of mammary duct(s) for collection of cytology specimen(s), in high risk individuals (GAIL risk scoring or prior personal history of breast cancer), each breast; single duct
- Catheter lavage of mammary duct(s) for collection of cytology specimen(s), in high risk individuals (GAIL risk scoring or prior personal history of breast cancer), each breast; each additional duct
- C-Brace Orthotronic Mobility System (Ottobock)
- Charcot-Marie-Tooth Neuropathy, Type 1 (CMT1, CMT2, ) CMTX
- CHEK2-related cancer test:The CHEK2-related cancer test may diagnose a personal and/or family history suggestive of hereditary breast and/or colon cancer
- Chemokine CC Motif Receptor 5 (CCR5) CCR5-Δ32 Polymorphism
- Chiropractic Biophysics (CBP) for Segmented Somatic Dysfunction of Spinal Regions
- Chromosomal Microarray Analysis Mitochondrial/Metabolic (MitoMet®) Testing
- "CJ" User Volume Adjustable Socket
- CMI Magnetocardiograph Model 2409 (CardioMag Imaging Inc.) for Diagnosis of Acute Chest Pain
- Coagulation Factor Deficiency NextGen Sequencing (NGS) Panel (Prevention Genetics)
- Coated VICRYL\* Plus Antibacterial (polyglactin 910) Suture
- COLMOL (OSU Wexner Medical Center Clinical Laboratories)
- ColoSense
- ColoNext™ for Hereditary Colorectal Cancer
- ColonSentry (Innovative Diagnostic Laboratory)
- Color Hereditary Cancer Test (30 genes)
- Color Test (Color Genomics )
- Combination Heat/Ice Devices for Use After Knee Surgery
- Combined Cardiac Panel (GeneDx)
- COMPASS; COMPASS is an assessment of bone marrow and/or blood workups that uses several technologies to provide results to a team of experts
- Complement Factor H (CFH) p.Tyr402His and Age-Related Maculopathy Susceptibility 2 (ARMS2) p.Ala69Ser Polymorphism Testing for Susceptibility to Age-Related Macular Degeneration (AMD)
- Comprehensive Brain Malformations Panel (GeneDX)
- Comprehensive Epilepsy Evaluation NGS Panel
- Comprehensive Non-Specific Intellectual Disability Panel
- Comprehensive Personalized Medicine Panel, (Alpha-Genomix Laboratories)
- Computer-Assisted Semen Analysis (CASA) for Infertility
- Computerized Neurocognitive Testing (CNT), e.g. ImPACT™, for Sports-Related Head Injury
- Conductive Keratoplasty for Treatment of Keratoconus
- Congenital Disorders of Glycosylation (CDG) Panel by Massively Parallel Sequencing (BCM-MitomeNGS) (Baylor Miraca Genetics Laboratories)
- Constant Therapy
- Coolief Cooled Radiofrequency (RF) System (Halyard Health) for Knee and Hip Pain
- Corneal incisions in the donor cornea created using a laser, in preparation for penetrating or lamellar keratoplasty (List separately in addition to code for primary procedure)

- Coronary Artery Calcium Scoring to Assess the Risk of Coronary Artery Disease in Asymptomatic Adults
- Cranial electrical stimulation (CES) for the treatment of migraine/headaches
- Cranial electrical stimulation (CES) for treatment of chronic pain (e.g. fibromyalgia, chronic pain from SCI)
- Craniosacral Therapy
- Craniosynostosis NGS Panel and/or HDT array (Connective Tissue Gene Tests)
- Cunningham Panel (Moleculera Labs)
- CureSight for Amblyopia in Children
- Cxbladder, (Pacific Edge Ltd), (e.g., Cxbladder Triage, Cxbladder Detect, and Cxbladder Monitor)
- CYP2C19 Genotyping to Predict Response to Voriconazole
- CYP2C19 Pharmacogenomic Genotyping to Direct Clopidogrel Therapy for Secondary Prevention in Patients with a History of Stroke and/or Transient Ischemic Attack (TIA)
- CYP2C19 Pharmacogenomic Genotyping to Direct Clopidogrel Therapy in Adult Patients Undergoing Percutaneous Coronary Intervention (PCI)
- CYP2D6 Genotyping to Guide Dosing with Eliglustat Tartrate (Cerdelga) in Gaucher Disease Type 1
- CYP3A4 Genotyping for Ivacaftor Metabolism and Toxicity
- Cytochrome P450 (CYP450) Genotyping to Predict Response to Antidepressant and Antipsychotic Medications
- DCISionRT (PreludeDx)
- Decipher Prostate Biopsy (Decipher Biosciences)
- Decipher Prostate Cancer Classifier
- Decipher® Prostate Cancer Test (GenomeDx Biosciences)
- Decision Dx Melanoma
- DecisionDx-GBM (Castle Biosciences Inc.)
- deCODE ProstateCancer™ (deCODE diagnostics)
- DecodEX Microbial Genetic Identification; NGS) test for the identification and relative abundance of microbial pathogens in a patient sample
- DeNovo NT Natural Tissue Graft (Zimmer Inc.) for Articular Cartilage Repair
- dermaPACE system (Sanuwave Inc) extracorporeal shock-wave system for treatment of chronic full thickness diabetic foot ulcers
- Destruction of localized lesion of choroids (e.g., choroidal neovascularization), transpupillary thermotherapy
- Destruction of macular drusen, photocoagulation
- Destruction/reduction of malignant breast tumor including breast carcinoma cells in the margins, microwave phased array thermotherapy, disposable catheter with combined temperature monitoring probe and microwave sensor, externally applied microwave energy, including interstitial placement of sensor
- devACT Clinical Management Panel
- devSEEK Sequence Analysis for Neurodevelopmental Disorders
- DGAT1 Single Gene (Fulgent Diagnostics)
- Diabetes Sentry Nocturnal Hypoglycemia Alarm
- Digital Fluoroscopic Grid System (HipGrid) for Total Hip Arthroplasty
- Discseel
- DNA Polymerase Gamma (POLG) - Related Disorders
- Dry Needling
- Dual energy x-ray absorptiometry (DEXA), body composition study, one or more sites
- Ear Popper™
- EDX110 nitrous oxide emitting dressing
- Ehlers-Danlos Syndrome (EDS) Classic Type
- ELANE (ELA2) Gene Testing for ELANE –related Neutropenia
- Electric cell signaling treatment (EST) ( Sanexas neoGEN-Series System)
- Electrical impedance scan of the breast, bilateral (risk assessment device for breast cancer)
- Electromagnetic Hearing Aids
- Electronic analysis of implanted peripheral subcutaneous field stimulation pulse generator, with reprogramming when performed
- Embrace 2: Physiological Signal Based Seizure Monitoring System
- Embryonic Stem Cell Transplants
- EndeavorRx
- EndoBarrier Endoluminal Liner
- Endolumenal Functional Lumen Imaging Probe (EndoFLIP; Medtronic Inc.)
- Endometrial Cancer Panel (GeneDx)
- Endoscopic Laser Assisted discectomy for cervical disc herniation
- Endoscopic Sleeve Gastroplasty
- Envisia Genomic Classifier (Veracyte)
- EpiMonitor (Empatica) System for Detection of Seizures
- Epilepsy and Seizure Disorders Panel (Emory Genetics Laboratory)

- Epilepsy NGS Panel (Fulgent Diagnostics )

- epiSEEK Comprehensive Sequence Analysis for Epilepsy and Seizure Disorders (Courtagen Life Sciences Inc.)
- ERCC1 Expression Analysis (Genzyme Genetics)
- Erector spinae block for treatment of chronic pain
- EsophyX® (transoral incisionless fundoplication)
- Esteem Totally Implantable Hearing System for Treatment of Moderate to Severe Sensorineural Hearing Loss in Adults
- Estradiol Implantation of Estradiol Pellets for Post-menopausal Disorders
- E-tegrity® Test (Hologic Inc.; distributed by Sepal Reproductive Devices) for Evaluation of Uterine Receptivity
- eXciteOSA
- Expanded Non-Invasive Prenatal Testing (NIPT) Panels
- Extracorporeal Magnetic Stimulation for Urinary Incontinence
- Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, low energy
- Extracranial vein Angioplasty for Treatment of Multiple Sclerosis
- External Beam Radiation Therapy for Treatment of Dupuytren's Contracture
- EyeBOX to aid in diagnosis of concussion
- Factor V (F5) HR2 Haplotype Testing for thrombophilia
- Factor V Leiden (FVL) Testing for Oral Contraceptive Use
- Factor VII (F7) p.Arg353Gln Polymorphism Testing (Quest Diagnostics Inc.)
- Factor XI Deficiency
- Factor XIII A1 (F13A1) p.Val34Leu Polymorphism Testing
- FHNNext
- FiberNet® autologous fibrin and platelet system
- Fibrinogen-Beta (FGB) c.-455G>A Polymorphism Testing (Rosalind Franklin University – Clinical Immunology Laboratory)
- Fluid status monitoring (i.e., OptiVol™, Medtronic)
- FM/a Test (EpicGenetics, Inc.) For Diagnosis of Fibromyalgia
- Focal and Segmental Glomerulosclerosis (FSGS) Evaluation (Athena Diagnostics®)
- Forkhead Box Protein G1 (FOXP1) for Congenital Variant Form of Rett
- FoundationOne Heme
- FoundationOne Liquid (Foundation Medicine)
- Freedom Spinal Cord Stimulator (SCS) System
- Full Sense Bariatric Device from BFKW LLC
- GammaTile™ Therapy for the Treatment of Recurrent Intracranial Tumors
- Ganglion Impar Block or Radiofrequency Thermocoagulation for the Treatment of Chronic Coccydynia
- Gastric Plication Surgery
- Gastric Vest System (ReShape)
- Generalized Epilepsy with Febrile Seizures Plus (GEFS+)
- GeneSight® Psychotropic Gene Panel
- GeneStrat (Biodesix) for all indications
- Genetic Testing for Alpha-Mannosidosis (MAN2B1 gene)
- Genetic testing for autism spectrum disorder (ASD) (e.g. for primary diagnosis of ASD, to aid in the evaluation of syndromic or complex ASD, to aid in the evaluation of idiopathic ASD)
- Genetic testing for Factor V Leiden in Women with Unexplained Recurrent Pregnancy loss
- Genetic Testing for Familial Hemiplegic Migraine (FHM)
- Genetic Testing for Family Members of Individuals with Brugada Syndrome
- Genetic Testing for FGFR-Related Craniosynostosis
- Genetic Testing for Fragile X-Associated Primary Ovarian Insufficiency
- Genetic Testing for Individuals Clinically Diagnosed with Brugada Syndrome
- Genetic testing for Inflammatory Bowel Disease
- Genetic Testing for Ki67 (MK167) Proliferation Marker Testing in DCIS and Breast Cancer
- Genetic Testing for Narcolepsy
- Genetic Testing for: Alzheimer's Disease (Athena Labs)
- Genetic Testing for: Friedreich Ataxia (FRDA) for Movement Disorders
- Genetic Testing for: Melanoma, CDKN2A (various manufacturers including Myriad)
- Genetic Testing in Patients with or Suspected of Congenital and/or Prelingual Nonsyndromic Hearing Loss (e.g., OtoSCOPE®)
- Genicular Nerve Blocks for Knee Pain
- Genomic Microarray Testing for Hematological Oncology Indications
- genTrue (True Health Diagnostics)
- GI Microbial Assay Plus (GI-MAP, Diagnostic Solutions Laboratory) for Evaluation of Gastrointestinal Microbiome

- Global Metabolomic
- Assisted Pathway Screen (Baylor Miraca Genetics Laboratories)
- Glucose Transporter Type 1 (Glut-1) Deficiency Syndrome
- Glutaric Acidemia Type I via the GCDH Gene (PreventionGenetics)
- gMS® DX (Glycominds Ltd.) to Aid in the Diagnosis of Multiple Sclerosis
- GPS Cancer (NantHealth)
- Guardant Reveal
- Guardant Shield
- H/I™ (HOXB13:IL17BR) Gene Expression Ratio (AviaraDx Inc.)
- Healthy Weight DNA Insight (Pathway Genomics)
- HeartFlow® FFRCT for Noninvasive Identification of Hemodynamically Significant Coronary Artery Stenosis
- Hematopoietic Stem Cell for autoimmune disorders
- Hematopoietic Stem Cell for ovarian cancer
- Hematopoietic Stem Cell for renal cell carcinoma
- Hereditary Hemochromatosis Panel (Invitae Corp.)
- Hereditary Thrombophilia Panel (Invitae Corp.)
- High power laser therapy for musculoskeletal disorders
- High/Moderate Risk Panel, (GeneDX Inc.)
- HipGrid with PhantomMSK for use in total hip arthroplasty
- HIRREM (High-resolution, relational, resonance-based, electroencephalic mirroring) for Post-Concussion Syndrome
- HistoSonics Image guided sonic beam therapy system
- Holmium Laser Endopyelotomy for Ureteropelvic Junction Obstruction in Adults
- Home Electrical Stimulation Devices, such as:
  - NESS H200; NESS L300; NESS L300 Plus
  - Bionicare Knee System
  - WalkAide
  - Odstock Dropped Foot Stimulator (ODFS) Pace
- HPA-1a (PLA1 Platelet Antigen) Genotyping (PLA2 Polymorphism Detection)
- Human Platelet Antigen 1 Genotype (Quest Diagnostics)
- Hydrodissection in the treatment of neuropathic pain
- Hyper-IgE Syndromes Panel
- IBD sgi Diagnostic Test, (Prometheus Inc.)
- iGene Cancer Panel, (ApolloGen Molecular Diagnostics Laboratory)
- Igenomix Endometrial Receptivity Analysis (ERA)
- Image-Guided Intranasal Sphenopalatine Ganglion (SPG) Block for Treatment of Migraine Headaches
- ImPACT™ Concussion Management Test
- Implantable Insulin Pump
- In vitro chemosensitivity testing for prediction of response to chemotherapy (i.e., ChemoFx® Assay by Precision Therapeutics)
- Inert gas rebreathing for cardiac output measurement during exercise
- Inert gas rebreathing for cardiac output measurement; during rest
- Infantile Epilepsy Panel
- Injectable Amniotic Tissue–Derived Allografts for Treatment of Chronic Plantar Fasciitis
- Insulialia® Diabetes Management Companion (voluntis) for management of diabetes mellitus
- Intellectual Disability NGS Panel (Fulgent)
- Intellijoint Hip System (IntellijointSurgical)
- Intense Pulsed Light Therapy for the Treatment of Dry Eye Disease
- Interleukin 28B (IL28B) Testing for Predict Response to Treatment of Hepatitis C with Interferons and Ribavirin
- INTRACEPT® Intraosseous Nerve Ablation System
- IntraGastric Balloons for Treatment of Obesity (e.g. ReShape Integrated Dual Balloon System, Orbera IntraGastric Balloon System)
- Intravascular optical coherence tomography (coronary native vessel or graft) during diagnostic evaluation and/or therapeutic intervention, including imaging supervision, interpretation, and report; initial vessel (List separately in addition to primary procedure)
- Intravascular optical coherence tomography (coronary native vessel or graft) during diagnostic evaluation and/or therapeutic intervention, including imaging supervision, interpretation, and report; each additional vessel (List separately in addition to primary procedure)
- Intravascular Ultrasound (IVUS) for guidance of percutaneous coronary interventions
- Intravenous Vitamin C for the Treatment of Cancer
- InVisionFirst-Lung (Invitae)
- Invitae Aortopathy Comprehensive Panel (Invitae Corp.)
- Invitae Breast Cancer High-Risk Panel
- Invitae Comprehensive Neuromuscular Disorders Panel

- Iontophoretic Drug Delivery for the Treatment of Axillary Hyperhidrosis
- Iontophoretic Drug Delivery for the Treatment of Primary Palmoplantar Hyperhidrosis
- iovera<sup>®</sup> system for the treatment of knee pain- Ablation, percutaneous, cryoablation, includes imaging guidance
- JACO Assistive Robotic Arm device for patients with neuromuscular diseases
- JaundiceChip Resequencing Array (Cincinnati Children's Hospital Molecular Genetics Laboratory)
- Juvederm for Vocal Cord Paralysis
- Kabuki Syndrome
- Know Error System (Diagnostic ID, LLC)
- LactoTYPE, (Prometheus)
- Laparoscopy, surgical, implantation or replacement of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity)
- Laparoscopy, surgical, revision or removal of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity)
- Laparotomy, implantation or replacement of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity)
- Laparotomy, revision or removal of gastric stimulation electrodes, lesser curvature (i.e., morbid obesity)
- Lariat Suture Delivery Device in left atrial appendage closure to reduce the risk of stroke in adult patients with NVAf
- Laser Interstitial Thermal Therapy (LITT), (e.g. NeuroBlate System)
- LDEX<sup>®</sup> U400 BIS Extracellular Fluid Analysis
- Left ventricular filling pressure, indirect measurement by computerized calibration of the arterial waveform response to Valsalva measurement
- LipiScan Dynamic Meibomian Imager for the evaluation of meibomian gland dysfunction
- Lipoprotein Subclass Quantification Using NMR LipoProfile<sup>®</sup> Test (LipoScience Inc.) for Atherosclerosis /Coronary Heart Disease (CHD)
- Lipoprotein, direct measurement, intermediate density lipoproteins (IDL) (remnant lipoproteins)
- Lokomat driven gait orthosis (DGO)
- Luminopia ONE for Treatment of -Amblyopia in Children
- LUKE Arm (Mobius Bionics LLC)
- LysoSEEK Sequence Analysis for Lysosomal Storage Disorders
- Macula Risk PGx (ArcticDx Inc.)
- Macular Translocation Surgery
- Magnetically controlled growing rods (MGRs) for the treatment of early-onset scoliosis (EOS) in children
- Mammostrat<sup>®</sup> (Clariant Inc.)
- Medicinal honey wound care dressings (i.e., Medihoney<sup>™</sup>)
- Medtronic METRx<sup>™</sup> Microdiscectomy System for lumbar disc herniation
- MelanoSITE<sup>™</sup> FISH Test
- Meniett Low-Pressure Pulse Generator for Treatment of Meniere's Disease
- Mesenchymal Stem cell therapy for treatment of orthopedic indications
- MI Profile test
- MI TumorSeek (Caris Life Sciences)
- Microcephaly NGS Panel
- Microcephaly Panel (Gene DX)
- Microcephaly Sequencing Panel
- Microcurrent electrical therapy (MET) for the treatment of musculoskeletal pain and the treatment of postoperative pain
- Microsurgery (e.g., transplanting lymph node(s) for preventing lymphedema, during surgery, for breast cancer)
- Microwave thermal ablation of tumors
- Migraine Headaches - Surgical Treatment
- Mild<sup>®</sup> Minimally Invasive Lumbar Decompression for Lumbar Spinal Stenosis
- Mindstreams<sup>®</sup> Cognitive Health Assessment (e.g., NeuroTrax<sup>®</sup>)
- Minimal Residual Disease (MRD) Tests
- Minimally Invasive Deformity Correction (MID-C) system for the treatment of adolescent idiopathic scoliosis
- Minimally invasive sacroiliac joint (SIJ) fusion with cylindrical threaded implants
- miraDry<sup>®</sup> (Miramar Labs<sup>®</sup>, Inc.) for the treatment of hyperhidrosis
- MIRE Therapy (Monochromatic Infrared Energy) for Peripheral Neuropathy
- Misha Knee System
- MitoSwab test
- MNG Transcriptome<sup>™</sup>
- Molecular Intelligence (Caris Life Sciences)
- Monarch external Trigeminal Nerve Stimulation (eTNS) System (NeuroSigma Inc.) for the treatment of attention-deficit/hyperactivity disorder (ADHD)
- Monogram Biosciences PhenoSense GT Plus Integrase
- MRI-Guided Laser Ablation using Visualase (Visualase Inc.) for Treatment of Seizures
- mtSEEK Whole Mitochondrial Genome Analysis (Courtagen Life Sciences Inc.)
- Multi cancer early detection test- Galleri
- Myeloma Prognostic Risk Signature (MyPRS Plus) Test for Myeloma (Signal Genetics LLC)



- Myoelectric orthosis — a custom orthosis that uses myoelectric signals to control brace function, providing assistive motion for joint function
- MyoPro upper extremity orthosis for all indications including muscle weakness, neurological disorders or neuro-muscular damage from conditions including, spinal cord injury, traumatic brain injury, amyotrophic lateral sclerosis, multiple sclerosis and other upper limb neuromuscular disorders
- myPath Melanoma (Myriad)
- MyRisk™
- Natera Miscarriage Test (Natera)
- Near-infrared guidance for vascular access requiring real-time digital visualization of subcutaneous vasculature for evaluation of potential access sites and vessel patency
- Nebulized antibiotic therapy (Except for the treatment of cystic fibrosis)
- Nerivio/remote electrical neuromodulation (REN)
- Neuroblastoma RAS Viral Oncogene (NRAS) for prediction of Treatment Response in Colorectal Cancer
- Neurodevelopment – Expanded (Ambry Genetics)
- NexCourse CRC (Genoptix Medical Laboratory)
- Next-Generation Sequencing (NGS) for Identification of Microbial Pathogens in Infections
- Next-Generation Sequencing (NGS) for Microbial Pathogens in Infection Outbreak Surveillance or Response
- NGS Epilepsy/Seizure Panel (Greenwood Genetic Center)
- NLRP3 Exon 3 Sequencing (GeneDx)
- NOD2/CARD15 gene testing for Crohn's Disease
- Noninvasive Cardiac Radioablation for Ventricular Tachycardia
- Noninvasive methods to assess skin cholesterol (e.g., PREVU™ Point of Care Skin Test)
- Nonsyndromic Peripheral Pulmonary Stenosis, PPS (Laboratory for Molecular Medicine)
- Norditropin for Female Infertility
- NuclearMitoDX(formerly MitoNucleomeDx) (MEDomics)
- nuSEEK Comprehensive Sequence Analysis of Nuclear Mitochondrial Exome (Courtagen Life Sciences Inc.)
- Occipital nerve stimulation (ONS) for treatment of cluster headache
- Oculofaciocardiodental (OFC) Syndrome (Syndromic Microphthalmia 2; MCOPS2)
- Oculopharyngeal Muscular Dystrophy (OPMD) (Athena Diagnostics Inc.)
- Office based minimally invasive joint arthroscopy (e.g. mi-eye 2, VisionScope®)
- OmniSeq Comprehensive (OmniSeq), OmniSeq Advanced (OmniSeq)
- Oncofocus (Oncologica)
- OncoGeneDx
- Oncopanel (DFCI)
- Oncotype DX AR-V7 Nucleus Detect Test
- Oncotype MAP™ Pan-Cancer Tissue (formerly Paradigm Cancer Diagnostic (PCDx))
- OncoVue® (InterGenetics Inc.) for Breast Cancer Risk Assessment
- One Touch Via disposable insulin delivery system
- Optic Atrophy Evaluation (OPA1) (Athena Diagnostics)
- AposTherapy System for the treatment of pain and loss of function associated with osteoarthritis of the knee, Apos Therapy System
- Osseointegrated Prostheses
- OvaNext Next-Gen Cancer Panel
- Ovarian Cancer Focus Panel (Fulgent Diagnostics)
- OvaSure™ (LabCorp)
- PancNext Next-Gen Cancer Panel (Ambry Genetics Corp.)
- PancreGEN (Interpace Diagnostics)
- Pancreatic Cancer Panel (GeneDX, Inc.)
- Panexia (Myriad Genetics Inc.)
- PAP-NAP
- Partial HPRT Deficiency (Kelley-Seegmiller Syndrome)
- Pathfinder TG®; Topographic Genotyping (RedPath)
- PAULA's Test (Protein Assays Utilizing Lung Cancer Analytes; Genesys Biolabs) for Early Detection of Lung Cancer
- Pediatric Neurology Region of Interest Trio (Claritas Genomics Inc.)
- Percepta Genomic Sequencing Classifier (GSC)
- Percutaneous Cervical Disc Decompression for Cervical Herniation
- Percutaneous mechanical thrombectomy for acute limb ischemia with AngioJet® Rheolytic Thrombectomy system (Possis Medical, Inc)
- Percutaneous or open implantation of neurostimulator electrode array(s), subcutaneous (peripheral subcutaneous field stimulation), including imaging guidance, when performed, cervical, thoracic or lumbar - for trial, including removal at the conclusion of trial period, or for permanent implantation, with implantation of a pulse generator.

- Revision or removal of related pulse generator and/or electrodes, including imaging guidance, when performed, including addition of new electrodes, when performed
- Percutaneous Transcatheter Coil Embolization for Pelvic Congestion Syndrome (PCS)
- PGxOne™ Plus (Admera Health)
- Pharmacogenetic testing for single-gene variants in the CYP2D6, CYP3A4, CYP3A5, ABCB1, and UGT2B7 genes for general opioid prescribing
- Pharmacogenetic testing/ psychopharmacology: (e.g., Genecept Assay, GeneSight®)
- Pharmacogenetic testing for Warfarin responsiveness
- Phenylalanine Hydroxylase (PAH) Deficiency (Including Phenylketonuria [PKU])
- Plasma proteins predict conversion to dementia from prodromal disease
- Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G (Quest Diagnostics)
- Platelet Rich Plasma (PRP) for bone healing and fusion
- Pontocerebellar Hypoplasia Panel (GeneDx)
- Positional adaptive spinal cord stimulation
- Powered Exoskeletal Mobility Device, (e.g. Rewalk)
- Prenatal Genetic Testing for Autism Spectrum Disorder
- Pre-Ovar KRAS-Variant Test
- PreTRM (Sera Prognostics)
- Preventest (GeneID Advanced Molecular Diagnostics LLC)
- Previstage™ GCC Colorectal Cancer Staging Test
- Previvo uterine embryo lavage catheter
- PRI-MUS™ (Prostate Risk Identification for Micro-Ultrasound) for diagnosis of prostate cancer
- Processed nerve allografts (Avance Nerve Graft) for repair of peripheral nerve discontinuities
- Proove Opioid Risk test
- Prospera (Natera)
- Prostate Core Mitomic Test (Mitomics Inc.)
- ProstateNext
- Prostatic Artery Embolization for BPH
- Proteus® Ingestible Event Marker (IEM)
- Provent Sleep Apnea Therapy
- Proveri Prostate Cancer Assay (PPCA) (Proveri Inc.)
- PTEN Gene Expression Testing in Non-Small Cell Lung Cancer (NSCLC)
- Pulsed radiofrequency treatment of chronic shoulder pain
- Pulsed radiofrequency treatment of complex regional pain syndrome of the lumbar region
- Radiofrequency Ablation of the Sural Nerve for Ankle Pain specialty
- Radiofrequency Ablation of Cluneal Nerves for Treatment of Chronic Lower Back Pain
- Radiofrequency Nerve Ablation for Treatment of Plantar Fasciitis
- Radiofrequency Neurotomy for Headaches
- Rapid Heme Panel (Dana Farber Cancer Institute/Brigham and Women's Hospital)
- Relieva Balloon Sinuplasty (Acclarent Inc.) for Chronic Sinusitis in children
- RenalNext Next-Generation Sequencing (NGS) Panel (Ambry Genetics Corp.)
- ResponseDX: Colon® for Colorectal Cancer Treatment
- ReStore Soft Exo-Suit™
- Retinal Dystrophy Panel (Blueprint Genetics)
- Rhinophototherapy, intranasal application of ultraviolet and visible light, bilateral
- RightMed Comprehensive Test
- Riscover Hereditary Cancer Test
- Robotic Rehabilitation of Upper Extremities in Patients with Degenerative Neurological Conditions
- RosettaGX Reveal (Rosetta Genomics Ltd.)
- Saethre-Chotzen Syndrome (TWIST) Sequencing and MLPA (Greenwood Genetic Center)
- Sclerotherapy for re-anastomosis after bariatric surgery
- ScolioScore Adolescent Idiopathic Scoliosis (AIS) Prognostic Test (Transgenomic Inc.)
- SelectMDx for Prostate Cancer (MDxHealth Inc.)
- Sensigene
- SensiGene Fetal RHD Genotyping for Rh Incompatibility (Sequenom Center for Molecular Medicine)
- SensiGene Fetal Sex Determination Testing (Sequenom Center for Molecular Medicine)
- Serological Assay for the Diagnosis and management of inflammatory bowel disease
- Serum autoantibody tests for diagnosis of autoimmune epilepsy (Athena Diagnostics)
- Signatera ctDNA test
- Single anastomosis duodenal switch

- Single Nucleotide Polymorphism (SNP) Testing for Breast Cancer Risk Assessment
- Single-pulse transcranial magnetic stimulation [sTMS] device for treatment of acute migraines
- Skeletal dysplasia ciliopathy NGS panel (Connective Tissue Gene Tests)
- SLCO1B1 Pharmacogenomic Genotyping for Statin Dosing or Selection
- SNaPshot Genetic Testing Panel
- SoundBite Hearing System (Sonitus Medical, Inc.)
- Spectroscopy, expired gas analysis
- Speculoscopy
- Speculoscopy, with directed sampling
- SPiN Thoracic Navigation System®
- STA2R SureGene Test for Antipsychotic and Antidepressant Response
- Stabilink MIS Interlaminar Spinal Fixation System for Spinal Fusion
- Stereotactic placement of infusion catheter(s) in the brain for delivery of therapeutic agent(s), including computerized stereotactic planning and burr hole(s)
- Stereotaxis Niobe Magnetic Navigation System (Stereotaxis Inc.) for Percutaneous Coronary Intervention in Coronary Artery Disease
- Stickler Syndrome
- Stretta Procedure (Mederi Therapeutics) for Gastroesophageal Reflux Disease (GERD)>(Stretta Radiofrequency Endoscopic Anti-reflux Procedure) (e.g., Stretta, Esophyx)
- Subchondral calcium phosphate (SCP) injections, knee
- Subcutaneous insertion of estradiol pellets for post-menopausal disorders
- Sublingual immunotherapy for the treatment of allergies and asthma  
(Except the following: Oralair, Grastek, Ragwitek and Odactra)
- SYMGENE68 NGS Cancer Panel, (CellNetix Pathology & Laboratories LLC)
- Syn-One
- Syndromic Autism Panel (NGS)
- TargetNow® Molecular Profiling Test (Caris™ Life Sciences)
- Telcare Glucose Monitor
- Tempus HRD
- Tenex Health Tx Procedure for tendon pain. Include Percutaneous ultrasonic tenotomy
- TenJet for treatment of plantar fasciitis
- The Genecept Assay
- The Morning Repositioner (SomnoMed) to Restore Proper Mandibular Alignment After Use of Overnight Sleep Apnea Appliance
- The ProMark Proteomic Prognostic Test
- The TransPyloric Shuttle (BAROnova Inc.)
- The Use of Information Communication Technology (ICT) to Improve Treatment Adherence in Patients with Diabetes
- TheraSEEK Sequence Analysis for Functional Disorders (Courtagen Life Sciences Inc.)
- Thermal Shrinkage
- Theta Burst Stimulation for Treatment-Resistant Unipolar Depression in Adults
- Thyroid Hormone Receptor Beta (THRB) Gene Testing
- Tinnitus Treatment/Rehabilitation (e.g., Neuromonics® and other programs)
- Tissue of Origin Test (ResponseDX; Response Genetics Inc.)
- Topaz® MicroDebrider (ArthroCare Corp.) for Treatment of Tendon Disorders of the Lower Extremities
- Topoisomerase II Alpha (TOP2A) Testing
- ToxProtect™ (Genotox Laboratories)
- TP63-Related Disorders (GeneDx Inc.)
- Transcatheter pulmonary valve implantation, percutaneous approach (Edward SAPEIN Valve)
- Transcranial Direct Current Stimulation
- Transcription Factor 4 (TCF4) Testing for Pitt-Hopkins Syndrome (PTHS)
- Transcutaneous Electrical Nerve Stimulation for Knee Osteoarthritis
- Transmembrane Activator and CAML Interactor (TACI) Gene, Full Gene Analysis (Mayo Medical Laboratories)
- Transoral Gastric Volume Reduction (TVGR)
- Transpalatal Advancement Pharyngoplasty for Sleep Apnea
- Transvascular Autonomic Modulation (TVAM)
- Treatment(s) for incontinence, pulsed magnetic neuromodulation, per day
- TreatmentMAP (Molecular Health)
- Urinalysis infectious agent detection, semi-quantitative analysis of volatile compounds
- Urinary Microsatellite Analysis
- Urine based ancillary tests designed to detect molecular changes (Tests may include, but are not limited to surviving, telomerase; Ancillary UroVysion™ aka FISH testing)
- Use of Anser IFX and Anser ADA to Monitor Treatment in Patients with Inflammatory Bowel Disease
- Use of Anti-Infliximab Antibody Levels to monitor treatment in patients with Inflammatory Bowel Disease (IBD)

- Use of Fractional CO2 laser therapy (e.g. Monalisa Touch®), radiofrequency technology (e.g. THERMlva®), and ER YAG laser therapy for vaginal rejuvenation and vaginal tightening
- USGI Primary Obesity Surgery Endolumenal (POSE)
- Uterine Transplantation for Uterine Factor Infertility
- Vercise Directional Deep Brain Stimulation (DBS) System (Boston Scientific) for Parkinson's Disease
- Vertebral Motion Analysis for Assessment of Spinal Instability
- Vestibular Evoked Myogenic Potential (VEMP) Auditory Testing
- Video Head Impulse testing (vHIT) for evaluation of vestibular disorders
- VistaSeq Hereditary Cancer Panel
- VivAer nasal airway remodeling with Radiofrequency to treat nasal obstruction
- Vizilite Oral Screening System
- Von Willebrand Factor (VWF)
- Whole Body Vibration for Promotion of Bone Growth in Postmenopausal Women
- Whole Exome Sequencing for Cancer Indications
- Wide-Area Transepithelial Sampling (WATS 3D) Biopsy for the Detection of Barrett's Esophagus or Esophageal Dysplasia
- Wireless capsule for measuring gastric emptying (SmartPill GI Monitoring System®)
- X-linked Charcot-Marie-Tooth Neuropathy, Type 1 (CMT1, CMT2, ) CMTX
- X-Linked Intellectual Disability (XLID) Multigene Panels
- Xenotransplant
- Zio Patch (iRhythm Technologies Inc.) Long-Term Ambulatory Cardiac Rhythm Monitoring

The following CPT/HCPCS procedure codes are investigational and unproven and are therefore not covered.

**\*\*NOTE:** Genetic and molecular diagnostic testing for Tufts Health Public Plan and Harvard Pilgrim Commercial Members is managed by AIM Specialty Health® (AIM). For Tufts Health Public Plan and Harvard Pilgrim Commercial Members Refer to Medical Necessity Guidelines: Genetic and Molecular Diagnostic Testing for Harvard Pilgrim Commercial, Tufts Health Direct, Tufts Health Together, Tufts Health RITogether, and Tufts Health One Care

**Note:** 'No specific code available' indicates an "unlisted code" or "miscellaneous code."

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0001U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Red blood cell antigen typing, DNA, human erythrocyte antigen gene analysis of 35 antigens from 11 blood groups, utilizing whole blood, common RBC alleles reported (PreciseType® HEA Test)	Investigational	February 1, 2017	November 21, 2024
0002U	Oncology (colorectal), quantitative assessment of three urine metabolites (ascorbic acid, succinic acid and carnitine) by liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring acquisition, algorithm reported as likelihood of adenomatous polyps (PolypDX™)	Investigational	February 1, 2017	August 30, 2024
0003U	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score (Overa (OVA1 Next Generation)	Investigational	February 1, 2017	August 30, 2024
0005U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate) gene expression profile by real-time RT-PCR of 3 genes (ERG, PCA3, and SPDEF), urine, algorithm reported as risk score (ExoDx® Prostate (IntelliScore), Exosome Diagnostics)	Investigational: Covered without PA for Tufts Health One Care	May 1, 2017	June 20, 2024
0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service (ToxProtect, Genotox Laboratories LTD)	Investigational	August 1, 2017	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0008U	Helicobacter pylori detection and antibiotic resistance, DNA, 16S and 23S rRNA, gyrA, pbp1, rdxA and rpoB, next generation sequencing, formalin-fixed paraffin embedded or fresh tissue, predictive, reported as positive or negative for resistance to clarithromycin, fluoroquinolones, metronidazole, amoxicillin, tetracycline and rifabutin (AmHPR Helicobacter pylori Antibiotic Resistance Next Generation Sequencing Panel, American Molecular Laboratories, Inc.)	Investigational	August 1, 2017	August 30, 2024
0009U	Oncology (breast cancer), ERBB2 (HER2) copy number by FISH, tumor cells from formalin fixed paraffin embedded tissue isolated using image-based dielectrophoresis (DEP) sorting, reported as ERBB2 gene amplified or non-amplified (DEPArray™ HER2)	Investigational	August 1, 2017	November 21, 2024
0010U	Infectious disease (bacterial), strain typing by whole genome sequencing, phylogenetic-based report of strain relatedness, per submitted isolate (Bacterial Typing by Whole Genome Sequencing, Mayo Clinic)	Investigational	August 1, 2017	October 17, 2024
0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service including all drug compounds and metabolites (Cordant CORE™)	Investigational	August 1, 2017	October 17, 2024
0019M	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations	Investigational	October 1, 2023	November 21, 2024
0020M *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass	Investigational	July 1, 2024	November 21, 2024
0015M	Adrenal cortical tumor, biochemical assay of 25 steroid markers, utilizing 24-hour urine specimen and clinical parameters, prognostic algorithm reported as a clinical risk and integrated clinical steroid risk for adrenal cortical carcinoma, adenoma, or other adrenal malignancy	Investigational	October 1, 2020	November 21, 2024
0016M **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)	Investigational	October 1, 2020	November 21, 2024
0017M **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (diffuse large B-cell lymphoma [DLBCL]), mRNA, gene expression profiling by fluorescent probe hybridization of 20 genes, formalin-fixed paraffin-embedded	Investigational	January 1, 2021	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Benefits Management	tissue, algorithm reported as cell of origin			
0019U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology, RNA, gene expression by whole transcriptome sequencing, formalin-fixed paraffin embedded tissue or fresh frozen tissue, predictive algorithm reported as potential targets for therapeutic agents (OncoTarget/ OncoTreat)	Investigational	October 1, 2017	November 21, 2024
0021U	Oncology (prostate), detection of 8 autoantibodies (ARF 6, NKX3-1, 5'-UTR-BMI1, CEP 164, 3'-UTR-Ropporin, Desmocollin, AURKAIP-1, CSNK2A2), multiplexed immunoassay and flow cytometry serum, algorithm reported as risk score (Apifyn <sup>®</sup> )	Investigational	October 1, 2017	November 21, 2024
0024U	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative (GlycA)	Investigational	January 1, 2018	November 21, 2024
0025U	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative (UrSure Tenofovir Quantification Test)	Investigational	January 1, 2018	November 21, 2024
0029U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis (ie, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, CYP3A5, CYP4F2, SLCO1B1, VKORC1 and rs12777823) (Focused Pharmacogenomics Panel)	Investigational	January 1, 2018	November 21, 2024
0030U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Drug metabolism (warfarin drug response), targeted sequence analysis (ie, CYP2C9, CYP4F2, VKORC1, rs12777823) (Warfarin Response Genotype)	Investigational	January 1, 2018	November 21, 2024
0031U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7) (Cytochrome P450 1A2 Genotype)	Investigational	January 1, 2018	November 21, 2024
0032U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	COMT (catechol-O-methyltransferase)(drug metabolism) gene analysis, c.472G>A (rs4680) variant (Catechol-O-Methyltransferase (COMT) Genotype)	Investigational	January 1, 2018	November 21, 2024
0033U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	HTR2A (5-hydroxytryptamine receptor 2A), HTR2C (5-hydroxytryptamine receptor 2C) (eg, citalopram metabolism) gene analysis, common variants (ie, HTR2A rs7997012 [c.614-2211T>C], HTR2C rs3813929 [c.-759C>T] and rs1414334 [c.551-3008C>G]) (Serotonin Receptor Genotype (HTR2A and HTR2C))	Investigational	January 1, 2018	November 21, 2024
0034U **Authorization review for HPHC and THPPs is managed by	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15)(eg, thiopurine metabolism), gene analysis, common	Investigational	January 1, 2018	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5) (Thiopurine Methyltransferase (TPMT) and Nudix Hydrolase (NUDT15) Genotyping)			
0035U	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative (e.g., Real-time quaking-induced conversion for prion detection (RT-QuIC); National Prion Disease Pathology Surveillance Center)	Investigational	April 1, 2018	November 21, 2024
0036U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Exome (ie, somatic mutations), paired formalin-fixed paraffin-embedded tumor tissue and normal specimen, sequence analyses (e.g., EXaCT-1 Whole Exome Testing; Wiell Cornell Medicine-Clinical Genomics Laboratory)	Investigational	April 1, 2018	November 21, 2024
0039U	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity (e.g., Anti-dsDNA, High Salt/Avidity; University of Washington, Department of Laboratory Medicine)	Investigational	April 1, 2018	October 17, 2024
0041U	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM (e.g., Lyme ImmunoBlot Igm; IGeneX Inc)	Investigational	April 1, 2018	October 17, 2024
0042T	Cerebral perfusion analysis using computed tomography with contrast administration, including post-processing of parametric maps with determination of cerebral blood flow, cerebral blood volume, and mean transit time	Investigational: Covered without PA for Tufts Health One Care	April 25, 2007	June 20, 2024
0042U	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG (e.g., Lyme ImmunoBlot IgG; IGeneX Inc)	Investigational	April 1, 2018	October 17, 2024
0043U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM (e.g., Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots Igm Test; IGeneX Inc)	Investigational	April 1, 2018	October 17, 2024
0044U	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG (e.g., Tick-Borne Relapsing Fever (TBRF) Borrelia ImmunoBlots IgG Test; IGeneX Inc)	Investigational	April 1, 2018	October 17, 2024
0045U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score (Oncotype DX Breast DCIS Score test (Genomic Health))	Investigational	July 1, 2018	November 21, 2024
0047U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score (Oncotype DX Genomic Prostate Score Genomic Health, Inc.)	Investigational	July 1, 2018	April 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0048U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s) (MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) Memorial Sloan Kettering Cancer Center)	Investigational	July 1, 2018	November 21, 2024
0050U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements (MyAML NGS Panel LabPMM LLC, an Invivoscribe Technologies, Inc. Company)	Investigational	July 1, 2018	November 21, 2024
0051U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	Investigational	July 1, 2018	October 17, 2024
0052U	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation	Investigational	July 1, 2018	November 21, 2024
0054T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on fluoroscopic images (List separately in addition to code for primary procedure)	Investigational	January 1, 2009	November 21, 2024
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service	Investigational	July 1, 2018	October 17, 2024
0055T	Computer-assisted musculoskeletal surgical navigational orthopedic procedure, with image-guidance based on CT/MRI images (List separately in addition to code for primary procedure)	Investigational	January 1, 2009	November 21, 2024
0055U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma (myTAIHEART TAI Diagnostics, Inc.)	Investigational	July 1, 2018	November 21, 2024
0058U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative (Merkel SmT Oncoprotein Antibody Titer University of Washington, Department of Laboratory Medicine)	Investigational	July 1, 2018	November 21, 2024
0059U	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein	Investigational	July 1, 2018	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	(VP1), serum, reported as positive or negative (Merkel Virus VP1 Capsid Antibody University of Washington, Department of Laboratory Medicine)			
0060U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood (Twins Zygosity PLA Natera, Inc.)	Investigational	July 1, 2018	August 30, 2024
0061U	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis (Transcutaneous multispectral measurement of tissue oxygenation and hemoglobin using Spatial Frequency Domain Imaging (SFDI) Modulated Imaging, Inc.)	Investigational	July 1, 2018	March 20, 2024
0062U	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score (SLE-key® Rule Out, Veracis Inc, Veracis Inc)	Investigational	October 1, 2018	October 17, 2024
0063U	Neurology (autism), 32 amines by LC-MS/MS, using plasma, algorithm reported as metabolic signature associated with autism spectrum disorder (NPDX ASD ADM Panel I, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc d/b/a NeuroPointDX)	Investigational	October 1, 2018	November 21, 2024
0067U	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score (BBDRisk Dx™, Silbiotech, Inc)	Investigational	October 1, 2018	November 21, 2024
0070U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, common and select rare variants (ie, *2, *3, *4, *4N, *5, *6, *7, *8, *9, *10, *11, *12, *13, *14A, *14B, *15, *17, *29, *35, *36, *41, *57, *61, *63, *68, *83, *xN) (CYP2D6 Common Variants and Copy Number, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0071T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	Investigational	January 1, 2006	August 30, 2024
0071U **Authorization review for HPHC and THPPs is managed by	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, full gene sequence (List separately in addition to code for primary procedure) (CYP2D6 Full Gene Sequencing,	Investigational	October 1, 2018	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	Mayo Clinic, Laboratory Developed Test)			
0072T	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue	Investigational	January 1, 2006	August 30, 2024
0072U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D6-2D7 hybrid gene) (List separately in addition to code for primary procedure) (CYP2D6-2D7 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0073U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, CYP2D7-2D6 hybrid gene) (List separately in addition to code for primary procedure) (CYP2D7-2D6 Hybrid Gene Targeted Sequence Analysis, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0074U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, non-duplicated gene when duplication/multiplication is trans) (List separately in addition to code for primary procedure) (CYP2D6 trans-duplication/ multiplication non-duplicated gene targeted sequence analysis, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0075T	Transcatheter placement of extracranial vertebral or intrathoracic carotid artery stent(s), including radiologic supervision and interpretation, percutaneous; initial vessel	Investigational: Covered without PA for Tufts Health One Care	January 1, 2006	June 20, 2024
0075U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 5' gene duplication/ multiplication) (List separately in addition to code for primary procedure) (CYP2D6 5' gene duplication/ multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0076T	Transcatheter placement of extracranial vertebral or intrathoracic carotid artery stent(s), including radiologic supervision and interpretation, percutaneous; each additional vessel	Investigational: Covered without PA for Tufts Health One Care	January 1, 2006	June 20, 2024
0076U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP2D6 (cytochrome P450, family 2, subfamily D, polypeptide 6) (eg, drug metabolism) gene analysis, targeted sequence analysis (ie, 3' gene duplication/ multiplication) (List separately in addition to code for primary procedure) (CYP2D6 3' gene duplication/multiplication targeted sequence analysis, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0077U	Immunoglobulin paraprotein (M-protein), qualitative, immunoprecipitation and mass spectrometry, blood or urine, including isotype (M-Protein Detection and Isotyping by MALDI-TOF Mass Spectrometry, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2018	November 21, 2024
0078U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder (INFINITI® Neural Response Panel, PersonalizeDx Labs, AutoGenomics Inc)	Investigational	October 1, 2018	November 21, 2024
0079U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Comparative DNA analysis using multiple selected single-nucleotide polymorphisms (SNPs), urine and buccal DNA, for specimen identity verification (ToxLok™, InSource Diagnostics, InSource Diagnostics)	Investigational	October 1, 2018	November 21, 2024
0080U	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	Investigational	January 1, 2019	November 21, 2024
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service	Investigational	January 1, 2019	October 17, 2024
0083U	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations	Investigational	January 1, 2019	November 21, 2024
0084U	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens	Investigational	July 1, 2019	November 21, 2024
0086U	Infectious disease (bacterial and fungal), organism identification, blood culture, using rRNA FISH, 6 or more organism targets, reported as positive or negative with phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility (Accelerate PhenoTest™ BC kit, Accelerate Diagnostics, Inc)	Investigational	July 1, 2019	October 17, 2024
0087U **Authorization review for HPHC and THPPs is managed by	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and	Investigational	July 1, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	injury algorithm reported as a probability score			
0088U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	Investigational	July 1, 2019	November 21, 2024
0089U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (melanoma), gene expression profiling by RTqPCR, <i>PRAME</i> and <i>LINC00518</i>, superficial collection using adhesive patch(es) (Pigmented Lesion Assay (PLA), DermTech )	Investigational: Covered without PA for Tufts Health One Care	July 1, 2019	November 21, 2024
0090U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a categorical result (ie, benign, indeterminate, malignant)	Investigational: Covered without PA for Tufts Health One Care	July 1, 2019	October 17, 2024
0091U	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result	Investigational	July 1, 2019	August 30, 2024
0092U	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy	Investigational: Covered without PA for Tufts Health One Care	July 1, 2019	October 17, 2024
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected	Investigational	July 1, 2019	October 17, 2024
0094U	Genome (eg, unexplained constitutional or heritable disorder or syndrome), rapid sequence analysis	Investigational	October 1, 2022	November 21, 2024
0095U	Eosinophilic esophagitis, Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}], enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis	Investigational	July 1, 2019	August 30, 2024
0096U	Human papillomavirus (HPV), high-risk types (ie, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68), male urine	Investigational	July 1, 2019	October 17, 2024
0095T	Removal of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in additional to code for primary procedure)-	Investigational	January 1, 2024	January 1, 2024
0100T	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy	Investigational	January 1, 2006	March 20, 2024

0101T	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified, high energy	Investigational	February 28, 2007	November 21, 2024
0101U **Authorization review for HPHC and THPPs is managed by	Hereditary colon cancer disorders (eg, Lynch syndrome, <i>PTEN</i> hamartoma syndrome, Cowden syndrome, familial adenomatosis	Investigational	July 1, 2019	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], <i>EPCAM</i> and <i>GREM1</i> [deletion/duplication only])			
0102T	Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle	Investigational	February 28, 2007	November 21, 2024
0102U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])	Investigational	July 1, 2019	November 21, 2024
0103U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], <i>EPCAM</i> [deletion/duplication only])	Investigational	July 1, 2019	August 30, 2024
0105U	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 <i>(TNFR1, TNFR2)</i>, and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including <i>APOL1</i> genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD) (KidneyIntelX™, RenalytixAI, RenalytixAI)	Investigational: Covered without PA for Tufts Health One Care	October 1, 2019	June 20, 2024
0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation	Investigational	January 1, 2006	June 20, 2024
0106U	Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (<sup>13</sup>C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of <sup>13</sup>CO<sub>2</sub> excretion (13C-Spirulina Gastric Emptying Breath Test (GEBT), Cairn Diagnostics d/b/a Advanced Breath Diagnostics, LLC, Cairn Diagnostics d/b/a Advanced Breath Diagnostics, LLC)	Investigational	October 1, 2019	August 30, 2024
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to	Investigational	January 1, 2006	June 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	assess large diameter fiber sensation			
0107U	Clostridium difficile toxin(s) antigen detection by immunoassay technique, stool, qualitative, multiple-step method (Singulex Clarity C.diff toxins A/B assay, Singulex)	Investigational	October 1, 2019	August 30, 2024
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational	January 1, 2006	June 20, 2024
0108U	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer (TissueCypher® Barrett's Esophagus Assay, Cernostics, Cernostics)	Investigational	October 1, 2019	August 30, 2024
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational	January 1, 2006	June 20, 2024
0109U	Infectious disease (Aspergillus species), real-time PCR for detection of DNA from 4 species <i>(A. fumigatus, A. terreus, A. niger, and A. flavus)</i>, blood, lavage fluid, or tissue, qualitative reporting of presence or absence of each species (MYCODART Dual Amplification Real Time PCR Panel for 4 Aspergillus species, RealTime Laboratories, Inc/MycoDART, Inc)	Investigational	October 1, 2019	October 17, 2024
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation	Investigational	January 1, 2006	June 20, 2024
0110U	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected (Oral OncolyticAssuranceRX, Firstox Laboratories, LLC, Firstox Laboratories, LLC)	Investigational	October 1, 2019	October 17, 2024
0112U	Infectious agent detection and identification, targeted sequence analysis (16S and 18S rRNA genes) with drug-resistance gene (MicroGenDX qPCR & NGS For Infection, MicroGenDX, MicroGenDX)	Investigational: Covered without PA for Tufts Health One Care	October 1, 2019	October 17, 2024
0113U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), measurement of <i>PCA3</i> and <i>TMPRSS2-ERG</i> in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk	Investigational	October 1, 2019	April 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	score (MiPS (Mi-Prostate Score), MLabs, MLabs)			
0114U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Gastroenterology (Barrett's esophagus), <i>VIM</i> and <i>CCNA1</i> methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus (EsoGuard™, Lucid Diagnostics, Lucid Diagnostics)	Investigational	October 1, 2019	August 30, 2024
0115U	Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected (ePlex Respiratory Pathogen (RP) Panel, GenMark Diagnostics, Inc, GenMark Diagnostics, Inc)	Investigational: Covered without PA for Tufts Health One Care	October 1, 2019	October 17, 2024
0116U	Prescription drug monitoring, enzyme immunoassay of 35 or more drugs confirmed with LC-MS/MS, oral fluid, algorithm results reported as a patient-compliance measurement with risk of drug to drug interactions for prescribed medications (Snapshot Oral Fluid Compliance, Ethos Laboratories)	Investigational	October 1, 2019	October 17, 2024
0117U	Pain management, analysis of 11 endogenous analytes (methylmalonic acid, xanthurenic acid, homocysteine, pyroglutamic acid, vanilmandelate, 5-hydroxyindoleacetic acid, hydroxymethylglutarate, ethylmalonate, 3-hydroxypropyl mercapturic acid (3-HPMA), quinolinic acid, kynurenic acid), LC-MS/MS, urine, algorithm reported as a pain-index score with likelihood of atypical biochemical function associated with pain (Foundation PI <sup>SM</sup> , Ethos Laboratories)	Investigational	October 1, 2019	October 17, 2024
0118U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA (Viracor TRAC™ dd-cfDNA, Viracor Eurofins, Viracor Eurofins)	Investigational	October 1, 2019	November 21, 2024
0119U	Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events (MI-HEART Ceramides, Plasma, Mayo Clinic, Laboratory Developed Test)	Investigational	October 1, 2019	November 21, 2024
0120U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter (Lymph3Cx Lymphoma Molecular	Investigational	October 1, 2019	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	Subtyping Assay, Mayo Clinic, Laboratory Developed Test)			
0121U	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood (Flow Adhesion of Whole Blood on VCAM-1 (FAB-V), Functional Fluidics, Functional Fluidics)	Investigational	October 1, 2019	November 21, 2024
0122U	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood (Flow Adhesion of Whole Blood to P-SELECTIN (WB-PSEL), Functional Fluidics, Functional Fluidics)	Investigational	October 1, 2019	November 21, 2024
0123U	Mechanical fragility, RBC, shear stress and spectral analysis profiling (Mechanical Fragility, RBC by shear stress profiling and spectral analysis, Functional Fluidics, Functional Fluidics)	Investigational	October 1, 2019	November 21, 2024
0130U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure) (+RNAinsight™ for ColoNext®, Ambry Genetics)	Investigational	October 1, 2019	August 30, 2024
0131U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary breast cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure) (+RNAinsight™ for BreastNext®, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024
0132U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary ovarian cancer–related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure) (+RNAinsight™ for OvaNext®, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024
0133U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary prostate cancer–related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure) (+RNAinsight™ for ProstateNext®, Ambry Genetics)	Investigational	October 1, 2019	April 17, 2024
0134U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure) (+RNAinsight™ for CancerNext®, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024
0135U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure) (+RNAinsight™ for GYNPlus®, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0136U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure) (+RNAinsight™ for ATM, Ambry Genetics)	Investigational	October 1, 2019	June 20, 2024
0137U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) (+RNAinsight™ for PALB2, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024
0138U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure) (+RNAinsight™ for BRCA1/2, Ambry Genetics)	Investigational	October 1, 2019	November 21, 2024
0140U	Infectious disease (fungi), fungal pathogen identification, DNA (15 fungal targets), blood culture, amplified probe technique, each target reported as detected or not detected	Investigational	December 18, 2019	October 17, 2024
0141U	Infectious disease (bacteria and fungi), gram-positive organism identification and drug resistance element detection, DNA (20 gram-positive bacterial targets, 4 resistance genes, 1 pan gram-negative bacterial target, 1 pan Candida target), blood culture, amplified probe technique, each target reported as detected or not detected	Investigational	December 18, 2019	October 17, 2024
0142U	Infectious disease (bacteria and fungi), gram-negative bacterial identification and drug resistance element detection, DNA (21 gram-negative bacterial targets, 6 resistance genes, 1 pan gram-positive bacterial target, 1 pan Candida target), amplified probe technique, each target reported as detected or not detected	Investigational	December 18, 2019	October 17, 2024
0152U	Infectious disease (bacteria, fungi, parasites, and DNA viruses), DNA, PCR and next-generation sequencing, plasma, detection of >1,000 potential microbial organisms for significant positive pathogens	Investigational	December 18, 2019	October 17, 2024
0153U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	Investigational	December 18, 2019	November 21, 2024
0156U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Copy number (eg, intellectual disability, dysmorphism), sequence analysis	Investigational	December 18, 2019	November 21, 2024
0157U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	APC (APC regulator of WNT signaling pathway) (eg, familial adenomatous polyposis [FAP]) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0158U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	MLH1 (mutL homolog 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0159U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	MSH2 (mutS homolog 2) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0160U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	MSH6 (mutS homolog 6) (eg, hereditary colon cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0161U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	PMS2 (PMS1 homolog 2, mismatch repair system component) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0162U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary colon cancer (Lynch syndrome), targeted mRNA sequence analysis panel (MLH1, MSH2, MSH6, PMS2) (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0163U	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRCscreening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas (BeScreened™-CRC, Beacon Biomedical Inc, Beacon Biomedical Inc)	Investigational	April 1, 2020	October 17, 2024
0164U	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for antiCdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results (ibs-smart™, Gemelli Biotech, Gemelli Biotech)	Investigational	April 1, 2020	August 30, 2024
0165U	Peanut allergen-specific IgE and quantitative assessment of 64 epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and interpretation (VeriMAP Peanut Dx – Bead-based Epitope Assay, AllerGenis, AllerGenis)	Investigational	April 1, 2020	May 15, 2024
0166U	Liver disease, 10 biochemical assays (α2- macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity,	Investigational	April 1, 2020	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	and steatosis with a summary interpretation (LiverFAST™, Fibronostics, Fibronostics)			
0169U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants (NT (NUDT15 and TPMT) genotyping panel, RPRD Diagnostics)	Investigational	April 1, 2020	November 21, 2024
0170U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis (Clarifi™, Quadrant Biosciences, Inc, Quadrant Biosciences, Inc)	Investigational	April 1, 2020	June 20, 2024
0171U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence (MyMRD® NGS Panel, Laboratory for Personalized Molecular Medicine, Laboratory for Personalized Molecular Medicine)	Investigational	April 1, 2020	November 21, 2024
0173U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Psychiatry (ie, depression, anxiety), genomic analysis panel, includes variant analysis of 14 genes, (Psych HealthPGx Panel)	Investigational	July 1, 2020	September 19, 2024
0174T	Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed concurrent with primary interpretation	Investigational	January 1, 2006	February 21, 2024
0174U	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents, ( LC-MS/MS Targeted Proteomic Assay)	Covered with prior authorization for RITogether only	July 1, 2020	November 21, 2024
0175T	Computer-aided detection (CAD) (computer algorithm analysis of digital image data for lesion detection) with further physician review for interpretation and report, with or without digitization of film radiographic images, chest radiograph(s), performed remote from primary interpretation	Investigational	January 1, 2006	February 21, 2024
0175U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Psychiatry (eg, depression, anxiety), genomic analysis panel, variant analysis of 15 genes, (Genomind®Professional PGx Express™ CORE)	Investigational	July 1, 2020	September 19, 2024
0176U	Cytotoxic distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA), (IBSchek®)	Investigational	July 1, 2020	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0178U	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction, (VeriMAP™ Peanut Sensitivity -Bead Based Epitope Assay)	Investigational	July 1, 2020	May 15, 2024
0180U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons ( Navigator ABO Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0181U	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1 ( Navigator CO Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0182U	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10 (Navigator CROM Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0183U	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19 (Navigator DI Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0184U	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2 (Navigator DO Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0185U	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4 (Navigator FUT1 Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0186U	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2 (Navigator FUT2 Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0187U	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2 (Navigator FY Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0188U	"Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4 (Navigator GE Sequencing)"	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0189U	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2 (Navigator GYPA Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0190U	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3 (Navigator GYPB Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0191U	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6 (Navigator IN Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0192U	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9 (Navigator JK Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0193U	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26 (Navigator JR Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0194U	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endopeptidase [Kell blood group]) exon 8 (Navigator KEL Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0195U	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13) (Navigator KLF1 Sequencing)	Investigational	July 1, 2020	November 21, 2024
0196U	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3 (-Navigator LU Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0197U	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1 (Navigator LW Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0198T	Measurement of ocular blood flow by repetitive intraocular pressure sampling, with interpretation and report	Investigational	January 1, 2009	March 20, 2024
0198U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5 (Navigator RHD/CE Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0199U	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12 (Navigator SC Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0200T	Percutaneous sacral augmentation (sacroplasty), unilateral injection(s), including the use of a balloon or mechanical device, when used, 1 or more needles, includes imaging guidance and bone biopsy, when performed	Investigational	July 1, 2009	November 21, 2024
0200U	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3 (Navigator XK Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0201T	Percutaneous sacral augmentation (sacroplasty), bilateral injections, including the use of a balloon or	Investigational	July 1, 2009	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	mechanical device, when used, 2 or more needles, includes imaging guidance and bone biopsy, when performed			
0201U	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2 (Navigator YT Sequencing)	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	July 1, 2020	November 21, 2024
0202T	Posterior vertebral joint(s) arthroplasty (e.g., facet joint[s] replacement) including facetectomy, laminectomy, foraminotomy and vertebral column fixation, with or without injection of bone cement, including fluoroscopy, single level, lumbar spine	Investigational	July 1, 2009	November 21, 2024
0202U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	Investigational: Covered without PA for Tufts Health One Care	July 1, 2022	October 17, 2024
0203U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness	Investigational	October 1, 2020	August 30, 2024
0205U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements	Investigational: Covered without PA for Tufts Health One Care	October 1, 2020	June 20, 2024
0206U	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease	Investigational	October 1, 2020	June 20, 2024
0207T	Evacuation of Meibomian glands, automated, using heat and intermittent pressure, unilateral	Investigational	January 1, 2010	March 20, 2024
0207U	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)	Investigational	October 1, 2020	June 20, 2024
0208T	Pure tone audiometry (threshold), automated (includes use of computer-	Investigational	January 1, 2010	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	assisted device); air only			
0209T	Pure tone audiometry (threshold), automated (includes use of computer-assisted device); air and bone	Investigational	January 1, 2010	February 21, 2024
0209U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	Investigational	October 1, 2020	November 21, 2024
0210T	Speech audiometry threshold, automated (includes use of computer-assisted device);	Investigational	January 1, 2010	February 21, 2024
0211T	Speech audiometry threshold, automated (includes use of computer-assisted device); with speech recognition	Investigational	January 1, 2010	February 21, 2024
0211U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	Investigational	October 1, 2020	November 21, 2024
0212U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0212U in conjunction with 81425)	Investigational	October 1, 2022	November 21, 2024
0213U	Rare diseases (constitutional/heritable disorders), whole genome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent, sibling) (Do not report 0213U in conjunction with 81426)	Investigational	October 1, 2022	November 21, 2024
0214U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, proband (Do not report 0214U in conjunction with 81415)	Investigational	October 1, 2022	November 21, 2024
0215U	Rare diseases (constitutional/heritable disorders), whole exome and mitochondrial DNA sequence analysis, including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants, each comparator exome (eg, parent,	Investigational	October 1, 2022	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	sibling) (Do not report 0215U in conjunction with 81416			
0212T	Comprehensive audiometry threshold evaluation and speech recognition (0209T, 0211T combined), automated (includes use of computer-assisted device)	Investigational	January 1, 2010	February 21, 2024
0213T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; single level	Investigational	January 1, 2010	October 17, 2024
0214T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; second level (List separately in addition to code for primary procedure)	Investigational	January 1, 2010	October 17, 2024
0215T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, cervical or thoracic; third and any additional level(s) (List separately in addition to code for primary	Investigational	January 1, 2010	October 17, 2024
0216T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; single level	Investigational	January 1, 2010	October 17, 2024
0216U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational	October 1, 2020	November 21, 2024
0217T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; second level (List separately in addition to code for primary procedure)	Investigational	January 1, 2010	October 17, 2024
0217U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational	October 1, 2020	November 21, 2024
0218T	Injection(s), diagnostic or therapeutic agent, paravertebral facet (zygapophyseal) joint (or nerves innervating that joint) with ultrasound guidance, lumbar or sacral; third and any additional level(s) (List separately in addition to code for primary procedure)	Investigational	January 1, 2010	October 17, 2024
0218U **Authorization review for HPHC and THPPs	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions,	Investigational	October 1, 2020	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
is managed by Carelon Medical Benefits Management	duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants			
0219T	Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; cervical	Investigational	January 1, 2010	November 21, 2024
0219U	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	Investigational	October 1, 2020	October 17, 2024
0220T	Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; thoracic	Investigational	January 1, 2010	November 21, 2024
0220U	Oncology (breast cancer), image analysis with artificial intelligence assessment of 12 histologic and immunohistochemical features, reported as a recurrence score	Investigational	October 1, 2020	November 21, 2024
0221T	Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; lumbar	Investigational	January 1, 2010	November 21, 2024
0221U	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis, next-generation sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene	Investigational, Cover when Member prescribed DARZALEX®, DARZALEX FASPRO®, and Sarclisa	October 1, 2020	November 21, 2024
0222T	Placement of posterior intrafacet implant(s), unilateral or bilateral, including imaging and placement of bone graft(s) or synthetic device(s), single level; each additional vertebral segment (List separately in addition to code for primary procedure)	Investigational	January 1, 2010	November 21, 2024
0222U	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3	Investigational	October 1, 2020	November 21, 2024
0223U	Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected	Investigational: Covered without PA for Tufts Health One Care	July 1, 2022	October 17, 2024
0225U	Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected	Investigational: Covered without PA for Tufts Health One Care	July 1, 2022	October 17, 2024
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass	Investigational	January 1, 2021	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation (Comprehensive Screen, Aspenti Health)			
0228U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer (PanGIA Prostate, Genetics Institute of America, Entopsis, LLC)	Investigational	January 1, 2021	April 17, 2024
0229U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	BCAT1 (Branched chain amino acid transaminase 1) or IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis (Colvera®, Clinical Genomics Pathology Inc.)	Investigational	January 1, 2021	November 21, 2024
0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	Investigational	July 1, 2010	November 21, 2024
0233U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	FXN (frataxin) (eg, Friedreich ataxia), gene analysis, including small sequence changes in exonic and intronic regions, deletions, duplications, short tandem repeat (STR) expansions, mobile element insertions, and variants in non-uniquely mappable regions (Genomic Unity® FXN Analysis, Variantyx Inc.)	Investigational	January 1, 2021	June 20, 2024
0234T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; renal artery	Investigational	January 1, 2011	October 17, 2024
0235T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; visceral artery (except renal), each vessel	Investigational	January 1, 2011	October 17, 2024
0236T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; abdominal aorta	Investigational	January 1, 2011	October 17, 2024
0237T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; brachiocephalic trunk and branches, each vessel	Investigational	January 1, 2011	October 17, 2024
0238T	Transluminal peripheral atherectomy, open or percutaneous, including radiological supervision and interpretation; iliac artery, each vessel	Investigational	January 1, 2011	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0243U	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia, (PIGF Preeclampsia Screen)	Investigational	April 1, 2021	August 30, 2024
0244U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue, (Oncotype MAP Pan-Cancer Tissue test)	Investigational: Covered without PA for Tufts Health One Care	April 1, 2021	November 21, 2024
0247U	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth, (PreTRM®)	Investigational	April 1, 2021	August 30, 2024
0248U	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug	Investigational	July 1, 2021	November 21, 2024
0249U	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	Investigational	July 1, 2021	November 21, 2024
0250U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	Investigational	July 1, 2021	November 21, 2024
0251U	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	Investigational	July 1, 2021	October 17, 2024
0252U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy	Investigational	July 1, 2021	August 30, 2024
0253T	Insertion of anterior segment aqueous drainage device, without extraocular reservoir; internal approach, into the suprachoroidal space	Investigational: Covered without PA for Tufts Health One Care	January 1, 2011	June 20, 2024
0253U **Authorization review for HPHC and THPPs is managed by	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as	Investigational	July 1, 2021	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)			
0254U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Reproductive medicine (preimplantation genetic assessment), analysis of 24 chromosomes using embryonic DNA genomic sequence analysis for aneuploidy, and a mitochondrial DNA score in euploid embryos, results reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplications, mosaicism, and segmental aneuploidy, per embryo tested	Investigational	July 1, 2021	June 20, 2024
0255U	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score (Cap-Score™ Test, Androvia LifeSciences, Avantor Clinical Services (previously known as Therapak))	Investigational	October 1, 2021	June 20, 2024
0256U	Trimethylamine/trimethylamine N-oxide (TMA/TMAO) profile, tandem mass spectrometry (MS/MS), urine, with algorithmic analysis and interpretive report (rimethylamine (TMA) and TMA N-Oxide, Children's Hospital Colorado Laboratory)	Investigational	October 1, 2021	June 20, 2024
0258U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics: (Mind.Px, Mindera, Mindera Corporation)	Investigational: Covered without PA for Tufts Health One Care	October 1, 2021	October 17, 2024
0260U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping (Augusta Optical Genome Mapping, Georgia Esoteric and Molecular (GEM) Laboratory, LLC, Bionano Genomics Inc)	Investigational	October 1, 2021	November 21, 2024
0261U	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score: (Immunoscore®, HalioDx, HalioDx)	Investigational	October 1, 2021	November 21, 2024
0262U	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	Investigational	October 1, 2021	November 21, 2024
0263T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections,	Investigational	July 1, 2011	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest			
0263U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD) (NPDx ASD and Central Carbon Energy Metabolism, Stemina Biomarker Discovery, Inc, Stemina Biomarker Discovery, Inc.)	Investigational	October 1, 2021	November 21, 2024
0264T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	Investigational	July 1, 2011	October 17, 2024
0264U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/ heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping (Praxis Optical Genome Mapping, Praxis Genomics LLC)	Investigational	October 1, 2021	November 21, 2024
0265T	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy	Investigational	July 1, 2011	October 17, 2024
0265U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Rare constitutional and other heritable disorders, whole genome and mitochondrial DNA sequence analysis, blood, frozen and formalin-fixed paraffin-embedded (FFPE) tissue, saliva, buccal swabs or cell lines, identification of single nucleotide and copy number variants (Praxis Whole Genome Sequencing, Praxis Genomics LLC)	Investigational	October 1, 2021	November 21, 2024
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational	July 1, 2011	November 21, 2024
0266U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes (Praxis Transcriptome, Praxis Genomics LLC)	Investigational	October 1, 2021	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0267T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed))	Investigational	July 1, 2011	November 21, 2024
0267U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing (Praxis Combined Whole Genome Sequencing and Optical Genome Mapping, Praxis Genomics LLC)	Investigational	October 1, 2021	November 21, 2024
0268T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed))	Investigational	July 1, 2011	November 21, 2024
0268U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	"Hematology (atypical hemolytic uremic syndrome [aHUS]), genomic sequence analysis of 15 genes, blood, buccal swab, or amniotic fluid (Versiti™ aHUS Genetic Evaluation, Versiti™ Diagnostic Laboratories, Versiti™)"	Investigational	October 1, 2021	November 21, 2024
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational	July 1, 2011	November 21, 2024
0269U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (autosomal dominant congenital thrombocytopenia), genomic sequence analysis of 14 genes, blood, buccal swab, or amniotic fluid (Versiti™ Autosomal Dominant Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0270T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed))	Investigational	July 1, 2011	November 21, 2024
0270U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (congenital coagulation disorders), genomic sequence analysis of 20 genes, blood, buccal swab, or amniotic fluid (Versiti™ Coagulation Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0271T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed))	Investigational	July 1, 2011	November 21, 2024
0271U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (congenital neutropenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid (Versiti™ Congenital Neutropenia Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex	Investigational	July 1, 2011	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);			
0272U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (genetic bleeding disorders), genomic sequence analysis of 51 genes, blood, buccal swab, or amniotic fluid, comprehensive (Versiti™ Comprehensive Bleeding Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0273T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (e.g., battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming	Investigational	July 1, 2011	November 21, 2024
0273U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (genetic hyperfibrinolysis, delayed bleeding), genomic sequence analysis of 8 genes (F13A1, F13B, FGA, FGB, FGG, SERPINA1, SERPINE1, SERPINF2, PLAU), blood, buccal swab, or amniotic fluid (Versiti™ Fibrinolytic Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0274T	Percutaneous laminotomy/laminectomy (intralaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy) any method under indirect image guidance (e.g., fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; cervical or thoracic	Investigational	July 1, 2011	November 21, 2024
0274U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (genetic platelet disorders), genomic sequence analysis of 43 genes, blood, buccal swab, or amniotic fluid (Versiti™ Comprehensive Platelet Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0275T	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), with or without the use of an endoscope, single or multiple levels, unilateral or bilateral; lumbar	Investigational	July 1, 2011	November 21, 2024
0275U	Hematology (heparin-induced thrombocytopenia), platelet antibody	Investigational	October 1, 2021	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	reactivity by flow cytometry, serum (Versiti™ Heparin-Induced Thrombocytopenia Evaluation – PEA, Versiti™ Diagnostic Laboratories, Versiti™)			
0276U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (inherited thrombocytopenia), genomic sequence analysis of 23 genes, blood, buccal swab, or amniotic fluid (Versiti™ Inherited Thrombocytopenia Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0277U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (genetic platelet function disorder), genomic sequence analysis of 31 genes, blood, buccal swab, or amniotic fluid (Versiti™ Platelet Function Disorder Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes)	Investigational	January 1, 2012	October 17, 2024
0278U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hematology (genetic thrombosis), genomic sequence analysis of 12 genes, blood, buccal swab, or amniotic fluid (Versiti™ Thrombosis Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0279U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen III binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen III binding	Investigational	January 19, 2022	November 21, 2024
0280U	Hematology (von Willebrand disease [VWD]), von Willebrand factor (VWF) and collagen IV binding by enzyme-linked immunosorbent assays (ELISA), plasma, report of collagen IV binding	Investigational	January 19, 2022	November 21, 2024
0281U	Hematology (von Willebrand disease [VWD]), von Willebrand propeptide, enzyme-linked immunosorbent assays (ELISA), plasma, diagnostic report of von Willebrand factor (VWF) propeptide antigen level	Investigational	January 19, 2022	November 21, 2024
0282U	Red blood cell antigen typing, DNA, genotyping of 12 blood group system genes to predict 44 red blood cell antigen phenotypes (Versiti™ Red Cell Genotyping Panel, Versiti™ Diagnostic Laboratories, Versiti™)	Investigational	October 1, 2021	November 21, 2024
0285U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score (RadTox™ cfDNA test, DiaCarta)	Investigational	January 1, 2022	November 21, 2024
0286U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CEP72 (centrosomal protein, 72-KDa), NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants (CNT (CEP72, TPMT, NUDT15) genotyping panel, RPRD Diagnostics)	Investigational	January 1, 2022	November 21, 2024
0289U **Authorization review	Neurology (Alzheimer disease), mRNA, gene expression profiling by	Investigational	January 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
for HPHC and THPPs is managed by Carelon Medical Benefits Management	RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score (MinX Blood Test (memory/alzheimers), MindX Sciences)			
0290U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score (MindX (Pain))	Investigational	January 1, 2022	November 21, 2024
0291U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score (MindX (Mood))	Investigational	January 1, 2022	November 21, 2024
0292U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score (MindX (Stress))	Investigational	January 1, 2022	November 21, 2024
0293U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score (MindX (Suicidality))	Investigational	January 1, 2022	November 21, 2024
0294U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score (MindX (Longevity))	Investigational	January 1, 2022	November 21, 2024
0295U	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score (DCISionRT, PrecludeDx, Preclude Corp)	Investigational	January 1, 2022	November 21, 2024
0296U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy (mRNA CancerDetect Viome Life Sciences Inc.)	Investigational	January 1, 2022	November 21, 2024
0297U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification (Praxis Somatic Whole Genome Sequencing, Praxis LLC)	Investigational	January 1, 2022	November 21, 2024
0298U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue,	Investigational	January 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Benefits Management	blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification (Praxis Somatic Transcriptome, Praxis LLC)			
0299U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification (Praxis Somatic Optical Genome Mapping)	Investigational	January 1, 2022	November 21, 2024
0300U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification (Oraxis Somatic Combined Whole Genome Sequencing and Optical Genome Mapping)	Investigational	January 1, 2022	November 21, 2024
0301U	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); (Bartonella ddPCR Galaxy Diagnostics Inc.)	Investigational	January 1, 2022	October 17, 2024
0302U	Infectious agent detection by nucleic acid (DNA or RNA), Bartonella henselae and Bartonella quintana, droplet digital PCR (ddPCR); following liquid enhancement (Bartonella Digital ePCR)	Investigational	January 1, 2022	October 17, 2024
0303U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic (Hypoxic BioChip Adhesion, BioChip Labs)	Investigational	January 1, 2022	November 21, 2024
0304U	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic (Nomaxic BioChip Adhesion)	Investigational	January 1, 2022	November 21, 2024
0305U	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index (Ektacytometry, BioChip)	Investigational	January 1, 2022	November 21, 2024
0308U	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]) with 3 clinical parameters (age, sex, history of cardiac intervention), plasma, algorithm reported as a risk score for obstructive CAD	Investigational	April 1, 2022	November 21, 2024
0309U	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	Investigational	April 1, 2022	November 21, 2024
0310U	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3	Investigational: Covered without PA for	April 1, 2022	October 17, 2024

		Tufts Health One Care		
--	--	-----------------------	--	--

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD			
0311U	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified	Investigational	April 1, 2022	October 17, 2024
0312U	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	Investigational: Covered without PA for Tufts Health One Care	April 1, 2022	October 17, 2024
0316U	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	Investigational	April 1, 2022	October 17, 2024
0321U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique	Investigational	April 1, 2022	October 17, 2024
0322U	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	Investigational	April 1, 2022	June 20, 2024
0326U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Targeted genomic sequence analysis panel, solid organ neoplasm, cell-free circulating DNA analysis of 83 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	Investigational	July 1, 2022	November 21, 2024
0328U	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient-adverse event, per date of service	Investigational	July 1, 2022	October 17, 2024
0329T	Monitoring of intraocular pressure for 24 hours or longer, unilateral or bilateral, with interpretation and report	Investigational	July 1, 2013	March 20, 2024
0329U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor	Investigational	July 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	with DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations			
0330T	Tear film imaging, unilateral or bilateral, with interpretation and report	Investigational	July 1, 2013	March 20, 2024
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab	Investigational	July 1, 2022	August 30, 2024
0331T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment;	Investigational	July 1, 2013	November 21, 2024
0331U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (hematolymphoid neoplasia), optical genome mapping for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alterations	Investigational	July 1, 2022	November 21, 2024
0332U	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy	Investigational	October 1, 2022	November 21, 2024
0333U	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in high-risk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gamma-carboxy-prothrombin (DCP), algorithm reported as normal or abnormal result	Investigational	October 1, 2022	November 21, 2024
0334U	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffin-embedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	Investigational	October 1, 2022	November 21, 2024
0335U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants	Investigational	October 1, 2022	November 21, 2024
0336U	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)	Investigational	October 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0337U	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood	Investigational	October 1, 2022	November 21, 2024
0338U	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood	Investigational	October 1, 2022	November 21, 2024
0340U	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate	Investigational	October 1, 2022	November 21, 2024
0341U	Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid	Investigational	October 1, 2022	November 21, 2024
0342U	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline (IMMray ® PanCan-d Test)	Investigational	October 1, 2022	November 21, 2024
0343U	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer	Investigational	October 1, 2022	November 21, 2024
0344U	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH	Investigational	October 1, 2022	August 30, 2024
0345U	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (GeneSight ®)	Investigational	October 1, 2022	September 19, 2024
0347U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes	Investigational	October 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0348U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes	Investigational	October 1, 2022	November 21, 2024
0349U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions	Investigational	October 1, 2022	November 21, 2024
0350U	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes	Investigational	October 1, 2022	November 21, 2024
0351U	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C-reactive protein, serum, algorithm reported as likelihood of bacterial infection (MeMed BV®)	Investigational	October 1, 2022	August 30, 2024
0355U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)	Investigational: Covered without PA for Tufts Health One Care	January 1, 2023	October 17, 2024
0356U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (oropharyngeal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence	Investigational	January 1, 2023	October 17, 2024
0358U	Neurology (mild cognitive impairment), analysis of B-amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative	Investigational	January 1, 2023	October 17, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0359U	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer	Investigational	January 1, 2023	October 17, 2024
0360U	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy	Investigational: Covered without PA for Tufts Health One Care	January 1, 2023	October 17, 2024
0361U	Neurofilament light chain, digital immunoassay, plasma, quantitative	Investigational	January 1, 2023	October 17, 2024
0362U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes and 10 housekeeping genes, fine needle aspirate or formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes	Investigational: Covered without PA for Tufts Health One Care	January 1, 2023	October 17, 2024
0363U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (urothelial), mRNA, gene-expression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma	Investigational: Covered without PA for Tufts Health One Care	January 1, 2023	October 17, 2024
0365U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer	Investigational	April 1, 2023	November 21, 2024
0366U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer	Investigational	April 1, 2023	November 21, 2024
0367U	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection	Investigational	April 1, 2023	November 21, 2024
0368U	Oncology (colorectal cancer), evaluation for mutations of APC, BRAF, CTNNB1, KRAS, NRAS, PIK3CA, SMAD4, and TP53, and methylation markers (MYO1G, KCNQ5, C9ORF50, FLI1, CLIP4, ZNF132 and TWIST1), multiplex quantitative polymerase chain reaction (qPCR), circulating cell-free DNA (cfDNA), plasma, report of risk score for advanced adenoma or colorectal cancer	Investigational	April 1, 2023	November 21, 2024
0369U	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification	Investigational	April 1, 2023	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	of 21 associated antibiotic-resistance genes, multiplex amplified probe technique			
0370U	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0371U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0372U	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0373U	Infectious agent detection by nucleic acid (DNA and RNA), respiratory tract infection, 17 bacteria, 8 fungus, 13 virus, and 16 antibiotic-resistance genes, multiplex amplified probe technique, upper or lower respiratory specimen	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0374U	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0375U	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	Investigational	April 1, 2023	November 21, 2024
0376U	Oncology (prostate cancer), image analysis of at least 128 histologic features and clinical factors, prognostic algorithm determining the risk of distant metastases, and prostate cancer-specific mortality, includes predictive algorithm to androgen deprivation-therapy response, if appropriate	Investigational	April 1, 2023	April 17, 2024
0377U	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)	Investigational	April 1, 2023	November 21, 2024
0378U	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab	Investigational	April 1, 2023	June 20, 2024
0379U	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite	Investigational	April 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	instability, and tumor mutational burden			
0381U	Maple syrup urine disease monitoring by patient-collected blood card sample, quantitative measurement of allo-isoleucine, leucine, isoleucine, and valine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	Investigational	April 1, 2023	October 17, 2024
0382U	Hyperphenylalaninemia monitoring by patient-collected blood card sample, quantitative measurement of phenylalanine and tyrosine, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	Investigational	April 1, 2023	October 17, 2024
0383U	Tyrosinemia type I monitoring by patient-collected blood card sample, quantitative measurement of tyrosine, phenylalanine, methionine, succinylacetone, nitisinone, liquid chromatography with tandem mass spectrometry (LC-MS/MS)	Investigational	April 1, 2023	October 17, 2024
0384U	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0385U	Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease	Investigational: Covered without PA for Tufts Health One Care	April 1, 2023	October 17, 2024
0387U	Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression	Investigational	July 1, 2023	November 21, 2024
0388U	Oncology (non-small cell lung cancer), next-generation sequencing with identification of single nucleotide variants, copy number variants, insertions and deletions, and structural variants in 37 cancer-related genes, plasma, with report for alteration detection	Investigational	July 1, 2023	November 21, 2024
0389U	Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD	Investigational	July 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0390U	Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score	Investigational	July 1, 2023	August 30, 2024
0391U	Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice-site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score	Investigational	July 1, 2023	November 21, 2024
0392U	Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug	Investigational	July 1, 2023	November 21, 2024
0393U	Neurology (eg, Parkinson disease, dementia with Lewy bodies), cerebrospinal fluid (CSF), detection of misfolded a-synuclein protein by seed amplification assay, qualitative	Investigational	July 1, 2023	June 20, 2024
0394U	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 16 PFAS compounds by liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma or serum, quantitative	Investigational	July 1, 2023	June 20, 2024
0395U	Oncology (lung), multi-omics (microbial DNA by shotgun next-generation sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease	Investigational	July 1, 2023	November 21, 2024
0398U	Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer	Investigational	July 1, 2023	August 30, 2024
0399U	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG-binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected	Investigational	July 1, 2023	June 20, 2024
0401U	Cardiology (coronary heart disease [CAD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event	Investigational	July 1, 2023	November 21, 2024
0403U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of	Investigational	October 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	likelihood of detecting clinically significant prostate cancer			
0404U	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression	Investigational	October 1, 2023	November 21, 2024
0405U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected	Investigational	October 1, 2023	November 21, 2024
0406U	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer	Investigational	October 1, 2023	November 21, 2024
0407U	Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function	Investigational	October 1, 2023	November 21, 2024
0408U	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	Investigational	October 1, 2023	November 21, 2024
0409U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (solid tumor), DNA (80 genes) and RNA (36 genes), by next-generation sequencing from plasma, including single nucleotide variants, insertions/deletions, copy number alterations, microsatellite instability, and fusions, report showing identified mutations with clinical actionability	Investigational	October 1, 2023	November 21, 2024
0410U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected	Investigational	October 1, 2023	November 21, 2024
0411U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	Investigational	October 1, 2023	November 21, 2024
0412U	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology	Investigational	October 1, 2023	November 21, 2024
0413U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations	Investigational	October 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0414U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffin-embedded (FFPE) tissue, reported as positive or negative for each biomarker	Investigational	October 1, 2023	November 21, 2024
0415U	Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS	Investigational	October 1, 2023	November 21, 2024
0417U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclear-encoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants	Investigational	October 1, 2023	November 21, 2024
0418U	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score	Investigational	October 1, 2023	November 21, 2024
0419U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype	Investigational	October 1, 2023	November 21, 2024
0439U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Cardiology (coronary heart disease [CHD]), DNA, analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD	Investigational	April 1, 2024	November 21, 2024
0440U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1], cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected	Investigational	April 1, 2024	November 21, 2024

	for CHD			
0441U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Infectious disease (bacterial, fungal, or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index	Investigational	April 1, 2024	November 21, 2024
0444U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (solid organ neoplasia), targeted genomic sequence analysis panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue, report of clinically significant variant(s)	Investigational	April 1, 2024	November 21, 2024
0445U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	B-amyloid (Abeta42) and phospho tau (181P) (pTau181), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	Investigational	April 1, 2024	November 21, 2024
0446U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity	Investigational	April 1, 2024	November 21, 2024
0447U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare	Investigational	April 1, 2024	November 21, 2024
0450U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides	Investigational	July 1, 2024	November 21, 2024
0451U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance	Investigational	July 1, 2024	November 21, 2024
0452U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer	Investigational	July 1, 2024	November 21, 2024
0453U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	Investigational	July 1, 2024	November 21, 2024
0454U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational	July 1, 2024	November 21, 2024

0455U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Infectious agents (sexually transmitted infection), Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis, multiplex amplified probe technique, vaginal, endocervical, gynecological specimens, oropharyngeal swabs, rectal swabs, female or male urine, each pathogen reported as detected or not detected	Investigational	July 1, 2024	November 21, 2024
0457U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative	Investigational	July 1, 2024	November 21, 2024
0458U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	Investigational	July 1, 2024	November 21, 2024
0459U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	B-amyloid (Abeta42) and total tau (tTau), electrochemiluminescent immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	Investigational	July 1, 2024	November 21, 2024
0460U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes	Investigational	July 1, 2024	November 21, 2024
0461U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes	Investigational	July 1, 2024	November 21, 2024
0462U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary	Investigational	July 1, 2024	November 21, 2024
0463U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker	Investigational	July 1, 2024	July 1, 2024
0464U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result	Investigational	July 1, 2024	November 21, 2024
0465U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative	Investigational	July 1, 2024	November 21, 2024



0466U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease	Investigational	July 1, 2024	November 21, 2024
0467U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden	Investigational	July 1, 2024	November 21, 2024
0468U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis	Investigational	July 1, 2024	November 21, 2024
0469U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination	Investigational	July 1, 2024	November 21, 2024
0470U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma	Investigational	July 1, 2024	November 21, 2024
0472U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiquantitative, blood, reported as predictive evidence of early Sjogren syndrome	Investigational	July 1, 2024	November 21, 2024
0474U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene	Investigational	July 1, 2024	November 21, 2024
0475U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative	Investigational	July 1, 2024	November 21, 2024

	genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer			
0476U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis and reported phenotypes	Investigational	October 1, 2024	October 1, 2024
0477U **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Drug metabolism, psychiatry (eg, major depressive disorder, general anxiety disorder, attention deficit hyperactivity disorder [ADHD], schizophrenia), whole blood, buccal swab, and pharmacogenomic genotyping of 14 genes and CYP2D6 copy number variant analysis, including impacted gene-drug interactions and reported phenotypes	Investigational	October 1, 2024	October 1, 2024
0478U *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Oncology (non-small cell lung cancer), DNA and RNA, digital PCR analysis of 9 genes (EGFR, KRAS, BRAF, ALK, ROS1, RET, NTRK 1/2/3, ERBB2, and MET) in formalin-fixed paraffin-embedded (FFPE) tissue, interrogation for single-nucleotide variants, insertions/deletions, gene rearrangements, and reported as actionable detected variants for therapy selection	Investigational	October 1, 2024	October 1, 2024
0479U	Tau, phosphorylated, pTau217	Investigational	October 1, 2024	October 1, 2024
0480U	Infectious disease (bacteria, viruses, fungi, and parasites), cerebrospinal fluid (CSF), metagenomic next-generation sequencing (DNA and RNA), bioinformatic analysis, with positive pathogen identification	Investigational	October 1, 2024	October 1, 2024
0481U **Authorization review for HPHC and THPPs is managed by Carelon Medical	IDH1 (isocitrate dehydrogenase 1 [NADP+]), IDH2 (isocitrate dehydrogenase 2 [NADP+]), and TERT (telomerase reverse transcriptase) promoter (eg, central nervous system [CNS] tumors), next-generation sequencing (single-nucleotide variants [SNV], deletions, and insertions)	Investigational	October 1, 2024	October 1, 2024
0482U	Obstetrics (preeclampsia), biochemical assay of soluble fmslike tyrosine kinase 1 (sFlt-1) and placental growth factor (PIGF), serum, ratio reported for sFlt1/PIGF, with risk of progression for preeclampsia with severe features within 2 weeks	Investigational	October 1, 2024	October 1, 2024
0483U	Infectious disease (Neisseria gonorrhoeae), sensitivity, ciprofloxacin resistance (gyrA S91F point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of fluoroquinolone resistance	Investigational	October 1, 2024	October 1, 2024

0484U	Infectious disease (Mycoplasma genitalium), macrolide sensitivity (23S rRNA point mutation), oral, rectal, or vaginal swab, algorithm reported as probability of macrolide resistance	Investigational	October 1, 2024	October 1, 2024
0485U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (solid tumor), cell-free DNA and RNA by next-generation sequencing, interpretative report for germline mutations, clonal hematopoiesis of indeterminate potential, and tumor-derived single-nucleotide variants, small insertions/deletions, copy number alterations, fusions, microsatellite instability, and tumor mutational burden	Investigational	October 1, 2024	October 1, 2024
0486U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (pan-solid tumor), nextgeneration sequencing analysis of tumor methylation markers present in cell-free circulating tumor DNA, algorithm reported as quantitative measurement of methylation as a correlate of tumor fraction	Investigational	October 1, 2024	October 1, 2024
0487U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (solid tumor), cell-free circulating DNA, targeted genomic sequence analysis panel of 84 genes, interrogation for sequence variants, aneuploidycorrected gene copy number amplifications and losses, gene rearrangements, and microsatellite instability	Investigational	October 1, 2024	October 1, 2024
0488U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Obstetrics (fetal antigen noninvasive prenatal test), cellfree DNA sequence analysis for detection of fetal presence or absence of 1 or more of the Rh, C, c, D, E, Duffy (Fya), or Kell (K) antigen in alloimmunized pregnancies, reported as selected antigen(s) detected or not detected	Investigational	October 1, 2024	October 1, 2024
0489U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Obstetrics (single-gene noninvasive prenatal test), cellfree DNA sequence analysis of 1 or more targets (eg, CFTR, SMN1, HBB, HBA1, HBA2) to identify paternally inherited pathogenic variants, and relative mutation-dosage analysis based on molecular counts to determine fetal inheritance of maternal mutation, algorithm reported as a fetal risk score for the condition (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemia)	Investigational	October 1, 2024	October 1, 2024
0490U	Oncology (cutaneous or uveal melanoma), circulating tumor cell selection, morphological characterization and enumeration based on differential CD146, high molecular-weight melanomaassociated antigen, CD34 and CD45 protein biomarkers, peripheral blood	Investigational	October 1, 2024	October 1, 2024
0491U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and	Investigational	October 1, 2024	October 1, 2024

	quantification of estrogen receptor (ER) protein biomarker-expressing cells, peripheral blood			
0492U	Oncology (solid tumor), circulating tumor cell selection, morphological characterization and enumeration based on differential epithelial cell adhesion molecule (EpCAM), cytokeratins 8, 18, and 19, CD45 protein biomarkers, and quantification of PD-L1 protein biomarker-expressing cells, peripheral blood	Investigational	October 1, 2024	October 1, 2024
0493U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Transplantation medicine, quantification of donor-derived cell-free DNA (cfDNA) using nextgeneration sequencing, plasma, reported as percentage of donor-derived cell-free DNA	Investigational	October 1, 2024	October 1, 2024
0494U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Red blood cell antigen (fetal RhD gene analysis), next-generation sequencing of circulating cell-free DNA (cfDNA) of blood in pregnant individuals known to be RhD negative, reported as positive or negative	Investigational	October 1, 2024	October 1, 2024
0495U	Oncology (prostate), analysis of circulating plasma proteins (tPSA, fPSA, KLK2, PSP94, and GDF15), germline polygenic risk score (60 variants), clinical information (age, family history of prostate cancer, prior negative prostate biopsy), algorithm reported as risk of likelihood of detecting clinically significant prostate cancer	Investigational	October 1, 2024	October 1, 2024
0496U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (colorectal), cell-free DNA, 8 genes for mutations, 7 genes for methylation by real-time RT-PCR, and 4 proteins by enzyme-linked immunosorbent assay, blood, reported positive or negative for colorectal cancer or advanced adenoma risk	Investigational	October 1, 2024	October 1, 2024
0497U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (prostate), mRNA geneexpression profiling by real-time RT-PCR of 6 genes (FOXM1, MCM3, MTUS1, TTC21B, ALAS1, and PPP2CA), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a risk score for prostate cancer	Investigational	October 1, 2024	October 1, 2024
0498U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (colorectal), nextgeneration sequencing for mutation detection in 43 genes and methylation pattern in 45 genes, blood, and formalin-fixed paraffin-embedded (FFPE) tissue, report of variants and methylation pattern with interpretation	Investigational	October 1, 2024	October 1, 2024
0499U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (colorectal and lung), DNA from formalin-fixed paraffinembedded (FFPE) tissue, nextgeneration sequencing of 8 genes (NRAS, EGFR, CTNNB1, PIK3CA, APC, BRAF, KRAS, and TP53), mutation detection	Investigational	October 1, 2024	October 1, 2024

0500U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Autoinflammatory disease (VEXAS syndrome), DNA, UBA1 gene mutations, targeted variant analysis (M41T, M41V, M41L, c.118-2A>C, c.118-1G>C, c.118-9_118-2del, S56F, S621C)	Investigational	October 1, 2024	October 1, 2024
0501U	Oncology (colorectal), blood, quantitative measurement of cellfree DNA (cfDNA)	Investigational	October 1, 2024	October 1, 2024
0502U	Human papillomavirus (HPV), E6/E7 markers for high-risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), cervical cells, branched-chain capture hybridization, reported as negative or positive for high risk for HPV	Investigational	October 1, 2024	October 1, 2024
0503U	Neurology (Alzheimer disease), beta amyloid (Aβ40, Aβ42, Aβ42/40 ratio) and tau-protein (ptau217, np-tau217, ptau217/nptau217 ratio), blood, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS), algorithm score reported as likelihood of positive or negative for amyloid plaques	Investigational	October 1, 2024	October 1, 2024
0504U	Infectious disease (urinary tract infection), identification of 17 pathologic organisms, urine, realtime PCR, reported as positive or negative for each organism	Investigational	October 1, 2024	October 1, 2024
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism	Investigational	October 1, 2024	October 1, 2024
0506U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Gastroenterology (Barrett's esophagus), esophageal cells, DNA methylation analysis by next-generation sequencing of at least 89 differentially methylated genomic regions, algorithm reported as likelihood for Barrett's esophagus	Investigational	October 1, 2024	October 1, 2024
0507U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (ovarian), DNA, wholegenome sequencing with 5-hydroxymethylcytosine (5hmC) enrichment, using whole blood or plasma, algorithm reported as cancer detected or not detected	Investigational	October 1, 2024	October 1, 2024
0508U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Transplantation medicine, quantification of donor-derived cell-free DNA using 40 singlenucleotide polymorphisms (SNPs), plasma, and urine, initial evaluation reported as percentage of donor-derived cellfree DNA with risk for active rejection	Investigational	October 1, 2024	October 1, 2024
0509U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Transplantation medicine, quantification of donor-derived cell-free DNA using up to 12 single-nucleotide polymorphisms (SNPs) previously identified, plasma, reported as percentage of donor-derived cell-free DNA with risk for active rejection	Investigational	October 1, 2024	October 1, 2024
0510U	Oncology (pancreatic cancer), augmentative algorithmic analysis of 16 genes from previously sequenced RNA wholetranscriptome data, reported as probability of predicted molecular subtype	Investigational	October 1, 2024	October 1, 2024

0511U	Oncology (solid tumor), tumor cell culture in 3D microenvironment, 36 or more drug panel, reported as tumor-response prediction for each drug	Investigational	October 1, 2024	October 1, 2024
0512U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) status, formalin-fixed paraffinembedded (FFPE) tissue, reported as increased or decreased probability of MSI-high (MSI-H)	Investigational	October 1, 2024	October 1, 2024
0513U	Oncology (prostate), augmentative algorithmic analysis of digitized whole-slide imaging of histologic features for microsatellite instability (MSI) and homologous recombination deficiency (HRD) status, formalin-fixed paraffin-embedded (FFPE) tissue, reported as increased or decreased probability of each biomarker	Investigational	October 1, 2024	October 1, 2024
0514U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of adalimumab (ADL) levels in venous serum in patients undergoing adalimumab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)	Investigational	October 1, 2024	October 1, 2024
0515U	Gastroenterology (irritable bowel disease [IBD]), immunoassay for quantitative determination of infliximab (IFX) levels in venous serum in patients undergoing infliximab therapy, results reported as a numerical value as micrograms per milliliter (µg/mL)	Investigational	October 1, 2024	October 1, 2024
0516U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Drug metabolism, whole blood, pharmacogenomic genotyping of 40 genes and CYP2D6 copy number variant analysis, reported as metabolizer status	Investigational	October 1, 2024	October 1, 2024
0517U	Therapeutic drug monitoring, 80 or more psychoactive drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally and maximally effective dose of prescribed and non-prescribed medications	Investigational	October 1, 2024	October 1, 2024
0518U	Therapeutic drug monitoring, 90 or more pain and mental health drugs or substances, LC-MS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and non-prescribed medications	Investigational	October 1, 2024	October 1, 2024
0519U	Therapeutic drug monitoring, medications specific to pain, depression, and anxiety, LCMS/MS, plasma, 110 or more drugs or substances, qualitative and quantitative therapeutic minimally effective range of prescribed, non-prescribed, and illicit medications in circulation	Investigational	October 1, 2024	October 1, 2024
0520U	Therapeutic drug monitoring, 200 or more drugs or substances, LCMS/MS, plasma, qualitative and quantitative therapeutic minimally effective range of prescribed and	Investigational	October 1, 2024	October 1, 2024

	non-prescribed medications			
0521U	Rheumatoid factor IgA and IgM, cyclic citrullinated peptide (CCP) antibodies, and scavenger receptor A (SR-A) by immunoassay, blood	Investigational	January 1, 2025	January 1, 2025
0522U	Carbonic anhydrase VI, parotid specific/secretory protein and	Investigational	January 1, 2025	January 1, 2025
0524U	Obstetrics (preeclampsia), sFlt1/PlGF ratio, immunoassay, utilizing serum or plasma, reported as a value	Investigational	January 1, 2025	January 1, 2025
0525U	Oncology, spheroid cell culture, 11-drug panel (carboplatin, docetaxel, doxorubicin, etoposide, gemcitabine, niraparib, olaparib, paclitaxel, rucaparib, topotecan, veliparib) ovarian, fallopian, or peritoneal response prediction for each drug	Investigational	January 1, 2025	January 1, 2025
0526U	Oephrology (renal transplant), quantification of CXCL10 chemokines, flow cytometry, urine, reported as pg/mL creatinine baseline and monitoring over time	Investigational	January 1, 2025	January 1, 2025
0527U	Herpes simplex virus (HSV) types 1 and 2 and Varicella zoster virus (VZV), amplified probe technique, each pathogen reported as detected or not detected	Investigational	January 1, 2025	January 1, 2025
0528U	Lower respiratory tract infectious agent detection, 18 bacteria, 8 viruses, and 7 antimicrobial resistance genes, amplified probe technique, including reverse transcription for RNA targets, each analyte reported as detected or not detected with semiquantitative results for 15 bacteria	Investigational	January 1, 2025	January 1, 2025
0529U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Hematology (venous thromboembolism [VTE]), genome-wide single-nucleotide polymorphism variants, including F2 and F5 gene analysis, and Leiden variant, by microarray analysis, saliva, report as risk score for VTE	Investigational	January 1, 2025	January 1, 2025
0530U **Authorization review for HPHC and THPPs is managed by Carelon Medical	Oncology (pan-solid tumor), ctDNA, utilizing plasma, next generation sequencing (NGS) of 77 genes, 8 fusions, microsatellite instability, and tumor mutation burden, interpretative report for single-nucleotide variants, copy number alterations, with therapy association	Investigational	January 1, 2025	January 1, 2025
0332T	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment, with tomographic SPECT	Investigational	July 1, 2013	November 21, 2024
0333T	Visual evoked potential screening of visual acuity, automated	Investigational	July 1, 2013	March 20, 2024
0335T	Insertion of sinus tarsi implant	Investigational	January 1, 2014	November 21, 2024

0338T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	Investigational	January 1, 2014	November 21, 2024
0339T	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast	Investigational	January 1, 2014	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral			
0342T	Therapeutic apheresis with selective HDL delipidation and plasma reinfusion	Investigational	January 1, 2014	November 21, 2024
0347T	Placement of interstitial device(s) in bone for radiostereometric analysis (RSA)	Investigational	July 1, 2014	November 21, 2024
0348T	Radiologic examination, radiostereometric analysis (RSA), spine, (includes, cervical, thoracic and lumbosacral, when performed)	Investigational	July 1, 2014	November 21, 2024
0349T	Radiologic examination, radiostereometric analysis (RSA), upper extremity(ies), (includes shoulder, elbow and wrist, when performed)	Investigational	July 1, 2014	November 21, 2024
0350T	Radiologic examination, radiostereometric analysis (RSA); lower extremity(ies), (includes hip, proximal femur, knee, and ankle, when performed) ankle, when performed)	Investigational	July 1, 2014	November 21, 2024
0351T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; real time intraoperative	Investigational	July 1, 2014	February 21, 2024
0352T	Optical coherence tomography of breast or axillary lymph node, excised tissue, each specimen; interpretation and report, real time or referred	Investigational	July 1, 2014	February 21, 2024
0353T	Optical coherence tomography of breast, surgical cavity; real time intraoperative	Investigational	July 1, 2014	February 21, 2024
0354T	Optical coherence tomography of breast, surgical cavity; interpretation and report, real time or referred	Investigational	July 1, 2014	February 21, 2024
0358T	Bioelectrical impedance analysis whole body composition assessment, supine position, with interpretation and report	Investigational	July 1, 2014	June 20, 2024
0378T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; review and interpretation with report by a physician or other qualified health care professional	Investigational	January 1, 2015	March 20, 2024
0379T	Visual field assessment, with concurrent real time data analysis and accessible data storage with patient initiated data transmitted to a remote surveillance center for up to 30 days; technical support and patient instructions, surveillance, analysis and transmission of daily and emergent data reports as prescribed by a physician or other qualified health care professional	Investigational	January 1, 2015	March 20, 2024
0394T	High dose rate electronic brachytherapy, skin surface application, per fraction, includes basic dosimetry, when performed	Investigational	January 1, 2016	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0395T	High dose rate electronic brachytherapy, interstitial or intracavitary treatment, per fraction, includes basic dosimetry, when performed	Investigational	January 1, 2016	November 21, 2024
0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	Investigational	January 1, 2016	August 30, 2024
0402T	Collagen cross-linking of cornea (including removal of the corneal epithelium and intraoperative pachymetry when performed)	Covered for <b>ICD-10 diagnosis code(s):</b> H18.621- H18.623 for ages 14 through age 64, all others will deny investigational	January 1, 2016	March 20, 2024
0408T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator with transvenous electrodes	Investigational	January 1, 2016	November 21, 2024
0409T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; pulse generator only	Investigational	January 1, 2016	November 21, 2024
0410T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; atrial electrode only	Investigational	January 1, 2016	November 21, 2024
0411T	Insertion or replacement of permanent cardiac contractility modulation system, including contractility evaluation when performed, and programming of sensing and therapeutic parameters; ventricular electrode only	Investigational	January 1, 2016	November 21, 2024
0412T	Removal of permanent cardiac contractility modulation system; pulse generator only	Investigational	January 1, 2016	November 21, 2024
0413T	Removal of permanent cardiac contractility modulation system; transvenous electrode (atrial or ventricular)	Investigational	January 1, 2016	November 21, 2024
0414T	Removal and replacement of permanent cardiac contractility modulation system pulse generator only	Investigational	January 1, 2016	November 21, 2024
0415T	Repositioning of previously implanted cardiac contractility modulation transvenous electrode, (atrial or ventricular lead)	Investigational	January 1, 2016	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0416T	Relocation of skin pocket for implanted cardiac contractility modulation pulse generator	Investigational	January 1, 2016	November 21, 2024
0417T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation system	Investigational	January 1, 2016	November 21, 2024
0418T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording and disconnection per patient encounter; implantable cardiac contractility modulation system	Investigational	January 1, 2016	November 21, 2024
0422T	Tactile breast imaging by computer-aided tactile sensors, unilateral or bilateral generator system for central sleep apnea	Investigational	January 1, 2016	February 21, 2024
0439T	Myocardial contrast perfusion echocardiography; at rest or with stress, for assessment of myocardial ischemia or viability (List separately in addition to code for primary procedure)	Investigational	July 1, 2016	November 21, 2024
0440T	Ablation, percutaneous, cryoablation, includes imaging guidance; upper extremity distal/peripheral nerve	Investigational	July 1, 2016	June 20, 2024
0441T	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	Investigational	July 1, 2016	June 20, 2024
0442T	Ablation, percutaneous, cryoablation, includes imaging guidance; nerve plexus or other truncal nerve (eg, brachial plexus, pudendal nerve)	Investigational	July 1, 2016	June 20, 2024
0443T	Real time spectral analysis of prostate tissue by fluorescence spectroscopy	Investigational	July 1, 2016	April 17, 2024
0444T	Initial placement of a drug-eluting ocular insert under one or more eyelids, including fitting, training, and insertion, unilateral or bilateral	Investigational	July 1, 2016	March 20, 2024
0445T	Subsequent placement of a drug-eluting ocular insert under one or more eyelids, including re-training, and removal of existing insert, unilateral or bilateral	Investigational	July 1, 2016	March 20, 2024
0446T	Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training	Investigational: Covered without PA for Tufts Health One Care	January 1, 2017	June 20, 2024
0447T	Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision	Investigational: Covered without PA for Tufts Health One Care	January 1, 2017	June 20, 2024
0448T	Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation	Investigational: Covered without PA for Tufts Health One Care	January 1, 2017	June 20, 2024
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report	Investigational	January 1, 2017	March 20, 2024
0469T	Retinal polarization scan, ocular screening with on-site automated results, bilateral	Investigational	July 1, 2017	March 20, 2024

0472T	Device evaluation, interrogation, and initial programming of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, with iterative adjustment of the implantable device to test functionality, select optimal permanent programmed values with analysis, including visual training, with review and report by a qualified health care professional	Investigational	July 1, 2017	March 20, 2024
0473T	Device evaluation and interrogation of intra-ocular retinal electrode array (eg, retinal prosthesis), in person, including reprogramming and visual training, when performed, with review and report by a qualified health care professional	Investigational	July 1, 2017	March 20, 2024
0474T	Insertion of anterior segment aqueous drainage device, with creation of intraocular reservoir, internal approach, into the supraciliary space (CyPass Micro-Stent)	Investigational: Covered without PA for Tufts Health One Care	July 1, 2017	June 20, 2024
0481T	Injection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed	Investigational	January 1, 2018	November 21, 2024
0483T	Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; percutaneous approach, including transseptal puncture, when performed	Investigational	January 1, 2018	November 21, 2024
0484T	Transcatheter mitral valve implantation/replacement (TMVI) with prosthetic valve; transthoracic exposure (eg, thoracotomy, transapical)	Investigational	January 1, 2018	November 21, 2024
0485T	Optical coherence tomography (OCT) of middle ear, with interpretation and report; unilateral	Investigational	January 1, 2018	February 21, 2024
0486T	Optical coherence tomography (OCT) of middle ear, with interpretation and report; bilateral	Investigational	January 1, 2018	February 21, 2024
0488T	Preventive behavior change, online/electronic structured intensive program for prevention of diabetes using a standardized diabetes prevention program curriculum, provided to an individual, per 30 days	Investigational	January 1, 2018	June 20, 2024
0489T	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; adipose tissue harvesting, isolation and preparation of harvested cells including incubation with cell dissociation enzymes, removal of non-viable cells and debris, determination of concentration and dilution of regenerative cells	Investigational	January 1, 2018	March 20, 2024
0490T	Autologous adipose-derived regenerative cell therapy for scleroderma in the hands; multiple injections in one or both hands	Investigational	January 1, 2018	March 20, 2024
0494T	Surgical preparation and cannulation of marginal (extended) cadaver donor lung(s) to ex vivo organ perfusion system, including decannulation, separation from the perfusion system, and cold preservation of the allograft prior to implantation, when performed	Investigational	January 1, 2018	November 21, 2024

0495T	Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left	Investigational	January 1, 2018	November 21, 2024
-------	--	-----------------	-----------------	-------------------

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; first two hours in sterile field			
0496T	Initiation and monitoring marginal (extended) cadaver donor lung(s) organ perfusion system by physician or qualified health care professional, including physiological and laboratory assessment (eg, pulmonary artery flow, pulmonary artery pressure, left atrial pressure, pulmonary vascular resistance, mean/peak and plateau airway pressure, dynamic compliance and perfusate gas analysis), including bronchoscopy and X ray when performed; each additional hour (List separately in addition to code for primary procedure)	Investigational	January 1, 2018	November 21, 2024
0505T	Endovenous femoral-popliteal arterial revascularization, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed, with crossing of the occlusive lesion in an extraluminal fashion	Investigational	July 1, 2018	October 17, 2024
0506T	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	Investigational	July 1, 2018	March 20, 2024
0507T	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	Investigational	July 1, 2018	March 20, 2024
0509T	Electroretinography (ERG) with interpretation and report, pattern (PERG)	Investigational: Covered without PA for Tufts Health One Care	December 1, 2023	June 20, 2024
0510T	Removal of sinus tarsi implant	Investigational	January 1, 2019	November 21, 2024
0511T	Removal and reinsertion of sinus tarsi implant	Investigational	January 1, 2019	November 21, 2024
0512T	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care, initial wound	Investigational	January 1, 2019	March 20, 2024
0513T	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)	Investigational	January 1, 2019	March 20, 2024
0515T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode	Investigational	January 1, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	and generator (transmitter and battery))			
0516T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only	Investigational	January 1, 2019	November 21, 2024
0517T	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; pulse generator component(s) (battery and/or transmitter) only	Investigational	January 1, 2019	November 21, 2024
0518T	Removal of only pulse generator component(s) (battery and/or transmitter) of wireless cardiac stimulator for left ventricular pacing	Investigational	January 1, 2019	November 21, 2024
0519T	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter)	Investigational	January 1, 2019	November 21, 2024
0520T	Removal and replacement of wireless cardiac stimulator for left ventricular pacing; pulse generator component(s) (battery and/or transmitter), including placement of a new electrode	Investigational	January 1, 2019	November 21, 2024
0521T	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing	Investigational	January 1, 2019	November 21, 2024
0522T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing	Investigational	January 1, 2019	November 21, 2024
0523T	Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)	Investigational	January 1, 2019	November 21, 2024
0524T	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	Investigational	January 1, 2019	October 17, 2024
0525T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational	January 1, 2019	November 21, 2024
0526T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead	Investigational	January 1, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	and monitor, initial system programming, and imaging supervision and interpretation; electrode only			
0527T	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	Investigational	January 1, 2019	November 21, 2024
0528T	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	Investigational	January 1, 2019	November 21, 2024
0529T	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	Investigational	January 1, 2019	November 21, 2024
0530T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, complete system (electrode and implantable monitor)	Investigational	January 1, 2019	November 21, 2024
0531T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, electrode only	Investigational	January 1, 2019	November 21, 2024
0532T	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation, implantable monitor only	Investigational	January 1, 2019	November 21, 2024
0541T	Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study;	Investigational	January 1, 2019	November 21, 2024
0542T	Myocardial imaging by magnetocardiography (MCG) for	Investigational	January 1, 2019	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report			
0543T	Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae	Investigational	July 1, 2019	November 21, 2024
0544T	Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture	Investigational	July 1, 2019	November 21, 2024
0545T	Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach	Investigational	July 1, 2019	November 21, 2024
0546T	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report	Investigational	July 1, 2019	June 20, 2024
0547T	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score	Investigational	July 1, 2019	June 20, 2024
0552T	Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional	Investigational	July 1, 2019	October 17, 2024
0554T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report	Investigational	July 1, 2019	June 20, 2024
0555T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data	Investigational	July 1, 2019	June 20, 2024
0556T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density	Investigational	July 1, 2019	June 20, 2024
0557T	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report	Investigational	July 1, 2019	June 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0558T	Computed tomography scan taken for the purpose of biomechanical computed tomography analysis	Investigational	July 1, 2019	June 20, 2024
0559T	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure	Investigational	July 1, 2019	February 21, 2024
0560T	Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)	Investigational	July 1, 2019	February 21, 2024
0561T	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide	Investigational	July 1, 2019	February 21, 2024
0562T	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)	Investigational	July 1, 2019	February 21, 2024
0563T	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral	Investigational	December 18, 2019	March 20, 2024
0565T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation	Investigational	December 18, 2019	November 21, 2024
0566T	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral	Investigational	December 18, 2019	November 21, 2024
0569T	Transcatheter tricuspid valve repair, percutaneous approach, initial prosthesis	Investigational	December 18, 2019	November 21, 2024
0570T	Transcatheter tricuspid valve repair, percutaneous approach, each additional prosthesis during same session (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
0571T	Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed	Investigational	December 18, 2019	November 21, 2024
0572T	Insertion of substernal implantable defibrillator electrode	Investigational	December 18, 2019	November 21, 2024
0573T	Removal of substernal implantable defibrillator electrode	Investigational	December 18, 2019	November 21, 2024
0574T	Repositioning of previously implanted substernal implantable defibrillator-pacing electrode	Investigational	December 18, 2019	November 21, 2024
0575T	Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of	Investigational	December 18, 2019	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional			
0576T	Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter	Investigational	December 18, 2019	November 21, 2024
0577T	Electrophysiological evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)	Investigational	December 18, 2019	November 21, 2024
0578T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional	Investigational	December 18, 2019	November 21, 2024
0579T	Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	Investigational	December 18, 2019	November 21, 2024
0580T	Removal of substernal implantable defibrillator pulse generator only	Investigational	December 18, 2019	November 21, 2024
0582T	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	Investigational	December 18, 2019	April 17, 2024
0583T	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	Investigational	December 18, 2019	February 21, 2024
0587T	Percutaneous implantation or replacement of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational	December 18, 2019	April 17, 2024
0588T	Revision or removal of integrated single device neurostimulation system including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational	December 18, 2019	April 17, 2024
0589T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive	Investigational	December 18, 2019	April 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters			
0590T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	Investigational: Covered without PA for Tufts Health One Care	December 18, 2019	June 20, 2024
0594T	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device	Investigational	July 1, 2020	November 21, 2024
0596T	Temporary female intraurethral valve-pump (ie, voiding prosthesis), initial insertion, including urethral measurement	Investigational	July 1, 2020	April 17, 2024
0597T	Temporary female intraurethral valve-pump (ie, voiding prosthesis), replacement	Investigational	July 1, 2020	April 17, 2024
0598T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)	Investigational	July 1, 2020	March 20, 2024
0599T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session, each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)	Investigational	July 1, 2020	March 20, 2024
0600T	Ablation, irreversible electroporation, 1 or more tumors per organ, including imaging guidance, when performed, percutaneous	Investigational	July 1, 2020	November 21, 2024
0601T	Ablation, irreversible electroporation, 1 or more tumors, including fluoroscopic and ultrasound guidance, when performed, open, (e.g. NanoKnife device)	Investigational	July 1, 2020	November 21, 2024
0602T	Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent	Investigational	July 1, 2020	April 17, 2024
0603T	Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours	Investigational	July 1, 2020	April 17, 2024
0604T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-	Investigational	July 1, 2020	March 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	up and patient education on use of equipment			
0605T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days	Investigational	July 1, 2020	March 20, 2024
0606T	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days	Investigational	July 1, 2020	March 20, 2024
0607T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment	Investigational	July 1, 2020	November 21, 2024
0608T	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional	Investigational	July 1, 2020	November 21, 2024
0609T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar), acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs	Investigational	July 1, 2020	February 21, 2024
0610T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar), transmission of biomarker data for software analysis	Investigational	July 1, 2020	February 21, 2024
0611T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar), postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs	Investigational	July 1, 2020	February 21, 2024
0612T	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar), interpretation and report	Investigational	July 1, 2020	February 21, 2024
0613T	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac	Investigational	July 1, 2020	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	echocardiography, and imaging guidance by the proceduralist, when performed			
0614T	Removal and replacement of substernal implantable defibrillator pulse generator	Investigational	July 1, 2020	November 21, 2024
0615T	Eye-movement analysis without spatial calibration, with interpretation and report	Investigational	July 1, 2020	June 20, 2024
0619T	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed	Investigational	July 1, 2020	April 17, 2024
0620T	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed	Investigational	January 1, 2021	October 17, 2024
0621T	Trabeculostomy ab interno by laser	Investigational	January 1, 2021	March 20, 2024
0622T	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	Investigational	January 1, 2021	March 20, 2024
0623T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational	January 1, 2021	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0624T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission	Investigational	January 1, 2021	November 21, 2024
0625T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography	Investigational	January 1, 2021	November 21, 2024
0626T	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational	January 1, 2021	November 21, 2024
0627T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level	Investigational	January 1, 2021	November 21, 2024
0628T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational	January 1, 2021	November 21, 2024
0629T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	Investigational	January 1, 2021	November 21, 2024
0630T	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational	January 1, 2021	November 21, 2024
0631T	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	Investigational	January 1, 2021	March 20, 2024
0632T	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational	January 1, 2021	November 21, 2024
0633T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	Investigational	January 1, 2021	November 21, 2024
0634T	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	Investigational	January 1, 2021	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0635T	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)	Investigational	January 1, 2021	February 21, 2024
0636T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)	Investigational	January 1, 2021	February 21, 2024
0637T	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)	Investigational	January 1, 2021	February 21, 2024
0638T	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)	Investigational	January 1, 2021	February 21, 2024
0639T	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed	Investigational	January 1, 2021	June 20, 2024
0640T	Noncontact near-infrared spectroscopy studies of flap or wound (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation [StO2]); image acquisition, interpretation and report, each flap or wound	Investigational	July 1, 2021	March 20, 2024
0643T	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach	Investigational	July 1, 2021	November 21, 2024
0644T	Transcatheter removal or debulking of intracardiac mass (eg, vegetations, thrombus) via suction (eg, vacuum, aspiration) device, percutaneous approach, with intraoperative reinfusion of aspirated blood, including imaging guidance, when performed	Investigational	July 1, 2021	November 21, 2024
0646T	Transcatheter tricuspid valve implantation/replacement (TTVI) with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	Investigational	July 1, 2021	November 21, 2024
0647T	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	Investigational	July 1, 2021	August 30, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0651T	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report	Investigational	July 1, 2021	August 30, 2024
0652T	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Investigational	July 1, 2021	August 30, 2024
0653T	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple	Investigational	July 1, 2021	August 30, 2024
0654T	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter	Investigational	July 1, 2021	August 30, 2024
0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging	Investigational	July 1, 2021	April 17, 2024
0658T	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score	Investigational	July 1, 2021	October 17, 2024
0659T	Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation	Investigational	July 1, 2021	November 21, 2024
0664T	Donor hysterectomy (including cold preservation); open, from cadaver donor	Investigational	July 1, 2021	November 21, 2024
0665T	Donor hysterectomy (including cold preservation); open, from living donor	Investigational	July 1, 2021	November 21, 2024
0666T	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor	Investigational	July 1, 2021	November 21, 2024
0667T	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor	Investigational	July 1, 2021	November 21, 2024
0668T	Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary	Investigational	July 1, 2021	November 21, 2024
0669T	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each	Investigational	July 1, 2021	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0670T	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each	Investigational	July 1, 2021	August 30, 2024
0671T	Insertion of anterior segment aqueous drainage device into the trabecular meshwork, without external reservoir, and without concomitant cataract removal, one or more	Investigational: Covered without PA for Tufts Health One Care	January 1, 2022	June 20, 2024
0672T	Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence	Investigational	January 1, 2022	October 17, 2024
0673T	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance (EchoLaser & generic service)	Investigational	January 1, 2022	June 20, 2024
0674T	Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s) (VisONE® Synchronized Diaphragmatic Stimulation™ (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0675T	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead (VisONE® Synchronized Diaphragmatic Stimulation™ (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0676T	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure) (VisONE® Synchronized Diaphragmatic Stimulation™ (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0677T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead (VisONE® Synchronized Diaphragmatic Stimulation™ (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0678T	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure) (VisONE® Synchronized Diaphragmatic Stimulation™ (SDS®) System)	Investigational	January 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0679T	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0680T	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s) (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0681T	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0682T	Removal of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0683T	Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0684T	Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0685T	Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function (VisONE® Synchronized Diaphragmatic StimulationTM (SDS®) System)	Investigational	January 1, 2022	November 21, 2024
0686T	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of	Investigational	January 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	malignant hepatocellular tissue, including image guidance (HistoSonics)			
0687T	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session	Investigational	January 1, 2022	March 20, 2024
0688T	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month	Investigational	January 1, 2022	March 20, 2024
0689T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)	Investigational	January 1, 2022	February 21, 2024
0690T	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	February 21, 2024
0691T	Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report (Unnamed Zebra Medical/Nanox product)	Investigational	January 1, 2022	February 21, 2024
0692T	Therapeutic ultrafiltration	Investigational	January 1, 2022	October 17, 2024
0693T	Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report (DARI motion procedure)	Investigational	January 1, 2022	October 17, 2024
0694T	3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative	Investigational	January 1, 2022	March 20, 2024
0695T	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement	Investigational	January 1, 2022	November 21, 2024
0696T	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation	Investigational	January 1, 2022	November 21, 2024
0697T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland,	Investigational	January 1, 2022	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	tissue, target structure) during the same session; multiple organs			
0698T	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	February 21, 2024
0699T	Injection, posterior chamber of eye, medication	Investigational	January 1, 2022	March 20, 2024
0700T	Molecular fluorescent imaging of suspicious nevus; first lesion	Investigational	January 1, 2022	October 17, 2024
0701T	Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	October 17, 2024
0704T	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment	Investigational	January 1, 2022	March 20, 2024
0705T	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days	Investigational	January 1, 2022	March 20, 2024
0706T	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month	Investigational	January 1, 2022	March 20, 2024
0707T	Injection(s), bone-substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization	Investigational	January 1, 2022	November 21, 2024
0708T	Intradermal cancer immunotherapy; preparation and initial injection	Investigational	January 1, 2022	November 21, 2024
0709T	Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	November 21, 2024
0710T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report	Investigational	January 1, 2022	October 17, 2024
0711T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission	Investigational	January 1, 2022	October 17, 2024
0712T	Noninvasive arterial plaque analysis using software processing of data from	Investigational	January 1, 2022	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability			
0713T	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report	Investigational	January 1, 2022	October 17, 2024
0714T	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50 mL	Investigational	July 1, 2022	July 1, 2024
0716T	Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score	Investigational	July 1, 2022	November 21, 2024
0717T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs	Investigational	July 1, 2022	November 21, 2024
0718T	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral	Investigational	July 1, 2022	November 21, 2024
0719T	Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment	Investigational	July 1, 2022	November 21, 2024
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation	Investigational	July 1, 2022	October 17, 2024
0723T	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session	Investigational	November 21, 2024	November 21, 2024
0724T	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	Investigational	November 21, 2024	November 21, 2024
0725T	Vestibular device implantation, unilateral	Investigational	July 1, 2022	February 21, 2024
0726T	Removal of implanted vestibular device, unilateral	Investigational	July 1, 2022	February 21, 2024

0727T	Removal and replacement of implanted vestibular device, unilateral	Investigational	July 1, 2022	February 21, 2024
0728T	Diagnostic analysis of vestibular implant, unilateral; with initial programming	Investigational	July 1, 2022	February 21, 2024
0729T	Diagnostic analysis of vestibular implant, unilateral; with subsequent programming	Investigational	July 1, 2022	February 21, 2024
0730T	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance	Investigational	July 1, 2022	March 20, 2024
0731T	Augmentative AI-based facial phenotype analysis with report	Investigational	July 1, 2022	March 20, 2024
0732T	Immunotherapy administration with electroporation, intramuscular	Investigational	July 1, 2022	May 15, 2024
0733T	Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional;	Investigational	July 1, 2022	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	supply and technical support, per 30 days			
0734T	Remote real-time, motion capture-based neurorehabilitative therapy ordered by a physician or other qualified health care professional; treatment management services by a physician or other qualified health care professional, per calendar month	Investigational	July 1, 2022	October 17, 2024
0735T	Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)	Investigational	July 1, 2022	November 21, 2024
0736T	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter	Investigational	July 1, 2022	August 30, 2024
0737T	Xenograft implantation into the articular surface	Investigational	July 1, 2022	November 21, 2024
0738T	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination	Investigational	January 1, 2023	August 30, 2024
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation	Investigational	January 1, 2023	August 30, 2024
0740T	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education	Investigational	January 1, 2023	June 20, 2024
0741T	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; provision of software, data collection, transmission, and storage, each 30 days	Investigational	January 1, 2023	June 20, 2024
0742T	Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	November 21, 2024
0743T	Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report	Investigational	January 1, 2023	February 21, 2024
0744T	Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when	Investigational	January 1, 2023	February 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed			
0745T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance	Investigational	January 1, 2023	November 21, 2024
0746T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan	Investigational	January 1, 2023	November 21, 2024
0747T	Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia	Investigational	January 1, 2023	November 21, 2024
0748T	Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)	Investigational	January 1, 2023	June 20, 2024
0749T	Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report;	Investigational	January 1, 2023	February 21, 2024
0750T	Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD	Investigational	January 1, 2023	February 21, 2024
0751T	Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0752T	Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0753T	Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0754T	Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List	Investigational	January 1, 2023	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	separately in addition to code for primary procedure)			
0755T	Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0756T	Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0757T	Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0758T	Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0759T	Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0760T	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0761T	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0762T	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	November 21, 2024
0763T	Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	November 21, 2024
0764T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy): related to concurrently performed	Investigational	January 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	electrocardiogram (List separately in addition to code for primary procedure)			
0765T	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram	Investigational	January 1, 2023	November 21, 2024
0766T	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve	Investigational	January 1, 2023	June 20, 2024
0767T	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, initial treatment, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	June 20, 2024
0770T	Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	October 17, 2024
0771T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older	Investigational	January 1, 2023	October 17, 2024
0772T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing	Investigational	January 1, 2023	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)			
0773T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older	Investigational	January 1, 2023	October 17, 2024
0774T	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	Investigational	January 1, 2023	October 17, 2024
0776T	Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment	Investigational	January 1, 2023	June 20, 2024
0777T	Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	November 21, 2024
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function	Investigational	January 1, 2023	October 17, 2024
0779T	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report	Investigational	January 1, 2023	August 30, 2024
0780T	Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract	Investigational	January 1, 2023	August 30, 2024
0781T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi	Investigational	January 1, 2023	October 17, 2024
0782T	Bronchoscopy, rigid or flexible, with insertion of esophageal protection	Investigational	January 1, 2023	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus			
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment	Investigational	January 1, 2023	October 17, 2024
0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed	Investigational	January 1, 2024	June 20, 2024
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator	Investigational	January 1, 2024	June 20, 2024
0786T	Insertion or replacement of percutaneous electrode array, sacral, with integrated neurostimulator, including imaging guidance, when performed	Investigational	January 1, 2024	June 20, 2024
0787T	Revision or removal of neurostimulator electrode array, sacral, with integrated neurostimulator	Investigational	January 1, 2024	June 20, 2024
0788T	Electronic analysis with simple programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 1-3 parameters	Investigational	January 1, 2024	June 20, 2024
0789T	Electronic analysis with complex programming of implanted integrated neurostimulation system (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, spinal cord or sacral nerve, 4 or more parameters	Investigational	January 1, 2024	June 20, 2024
0790T	Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed	Investigational	January 1, 2024	June 20, 2024
0791T	Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)	Investigational	July 1, 2023	October 17, 2024

0792T	Application of silver diamine fluoride 38%, by a physician or other qualified health care professional	Investigational	July 1, 2023	June 20, 2024
0793T	Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational	July 1, 2023	June 20, 2024
0794T	Patient-specific, assistive, rules-based algorithm for ranking pharmacologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately	Investigational	July 1, 2023	November 21, 2024
0795T	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; complete system (ie, right atrial and right ventricular pacemaker components)	Investigational	July 1, 2023	November 21, 2024
0796T	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)	Investigational	July 1, 2023	November 21, 2024
0797T	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational	July 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0798T	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (ie, right atrial and right ventricular pacemaker components)	Investigational	July 1, 2023	November 21, 2024
0799T	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component	Investigational	July 1, 2023	November 21, 2024
0800T	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational	July 1, 2023	November 21, 2024
0801T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; dual-chamber system (ie, right atrial and right ventricular pacemaker components)	Investigational	July 1, 2023	November 21, 2024
0802T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right atrial pacemaker component	Investigational	July 1, 2023	November 21, 2024
0803T	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational	July 1, 2023	November 21, 2024
0804T	Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care	Investigational	July 1, 2023	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	professional, leadless pacemaker system in dual cardiac chambers			
0805T	Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); percutaneous femoral vein approach	Investigational	July 1, 2023	November 21, 2024
0806T	Transcatheter superior and inferior vena cava prosthetic valve implantation (ie, caval valve implantation [CAVI]); open femoral vein approach	Investigational	July 1, 2023	November 21, 2024
0807T	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	Investigational	July 1, 2023	October 17, 2024
0808T	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	Investigational	July 1, 2023	October 17, 2024
0810T	Subretinal injection of a pharmacologic agent, including vitrectomy and 1 or more retinotomies	Investigational	July 1, 2023	March 20, 2024
0811T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); set-up and patient education on use of equipment	Investigational	January 1, 2024	June 20, 2024
0812T	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days	Investigational	January 1, 2024	June 20, 2024
0813T	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon	Investigational	January 1, 2024	August 30, 2024
0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral	Investigational	January 1, 2024	February 21, 2024
0815T	Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine	Investigational	January 1, 2024	February 21, 2024
0816T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subcutaneous	Investigational	January 1, 2024	June 20, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0817T	Open insertion or replacement of integrated neurostimulation system for bladder dysfunction including electrode(s) (eg, array or leadless), and pulse generator or receiver, including analysis, programming, and imaging guidance, when performed, posterior tibial nerve; subfascial	Investigational	January 1, 2024	June 20, 2024
0818T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subcutaneous	Investigational	January 1, 2024	June 20, 2024
0819T	Revision or removal of integrated neurostimulation system for bladder dysfunction, including analysis, programming, and imaging, when performed, posterior tibial nerve; subfascial	Investigational	January 1, 2024	June 20, 2024
0820T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour	Investigational	January 1, 2024	September 19, 2024
0821T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	September 19, 2024
0822T	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	September 19, 2024
0823T	Transcatheter insertion of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation (eg, interrogation or programming), when performed	Investigational	January 1, 2024	November 21, 2024
0824T	Transcatheter removal of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography), when performed	Investigational	January 1, 2024	November 21, 2024
0825T	Transcatheter removal and replacement of permanent single-chamber leadless pacemaker, right atrial, including imaging guidance (eg, fluoroscopy, venous ultrasound, right atrial angiography and/or right ventriculography, femoral venography, cavography) and device evaluation	Investigational	January 1, 2024	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	(eg, interrogation or programming), when performed			
0826T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, leadless pacemaker system in single-cardiac chamber	Investigational	January 1, 2024	November 21, 2024
0827T	Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0828T	Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0829T	Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0830T	Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0831T	Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0832T	Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0833T	Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0834T	Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0835T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0836T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine	Investigational	January 1, 2024	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure)			
0837T	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0838T	Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0839T	Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0840T	Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0841T	Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0842T	Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0843T	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0844T	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0845T	Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0846T	Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0847T	Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0848T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0849T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0850T	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0851T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0852T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0853T	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0854T	Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0855T	Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0856T	Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	October 17, 2024
0857T	Opto-acoustic imaging, breast, unilateral, including axilla when performed, real-time with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	February 21, 2024
0858T	Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report	Investigational	January 1, 2024	June 20, 2024
0859T	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0860T	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities	Investigational	January 1, 2024	February 21, 2024
0861T	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)	Investigational	January 1, 2024	November 21, 2024
0862T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only	Investigational	January 1, 2024	November 21, 2024
0863T	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only	Investigational	January 1, 2024	November 21, 2024
0864T	Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy	Investigational	January 1, 2024	October 17, 2024
0865T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session	Investigational	January 1, 2024	February 21, 2024
0866T	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	February 21, 2024
0867T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL	Investigational	July 1, 2024	July 1, 2024
0868T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report	Investigational	July 1, 2024	August 30, 2024
0869T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Injection(s), bone-substitute material for bone and/or soft tissue hardware fixation augmentation, including intraoperative imaging guidance, when performed	Investigational	July 1, 2024	July 1, 2024
0870T*Authorization review for THPPs is managed by Carelon Medical Benefits	Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled	Investigational	July 1, 2024	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Management	indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed			
0871T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed	Investigational	July 1, 2024	August 30, 2024
0872T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed	Investigational	July 1, 2024	August 30, 2024
0873T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed	Investigational	July 1, 2024	August 30, 2024
0874T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters	Investigational	July 1, 2024	August 30, 2024
0875T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional	Investigational	July 1, 2024	August 30, 2024
0876T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)	Investigational	July 1, 2024	July 1, 2024
0877T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging	Investigational	July 1, 2024	July 1, 2024
0878T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure	Investigational	July 1, 2024	July 1, 2024
0879T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission	Investigational	July 1, 2024	July 1, 2024
0880T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report	Investigational	July 1, 2024	July 1, 2024
0881T *Authorization review for THPPs is managed by Carelon Medical	Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance	Investigational	July 1, 2024	July 1, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Benefits Management	to treatment, and removal of the oral device			
0882T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)	Investigational	July 1, 2024	July 1, 2024
0883T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)	Investigational	July 1, 2024	July 1, 2024
0884T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed		July 1, 2024	August 30, 2024
0885T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Colonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed	Investigational	July 1, 2024	August 30, 2024
0886T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed	Investigational	July 1, 2024	August 30, 2024
0887T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)	Investigational	July 1, 2024	July 1, 2024
0888T*Authorization review for THPPs is managed by Carelon Medical Benefits Management	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance	Investigational	July 1, 2024	November 21, 2024
0889T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation	Investigational	July 1, 2024	July 1, 2024
0890T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day	Investigational	July 1, 2024	July 1, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0891T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day	Investigational	July 1, 2024	July 1, 2024
0892T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day	Investigational	July 1, 2024	July 1, 2024
0893T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report	Investigational	July 1, 2024	July 1, 2024
0894T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion	Investigational	July 1, 2024	July 1, 2024
0895T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)	Investigational	July 1, 2024	July 1, 2024
0896T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)	Investigational	July 1, 2024	July 1, 2024
0897T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report	Investigational	July 1, 2024	November 21, 2024
0898T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report	Investigational	July 1, 2024	November 21, 2024
0899T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Noninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by	Investigational	July 1, 2024	November 21, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	a physician or other qualified health care professional (List separately in addition to code for primary procedure)			
0900T *Authorization review for THPPs is managed by Carelon Medical Benefits Management	Noninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)	Investigational	July 1, 2024	November 21, 2024
0901T	Placement of bone marrow sampling port, including imaging guidance when performed	Investigational	January 1, 2025	January 1, 2025
0902T	QTc interval derived by augmentative algorithmic analysis of input from an external, patient-activated mobile ECG device	Investigational	January 1, 2025	January 1, 2025
0903T	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; with interpretation and report	Investigational	January 1, 2025	January 1, 2025
0904T	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; tracing only	Investigational	January 1, 2025	January 1, 2025
0905T	Electrocardiogram, algorithmically generated 12-lead ECG from a reduced-lead ECG; interpretation and report only	Investigational	January 1, 2025	January 1, 2025
0906T	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; first application, total wound(s) surface area less than or equal to 50 sq cm	Investigational	January 1, 2025	January 1, 2025
0907T	Concurrent optical and magnetic stimulation (COMS) therapy, wound assessment and dressing care; each additional application, total wound(s) surface area less than or equal to 50 sq cm (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
0908T	Open implantation of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed	Investigational	January 1, 2025	January 1, 2025
0909T	Replacement of integrated neurostimulation system, vagus nerve, including analysis and programming, when performed	Investigational	January 1, 2025	January 1, 2025
0910T	Removal of integrated neurostimulation system, vagus nerve	Investigational	January 1, 2025	January 1, 2025
0911T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; without programming by physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0912T	Electronic analysis of implanted integrated neurostimulation system, vagus nerve; with simple programming by physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0913T	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting), including mechanical dilation by	Investigational	January 1, 2025	January 1, 2025

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch			
0914T	Percutaneous transcatheter therapeutic drug delivery by intracoronary drug-delivery balloon (eg, drug-coated, drug-eluting) performed on a separate target lesion from the target lesion treated with balloon angioplasty, coronary stent placement or coronary atherectomy, including mechanical dilation by nondrug-delivery balloon angioplasty, endoluminal imaging using intravascular ultrasound (IVUS) or optical coherence tomography (OCT) when performed, imaging supervision, interpretation, and report, single major coronary artery or branch (List separately in addition to code for percutaneous coronary stent or atherectomy intervention)	Investigational	January 1, 2025	January 1, 2025
0915T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator and dual transvenous electrodes/leads (pacing and defibrillation)	Investigational	January 1, 2025	January 1, 2025
0916T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; pulse generator only	Investigational	January 1, 2025	January 1, 2025
0917T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; single transvenous lead (pacing or defibrillation) only	Investigational	January 1, 2025	January 1, 2025
0918T	Insertion of permanent cardiac contractility modulation-defibrillation system component(s), including fluoroscopic guidance, and evaluation and programming of sensing and therapeutic parameters; dual transvenous leads (pacing and defibrillation) only	Investigational	January 1, 2025	January 1, 2025
0919T	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); pulse generator only	Investigational	January 1, 2025	January 1, 2025
0920T	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous pacing lead only	Investigational	January 1, 2025	January 1, 2025
0921T	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); single transvenous defibrillation lead only	Investigational	January 1, 2025	January 1, 2025

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0922T	Removal of a permanent cardiac contractility modulation-defibrillation system component(s); dual (pacing and defibrillation) transvenous leads only	Investigational	January 1, 2025	January 1, 2025
0923T	Removal and replacement of permanent cardiac contractility modulation-defibrillation pulse generator only	Investigational	January 1, 2025	January 1, 2025
0924T	Repositioning of previously implanted cardiac contractility modulation-defibrillation transvenous electrode(s)/lead(s), including fluoroscopic guidance and programming of sensing and therapeutic parameters	Investigational	January 1, 2025	January 1, 2025
0925T	Relocation of skin pocket for implanted cardiac contractility modulation-defibrillation pulse generator	Investigational	January 1, 2025	January 1, 2025
0926T	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, implantable cardiac contractility modulation-defibrillation system	Investigational	January 1, 2025	January 1, 2025
0927T	Interrogation device evaluation (in person) with analysis, review, and report, including connection, recording, and disconnection, per patient encounter, implantable cardiac contractility modulation-defibrillation system	Investigational	January 1, 2025	January 1, 2025
0928T	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system with interim analysis and report(s) by a physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0929T	Interrogation device evaluation (remote), up to 90 days, cardiac contractility modulation-defibrillation system, remote data acquisition(s), receipt of transmissions, technician review, technical support, and distribution of results	Investigational	January 1, 2025	January 1, 2025
0930T	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), at time of initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator	Investigational	January 1, 2025	January 1, 2025
0931T	Electrophysiologic evaluation of cardiac contractility modulation-defibrillator leads, including defibrillation-threshold evaluation (induction of arrhythmia, evaluation of sensing and therapy for arrhythmia termination), separate from initial implantation or replacement with testing of cardiac contractility modulation-defibrillator pulse generator	Investigational	January 1, 2025	January 1, 2025

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0932T	Noninvasive detection of heart failure derived from augmentative analysis of an echocardiogram that demonstrated preserved ejection fraction, with interpretation and report by a physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0933T	Transcatheter implantation of wireless left atrial pressure sensor for long-term left atrial pressure monitoring, including sensor calibration and deployment, right heart catheterization, transeptal puncture, imaging guidance, and radiological supervision and interpretation	Investigational	January 1, 2025	January 1, 2025
0934T	Remote monitoring of a wireless left atrial pressure sensor for up to 30 days, including data from daily uploads of left atrial pressure recordings, interpretation(s) and trend analysis, with adjustments to the diuretics plan, treatment paradigm thresholds, medications or lifestyle modifications, when performed, and report(s) by a physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0935T	Cystourethroscopy with renal pelvic sympathetic denervation, radiofrequency ablation, retrograde ureteral approach, including insertion of guide wire, selective placement of ureteral sheath(s) and multiple conformable electrodes, contrast injection(s), and fluoroscopy, bilateral	Investigational	January 1, 2025	January 1, 2025
0936T	Photobiomodulation therapy of retina, single session	Investigational	January 1, 2025	January 1, 2025
0937T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; including recording, scanning analysis with report, review and interpretation by a physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0938T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; recording (including connection and initial recording)	Investigational	January 1, 2025	January 1, 2025
0939T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; scanning analysis with report	Investigational	January 1, 2025	January 1, 2025
0940T	External electrocardiographic recording for greater than 15 days up to 30 days by continuous rhythm recording and storage; review and interpretation by a physician or other qualified health care professional	Investigational	January 1, 2025	January 1, 2025
0941T	Cystourethroscopy, flexible; with insertion and expansion of prostatic urethral scaffold using integrated cystoscopic visualization	Investigational	January 1, 2025	January 1, 2025
0942T	Cystourethroscopy, flexible; with removal and replacement of prostatic urethral scaffold	Investigational	January 1, 2025	January 1, 2025

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
0943T	Cystourethroscopy, flexible; with removal of prostatic urethral scaffold	Investigational	January 1, 2025	January 1, 2025
0944T	3D contour simulation of target liver lesion(s) and margin(s) for image-guided percutaneous microwave ablation	Investigational	January 1, 2025	January 1, 2025
0945T	Intraoperative assessment for abnormal (tumor) tissue, in-vivo, following partial mastectomy (eg, lumpectomy) using computer-aided fluorescence imaging (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
0946T	Orthopedic implant movement analysis using paired computed tomography (CT) examination of the target structure, including data acquisition, data preparation and transmission, interpretation and report (including CT scan of the joint or extremity performed with paired views)	Investigational	January 1, 2025	January 1, 2025
0947T	Magnetic resonance image guided low intensity focused ultrasound (MRgFUS), stereotactic blood-brain barrier disruption using microbubble resonators to increase the concentration of blood-based biomarkers of target, intracranial, including stereotactic navigation and frame placement, when performed	Investigational	January 1, 2025	January 1, 2025
10040	Acne surgery (e.g., marsupialization, opening or removal of multiple milia, comedones, cysts, pustules)	Investigational	January 1, 2007	March 20, 2024
20560	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	Investigational	December 18, 2019	October 17, 2024
20561	Needle insertion(s) without injection(s); 3 or more muscles	Investigational	December 18, 2019	October 17, 2024
20985	Computer-assisted surgical navigational procedure for musculoskeletal procedures; image-less ( MAKO Surgical Corp® (Stryker), RIO® Robotic Arm)	Investigational	January 1, 2006	November 21, 2024
22505	Manipulation of spine requiring anesthesia, any region	Investigational	November 20, 2006	November 21, 2024
22526	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level (IDET)	Investigational	April 25, 2007	November 21, 2024
22527	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; one or more additional levels (IDET)	Investigational	April 25, 2007	November 21, 2024
22586	Arthrodesis, pre-sacral interbody	Investigational	August 1, 2015	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	technique, including disc space preparation, discectomy, with posterior instrumentation, with image guidance, includes bone graft when performed, L5-S1 interspace			
22860	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression); second interspace, lumbar (List separately in addition to code for primary procedure)	Investigational	January 1, 2023	November 21, 2024
22867	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level	Investigational	February 17, 2017	November 21, 2024
22868	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)	Investigational	February 17, 2017	November 21, 2024
22869	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	Investigational	February 17, 2017	November 21, 2024
22870	Insertion of interlaminar/ interspinous process stabilization/ distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)	Investigational	February 17, 2017	November 21, 2024
0259U	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myo-inositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative (GFR by NMR, Labtech™ Diagnostics)	Investigational	October 1, 2021	December 18, 2024
27278	Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device	Investigational	January 1, 2024	November 21, 2024
27280	Arthrodesis, open, sacroiliac joint, include obtaining bone graft, including instrumentation, when performed	Considered investigational for treatment of low back pain and SI joint pain/inflammation	November 25, 2013	November 21, 2024
28035	Release, tarsal tunnel (posterior tibial nerve decompressi	Investigational when billed with at least two of these additional CPT codes: 64704, 64708, 64712, 64722	October 1, 2009	November 21, 2024
28446	Open Osteochondral Autograft, talus (includes obtaining graft[s])	Investigational	January 1, 2019	November 21, 2024

28890	Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia	Investigational	February 28, 2007	November 21, 2024
30468	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)	Investigational	January 1, 2021	February 21, 2024
30469	Repair of nasal valve collapse with low energy, temperature-controlled (ie,	Investigational	January 1, 2023	February 21, 2024
31242	Nasal/sinus endoscopy, surgical; with destruction by radiofrequency ablation, posterior nasal nerve	Investigational	January 1, 2024	February 21, 2024
31243	Nasal/sinus endoscopy, surgical; with destruction by cryoablation, posterior nasal nerve	Investigational	January 1, 2024	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	radiofrequency) subcutaneous/submucosal remodeling			
32994	Ablation therapy for reduction or eradication of 1 or more pulmonary tumor(s) including pleura or chest wall when involved by tumor extension, percutaneous, including imaging guidance when performed, unilateral; cryoablation	Investigational	January 1, 2018	August 30, 2024
33267	Exclusion of left atrial appendage, open, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip)	Investigational	January 1, 2022	November 21, 2024
33268	Exclusion of left atrial appendage, open, performed at the time of other sternotomy or thoracotomy procedure(s), any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip) (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	November 21, 2024
33269	Exclusion of left atrial appendage, thoracoscopic, any method (eg, excision, isolation via stapling, oversewing, ligation, plication, clip)	Investigational	January 1, 2022	November 21, 2024
33274	Transcatheter insertion or replacement of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography) and device evaluation (eg, interrogation or programming), when performed	Investigational	January 1, 2019	November 21, 2024
33275	Transcatheter removal of permanent leadless pacemaker, right ventricular	Investigational	January 1, 2019	November 21, 2024
33276	Insertion of phrenic nerve stimulator system (pulse generator and stimulating lead[s]), including vessel catheterization, all imaging guidance, and pulse generator initial analysis with diagnostic mode activation, when performed	Investigational	January 1, 2024	June 20, 2024
33277	Insertion of phrenic nerve stimulator transvenous sensing lead (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	June 20, 2024
33278	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; system, including pulse generator and lead(s)	Investigational	January 1, 2024	June 20, 2024
33279	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s) only	Investigational	January 1, 2024	June 20, 2024
33280	Removal of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; pulse generator only	Investigational	January 1, 2024	June 20, 2024
33281	Repositioning of phrenic nerve stimulator transvenous lead(s)	Investigational	January 1, 2024	June 20, 2024
33287	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and	Investigational	January 1, 2024	June 20, 2024



	programming, when performed; pulse generator			
33288	Removal and replacement of phrenic nerve stimulator, including vessel catheterization, all imaging guidance, and interrogation and programming, when performed; transvenous stimulation or sensing lead(s)	Investigational	January 1, 2024	June 20, 2024
33370	Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure)	Investigational	January 1, 2022	June 20, 2024
33548	Surgical ventricular restoration procedure, includes prosthetic patch, when performed (e.g., ventricular remodeling, SVR, SAVER, Dor procedures)	Investigational	November 20, 2006	November 21, 2024
34717	Endovascular repair of iliac artery at the time of aorto-iliac artery endograft placement by deployment of an iliac branched endograft including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal	Investigational	December 18, 2019	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for rupture or other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer, traumatic disruption), unilateral (List separately in addition to code for primary procedure)			
34718	Endovascular repair of iliac artery, not associated with placement of an aorto-iliac artery endograft at the same session, by deployment of an iliac branched endograft, including pre-procedure sizing and device selection, all ipsilateral selective iliac artery catheterization(s), all associated radiological supervision and interpretation, and all endograft extension(s) proximally to the aortic bifurcation and distally in the internal iliac, external iliac, and common femoral artery(ies), and treatment zone angioplasty/stenting, when performed, for other than rupture (eg, for aneurysm, pseudoaneurysm, dissection, arteriovenous malformation, penetrating ulcer), unilateral	Investigational	December 18, 2019	October 17, 2024
37241	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles){e.g., Percutaneous Transcatheter Coil Embolization for Pelvic Congestion Syndrome}	Investigational when billed with the following <b>ICD-10 diagnosis code(s)</b> : N83.9, N83.8, N94.19, N94.10, N94.9, N94.89, I86.2, R10.2	April 1, 2018	August 30, 2024
37252	Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation; initial noncoronary vessel (List separately in addition to code for primary procedure)	Investigational	January 1, 2016	February 21, 2024
37253	Intravascular ultrasound (noncoronary vessel) during diagnostic evaluation and/or therapeutic intervention,	Investigational	January 1, 2016	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	including radiological supervision and interpretation; each additional noncoronary vessel (List separately in addition to code for primary procedure)			
37790	Penile venous occlusive procedure	Investigational	November 20, 2006	April 17, 2024
41512	Tongue base suspension, permanent suture technique	Investigational: Covered without PA for Tufts Health One Care	October 1, 2014	June 20, 2024
41530	Submucosal ablation of the tongue base, radiofrequency, one or more sites, per session	Investigational	January 1, 2006	August 30, 2024
43206	Esophagoscopy, rigid or flexible, with optical endomicroscopy	Investigational	January 1, 2013	August 30, 2024
43210	Esophagogastroduodenoscopy, flexible, transoral; with esophagogastric fundoplasty, partial or complete, includes duodenoscopy when performed	Investigational	January 1, 2016	August 30, 2024
43236	Esophagogastroduodenoscopy, flexible, transoral; with directed submucosal injection(s), any substance	Investigational	January 1, 2024	January 1, 2024
43252	Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate, with optical endomicroscopy	Investigational	January 1, 2013	August 30, 2024
43257	Upper Gastrointestinal Endoscopy with delivery of thermal energy to the muscle of lower esophageal sphincter and/or gastric cardia, for treatment of gastroesophageal reflux disease, (e.g., Stretta procedure, the Bard® EndoCinch™ Suturing System, Plicator™ and Enteryx™ )	Investigational	November 20, 2006	August 30, 2024
43284	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed, (e.g., Linx Reflux Management System)	Investigational	January 1, 2017	August 30, 2024
43285	Removal of esophageal sphincter augmentation device, (e.g., Linx Reflux Management System)	Investigational	January 1, 2017	August 30, 2024
43648	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum	Investigational	January 1, 2007	August 30, 2024
44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen	Investigational <b>EXCEPT</b> when billed with any of the following <b>ICD-10 diagnosis code(s):</b> A04.71, A04.72	January 1, 2013	August 30, 2024
51721	Insertion of transurethral ablation transducer for delivery of thermal ultrasound for prostate tissue ablation, including suprapubic tube placement during the same session and placement of an endorectal cooling device, when performed	Investigational	January 1, 2025	January 1, 2025

52284	Cystourethroscopy, with mechanical urethral dilation and urethral therapeutic drug delivery by drug-coated balloon catheter for urethral stricture or stenosis, male, including fluoroscopy, when performed	Investigational	January 1, 2024	January 1, 2024
53451	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance (ProAct (Uromedica))	Investigational	January 1, 2022	April 17, 2024
53452	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance (ProAct (Uromedica))	Investigational	January 1, 2022	April 17, 2024
53453	Periurethral transperineal adjustable balloon continence device; removal, each balloon (ProAct (Uromedica))	Investigational	January 1, 2022	April 17, 2024
53454	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume (ProAct (Uromedica))	Investigational	January 1, 2022	April 17, 2024
53855	Insertion of a temporary prostatic	Investigational	January 1, 2006	April 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	urethral stent, including urethral measurement			
53860	Transurethral, radiofrequency micro-remodeling of the female bladder neck and proximal urethra for stress urinary incontinence	Investigational	January 1, 2009	April 17, 2024
53865	Cystourethroscopy with insertion of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate	Investigational	January 1, 2025	January 1, 2025
53866	Catheterization with removal of temporary device for ischemic remodeling (ie, pressure necrosis) of bladder neck and prostate	Investigational	January 1, 2025	January 1, 2025
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	Investigational	January 1, 2021	April 17, 2024
55881	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation;	Investigational	January 1, 2025	January 1, 2025
55882	Ablation of prostate tissue, transurethral, using thermal ultrasound, including magnetic resonance imaging guidance for, and monitoring of, tissue ablation; with insertion of transurethral ultrasound transducer for delivery of thermal ultrasound, including suprapubic tube placement and placement of an endorectal cooling device, when performed	Investigational	January 1, 2025	January 1, 2025
60660	Ablation of 1 or more thyroid nodule(s), one lobe or the isthmus, percutaneous, including imaging guidance, radiofrequency	Investigational	January 1, 2025	January 1, 2025
60661	Ablation of 1 or more thyroid nodule(s), additional lobe, percutaneous, including imaging guidance, radiofrequency (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
61630	Balloon angioplasty, intracranial (e.g., atherosclerotic stenosis), percutaneous	Investigational	May 7, 2007	February 21, 2024
61635	Transcatheter placement of intravascular stent(s), intracranial (e.g., atherosclerotic stenosis), including balloon angioplasty, if performed	Investigational	May 7, 2007	June 20, 2024
61640	Balloon dilatation of intracranial vasospasm, percutaneous; initial vessel	Investigational	May 7, 2007	February 21, 2024
61641	Balloon dilatation of intracranial vasospasm, percutaneous; each additional vessel in same vascular family	Investigational	May 7, 2007	February 21, 2024
61642	Balloon dilatation of intracranial vasospasm, percutaneous; each additional vessel in different vascular family	Investigational	May 7, 2007	February 21, 2024
61715	Magnetic resonance image guided high intensity focused ultrasound (MRgFUS), stereotactic ablation of target, intracranial, including stereotactic navigation and frame placement, when performed	Investigational	January 1, 2025	January 1, 2025

61736	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion	Investigational	January 1, 2022	June 20, 2024
61737	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s)	Investigational	January 1, 2022	June 20, 2024
61889	Insertion of skull-mounted cranial neurostimulator pulse generator or receiver, including craniectomy or craniotomy, when performed, with direct or inductive coupling, with connection to depth and/or cortical strip electrode array(s)	Investigational	January 1, 2024	June 20, 2024
61891	Revision or replacement of skull-mounted cranial neurostimulator pulse generator or receiver with connection to depth and/or cortical strip electrode array(s)	Investigational	January 1, 2024	June 20, 2024
61892	Removal of skull-mounted cranial neurostimulator pulse generator or receiver with cranioplasty, when performed	Investigational	January 1, 2024	June 20, 2024
62263	Percutaneous lysis of epidural adhesions using solution injection (e.g., hypertonic saline, enzyme) or mechanical means (e.g., catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	Investigational	July 1, 2008	November 21, 2024
62264	Percutaneous lysis of epidural adhesions using solution injection (e.g., hypertonic saline, enzyme) or mechanical means (e.g., catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	Investigational	July 1, 2008	November 21, 2024
62287	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with the use of an endoscope, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	Investigational	April 25, 2007	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
62290	Injection procedure for discography, each level; lumbar	Investigational	April 1, 2018	November 21, 2024
62291	Injection procedure for discography, each level; cervical or thoracic	Investigational	April 1, 2018	November 21, 2024
64405	Injection(s), anesthetic agent(s) and/or steroid, greater occipital nerve	Investigational when billed with the following <b>ICD-10 diagnosis</b> code(s): G43.701, G43.709, G43.711, G43.719  Investigational: Covered without PA for Tufts Health One Care	April 1, 2020	June 20, 2024
64454	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	Investigational	September 1, 2021	May 1, 2024
64505	Injection, anesthetic agent; sphenopalatine ganglion	Investigational	October 1, 2019	June 20, 2024
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve) (e.g. SPRINT PNS System (SPR Therapeutics) for Chronic Pain)	Investigational	October 1, 2019	October 17, 2024
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array	Investigational	January 1, 2024	November 21, 2024
64597	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; each additional electrode array (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	November 21, 2024
64598	Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator	Investigational	January 1, 2024	November 21, 2024
64624	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	Investigational	December 18, 2019	November 21, 2024
64625	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	Investigational	December 18, 2019	November 21, 2024
64704	Neuroplasty, nerve of hand or foot	Investigational when billed with at least two of these additional codes <b>CPT Code(s):</b> 28035, 64708, 64712, 64722	October 1, 2009	November 21, 2024
64708	Neuroplasty, major peripheral nerve, arm or leg; other than specified	Investigational when billed with at least two of these additional <b>CPT Code(s):</b> 28035, 64704, 64712, 64722	October 1, 2009	November 21, 2024

64712	Neuroplasty, sciatic nerve	Investigational when billed with at least two of these additional <b>CPT Code(s)</b> : 28035, 64704, 64708, 64722	October 1, 2009	November 21, 2024
64722	Decompression; unspecified nerve(s) (specify)	Investigational when billed with at least two of these additional codes: <b>CPT Code(s)</b> : 28035, 64704, 64708, 64712	October 1, 2009	November 21, 2024
65710	Keratoplasty (corneal transplant); lamellar	Investigational	January, 1,2007	March 20, 2024
65760	Keratomileusis	Investigational	April 17, 2019	March 20, 2024
65765	Keratophakia	Investigational	April 17, 2019	March 20, 2024
65771	Radial keratotomy	Investigational	April 17, 2019	March 20, 2024
65785	Implantation of intrastromal corneal ring segments	Investigational	January 1, 2016	March 20, 2024
66174	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); without retention of device or stent	Investigational	January 1, 2008	March 20, 2024
66175	Transluminal dilation of aqueous outflow canal (eg, canaloplasty); with retention of device or stent	Investigational	January 1, 2008	March 20, 2024
66179	Aqueous shunt to extraocular	Investigational	January 1, 2015	March 20, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	equatorial plate reservoir, external approach; without graft			
66184	Revision of aqueous shunt to extraocular equatorial plate reservoir; without graft	Investigational	January 1, 2015	March 20, 2024
66683	Implantation of iris prosthesis, including suture fixation and repair or removal of iris, when performed	Investigational	January 1, 2025	January 1, 2025
67221	Destruction of localized lesion of choroid (e.g., choroidal neovascularization); photodynamic therapy (includes intravenous therapy)	Covered when billed with any of the following <b>ICD-10 diagnosis code(s)</b> : H35.051-H35.059; H35.711-H35.719	April 1, 2010	March 20, 2024
67225	Destruction of localized lesion of choroid (e.g., choroidal neovascularization); photodynamic therapy, second eye, at single session (List separately in addition to code for primary eye treatment)	Covered when billed with any of the following <b>ICD-10 diagnosis code(s)</b> : H35.051-H35.059; H35.711-H35.719	April 1, 2010	March 20, 2024
67516	Suprachoroidal space injection of pharmacologic agent (separate procedure)	Investigational	January 1, 2024	November 21, 2024
68841	Insertion of drug-eluting implant, including punctal dilation when performed, into lacrimal canaliculus, each	Investigational	January 1, 2022	March 20, 2024
72285	Discography, cervical or thoracic, radiological supervision and interpretation	Investigational	April 1, 2018	November 21, 2024
72295	Discography, lumbar, radiological supervision and interpretation	Investigational	April 1, 2018	November 21, 2024
75571	Computed tomography, heart, without contrast material, with quantitative evaluation of coronary calcium	Investigational	January 1, 2007	November 21, 2024
75958	Placement of proximal extension prosthesis for endovascular repair of descending thoracic aorta (e.g., aneurysm, pseudoaneurysm, dissection, penetrating ulcer, intramural hematoma, or traumatic disruption), radiological supervision and interpretation	Investigational	November 20, 2006	June 20, 2024
76977	Ultrasound bone density measurement and interpretation, peripheral site(s), any method	Investigational	July 1, 2016	February 21, 2024
76981	Ultrasound, elastography, parenchyma (eg, organ)	Investigational	February 12, 2019	February 21, 2024
76982	Ultrasound, elastography, first target lesion	Investigational	February 12, 2019	February 21, 2024
76983	Ultrasound, elastography, each additional target lesion (List separately in addition to code for primary procedure)	Investigational	February 12, 2019	February 21, 2024
77089	Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk	Investigational	January 1, 2022	October 17, 2024

78434	Absolute quantitation of myocardial blood flow (AQMBF), positron emission tomography (PET), rest and pharmacologic stress (List separately in addition to code for primary procedure)	Investigational	December 18, 2019	November 21, 2024
-------	---	-----------------	-------------------	-------------------

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
78801	Radiopharmaceutical localization of tumor or distribution of radiopharmaceutical agent(s); multiple areas	Investigational- <b>For Breast Imaging only</b>	July 1, 2011	February 21, 2024
81105	Human Platelet Antigen 1 genotyping (HPA-1), ITGB3 (integrin, beta 3 [platelet glycoprotein IIIa], antigen CD61 (GPIIIa)) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion purpura), gene analysis, common variant, HPA-1a/b (L33P)	Investigational	January 1, 2018	November 21, 2024
81106	Human Platelet Antigen 2 genotyping (HPA-2), GP1BA (glycoprotein 1b [platelet], alpha polypeptide [GpIba]) (eg, neonatal alloimmune thrombocytopenia [NAIT], post-transfusion pupura), gene analysis, common variant, HPA-2a/b (T145M)	Investigational	January 1, 2018	November 21, 2024
81195 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Cytogenomic (genome-wide) analysis, hematologic malignancy, structural variants and copy number variants, optical genome mapping (OGM)	Investigational	January 1, 2025	January 1, 2025
81230 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP3A5 (cytochrome P450 family 3 subfamily A member 4) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *22)	Investigational	January 1, 2018	November 21, 2024
81231 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	CYP3A5 (cytochrome P450 family 3 subfamily A member 5) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3, *4, *5, *6, *7)	Investigational	January 1, 2018	November 21, 2024
81232 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	DPYD (dihydropyrimidine dehydrogenase) (eg, 5 fluorouracil/5-FU and capecitabine drug metabolism), gene analysis, common variant(s) (eg, *2A, *4, *5, *6)	Investigational	January 1, 2018	November 21, 2024
81277 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities	Investigational	December 18, 2019	November 21, 2024
81284 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; evaluation to detect abnormal (expanded) alleles	Investigational	January 1, 2019	November 21, 2024
81285 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	FXN (frataxin) (eg, Friedreich ataxia) gene analysis, characterization of alleles (eg, expanded size)	Investigational	January 1, 2019	November 21, 2024
81286 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	FXN (frataxin) (eg, Friedreich ataxia) gene analysis; full gene sequence	Investigational	January 1, 2019	November 21, 2024

81289 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	FXN (frataxin) (eg, Friedreich ataxia) gene analysis, known familial variant(s)	Investigational	January 1, 2019	November 21, 2024
--	---	-----------------	-----------------	-------------------

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
81291 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	MTHFR (5,10-methylenetetrahydrofolate reductase) (e.g., hereditary hypercoagulability) gene analysis, common variants (e.g., 677T, 1298C)	Investigational	January 1, 2012	November 21, 2024
81306 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)	Investigational	January 1, 2019	November 21, 2024
81313 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	PCA3/KLK3 (prostate cancer antigen 3 [non-protein coding]/kallikrein-related peptidase 3 [prostate specific antigen]) ratio (e.g., prostate cancer)	Investigational	January 1, 2015	April 17, 2024
81327 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	SEPT9 (Septin9) (eg, colorectal cancer) promoter methylation analysis (Epi proColon (Epigenomics Inc.))	Investigational	November 28, 2012	August 30, 2024
81328 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	SLCO1B1 (solute carrier organic anion transporter family, member 1B1) (eg, adverse drug reaction), gene analysis, common variant(s) (eg, *5)	Investigational	January 1, 2018	November 21, 2024
81335 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	TPMT (thiopurine S-methyltransferase) (eg, drug metabolism), gene analysis, common variants (eg, *2, *3)	Investigational	January 1, 2018	November 21, 2024
81346 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	TYMS (thymidylate synthetase) (eg, 5-fluorouracil/5-FU drug metabolism), gene analysis, common variant(s) (eg, tandem repeat variant)	Investigational	January 1, 2018	November 21, 2024
81355 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	VKORC1 (vitamin K epoxide reductase complex, subunit 1) (e.g., warfarin metabolism), gene analysis, common variants (e.g., -1639/3673)	Investigational	January 1, 2012	November 21, 2024
81418	Drug metabolism (eg, pharmacogenomics) genomic sequence analysis panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplication/deletion analysis	Investigational	January 1, 2023	November 21, 2024
81419 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Epilepsy genomic sequence analysis panel, must include analyses for ALDH7A1, CACNA1A, CDKL5, CHD2, GABRG2, GRIN2A, KCNQ2, MECP2, PCDH19, POLG, PRRT2, SCN1A, SCN1B, SCN2A, SCN8A, SLC2A1, SLC9A6, STXBP1, SYNGAP1, TCF4, TPP1, TSC1, TSC2, and ZEB2	Investigational	January 1, 2021	June 20, 2024
81422 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Fetal chromosomal microdeletion(s) genomic sequence analysis (e.g., DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood	Investigational	January 1, 2017	November 21, 2024
81440	Nuclear encoded mitochondrial genes (e.g., neurologic or myopathic)	Investigational	January 1, 2015	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
**Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	phenotypes), genomic sequence panel, must include analysis of at least 100 genes, including BCS1L, C10orf2, COQ2, COX10, DGUOK, MPV17, OPA1, PDSS2, POLG, POLG2, RRM2B, SCO1, SCO2, SLC25A4, SUCLA2, SUCLG1, TAZ, TK2, and TYMP			
81442 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Noonan spectrum disorders (e.g., Noonan syndrome, cardio-facio-cutaneous syndrome, Costello syndrome, LEOPARD syndrome, Noonan-like syndrome), genomic sequence analysis panel, must include sequencing of at least 12 genes, including BRAF, CBL, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, PTPN11, RAF1, RIT1, SHOC2, and SOS1	Investigational	January 1, 2016	November 21, 2024
81448 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Hereditary peripheral neuropathies (eg, Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (eg, BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1)	Investigational	January 1, 2018	November 21, 2024
81456	Targeted genomic sequence analysis panel, solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes (eg, ALK, BRAF, CDKN2A, CEBPA, DNMT3A, EGFR, ERBB2, EZH2, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, MET, MLL, NOTCH1, NPM1, NRAS, PDGFRA, PDGFRB, PGR, PIK3CA, PTEN, RET), interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	Investigational	January 1, 2023	November 21, 2024
81460 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Whole mitochondrial genome (e.g., Leigh syndrome, mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes [MELAS], myoclonic epilepsy with ragged-red fibers [MERFF], neuropathy, ataxia, and retinitis pigmentosa [NARP], Leber hereditary optic neuropathy [LHON]), genomic sequence, must include sequence analysis of entire mitochondrial genome with heteroplasmy detection	Investigational	January 1, 2015	November 21, 2024
81465 **Authorization review for HPHC and THPPs is managed by	Whole mitochondrial genome large deletion analysis panel (e.g., Kearns-Sayre syndrome, chronic progressive	Investigational	January 1, 2015	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Carelon Medical Benefits Management	external ophthalmoplegia), including heteroplasmy detection, if performed			
81470 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); genomic sequence analysis panel, must include sequencing of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	Investigational	January 1, 2015	November 21, 2024
81471 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	X-linked intellectual disability (XLID) (e.g., syndromic and non-syndromic XLID); duplication/deletion gene analysis, must include analysis of at least 60 genes, including ARX, ATRX, CDKL5, FGD1, FMR1, HUWE1, IL1RAPL, KDM5C, L1CAM, MECP2, MED12, MID1, OCRL, RPS6KA3, and SLC16A2	Investigational	January 1, 2015	November 21, 2024
81490	Autoimmune (rheumatoid arthritis), analysis of 12 biomarkers using immunoassays, utilizing serum, prognostic algorithm reported as a disease activity score, (e.g., Vectra® DA)	Investigational: Covered without PA for Tufts Health One Care	January 1, 2016	October 17, 2024
81493 ** Authorization review for THPPs is managed by Carelon Medical Benefits Management"	Coronary artery disease, mRNA, gene expression profiling by real-time RT-PCR of 23 genes, utilizing whole peripheral blood, algorithm reported as a risk score, (e.g., Corus® CAD)	Investigational	January 1, 2016	November 21, 2024
81500	Oncology (ovarian), biochemical assays of two proteins (CA-125 and HE4), utilizing serum, with menopausal status, algorithm reported as a risk score, (e.g., Risk of Ovarian Malignancy Algorithm (ROMA™))	Investigational	January 1, 2013	November 21, 2024
81503	Oncology (ovarian), biochemical assays of five proteins (CA-125, apolipoprotein A1, beta-2 microglobulin, transferrin and pre-albumin), utilizing serum, algorithm reported as a risk score (OVA1™, Vermillion, Inc.)	Investigational	January 1, 2013	November 21, 2024
81506	Endocrinology (type 2 diabetes), biochemical assays of seven analytes (glucose, HbA1c, insulin, hs-CRP, adiponectin, ferritin, interleukin 2-receptor alpha), utilizing serum or plasma, algorithm reporting a risk score, (e.g., PreDx™ Diabetes Risk Score)	Investigational	January 1, 2013	June 20, 2024
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megaspheera type 1, and Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, when reported	Investigational	January 1, 2025	January 1, 2025

81517	Liver disease, analysis of 3 biomarkers (hyaluronic acid [HA], procollagen III amino terminal peptide [PIIINP], tissue inhibitor of metalloproteinase 1 [TIMP-1]), using immunoassays, utilizing serum, prognostic algorithm reported as a risk score and risk of liver fibrosis and liver-related clinical events within 5 years	Investigational	January 1, 2024	November 21, 2024
81525 ** Authorization review for THPPs is managed by Carelon Medical Benefits Management"	Oncology (colon), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a recurrence score, (Oncotype DX® Colon Cancer Assay, Genomic Health)	Investigational	January 1, 2016	November 21, 2024
81529 ** Authorization review for THPPs is managed by Carelon Medical Benefits Management"	Oncology (cutaneous melanoma), mRNA, gene expression profiling by real-time RT-PCR of 31 genes (28 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence risk, including likelihood of sentinel lymph node metastasis	Investigational: Covered without PA for Tufts Health One Care	January 1, 2021	October 17, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
81535	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; first single drug or drug combination, (ChemoFx, Helomics)	Investigational	January 1, 2016	November 21, 2024
81536	Oncology (gynecologic), live tumor cell culture and chemotherapeutic response by DAPI stain and morphology, predictive algorithm reported as a drug response score; each additional single drug or drug combination (List separately in addition to code for primary procedure), (ChemoFx, Helomics)	Investigational	January 1, 2016	November 21, 2024
81538	Oncology (lung), mass spectrometric 8-protein signature, including amyloid A, utilizing serum, prognostic and predictive algorithm reported as good versus poor overall survival, (VeriStrat, Biodesix, Inc.)	Covered with prior authorization for RITogether only	January 1, 2016	November 21, 2024
81539	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score (e.g., OPKO 4Kscore® Blood Test)	Covered with prior authorization for RITogether only	July 23, 2015	April 17, 2024
81542 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), mRNA, microarray gene expression profiling of 22 content genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as metastasis risk score	Investigational	December 18, 2019	November 21, 2024
81551 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Oncology (prostate), promoter methylation profiling by real-time PCR of 3 genes (GSTP1, APC, RASSF1), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a likelihood of prostate cancer detection on repeat biopsy (ConfirmMDx® for Prostate Cancer, MDxHealth Inc.)	Investigational: Covered without PA for Tufts Health One Care	January 1, 2018	June 20, 2024
81554 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Pulmonary disease (idiopathic pulmonary fibrosis [IPF]), mRNA, gene expression analysis of 190 genes, utilizing transbronchial biopsies, diagnostic algorithm reported as categorical result (eg, positive or negative for high probability of usual interstitial pneumonia [UIP])	Investigational: Covered without PA for Tufts Health One Care	January 1, 2021	October 17, 2024
81558 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	Transplantation medicine (allograft rejection, kidney), mRNA, gene expression profiling by quantitative polymerase chain reaction (qPCR) of 139 genes, utilizing whole blood, algorithm reported as a binary categorization as transplant excellence, which indicates immune quiescence, or not transplant excellence, indicating subclinical rejection	Investigational	January 1, 2025	January 1, 2025

81560	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score (Pleximmune test)	Investigational	January 1, 2022	November 21, 2024
81596	Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays (ALT, A2-macroglobulin, apolipoprotein A-1, total bilirubin, GGT, and haptoglobin) utilizing serum,	Investigational	January 1, 2019	August 30, 2024
82233	Beta-amyloid; 1-40 (Abeta 40)	Investigational	January 1, 2025	January 1, 2025
82234	Beta-amyloid; 1-42 (Abeta 42)	Investigational	January 1, 2025	January 1, 2025

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver			
82777	Galectin-3	Investigational	January 1, 2013	November 21, 2024
83006	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	Investigational	January 1, 2015	November 21, 2024
83037	Glycosylated (A1C) by device cleared by FDA for home use (e.g., A1CNow+ <sup>®</sup> )	Investigational	April 1, 2009	June 20, 2024
83631	Lactoferrin, fecal, quantitative	Investigational	November 20, 2006	August 30, 2024
83884	Neurofilament light chain (NfL)	Investigational	January 1, 2025	January 1, 2025
83987	pH; exhaled breath condensate	Investigational	January 1, 2006	August 30, 2024
83993	Calprotectin, fecal	Investigational	April 1, 2018	August 30, 2024
84145	Procalcitonin (PCT)	Investigational	January 1, 2009	October 17, 2024
84393	Tau, phosphorylated (eg, pTau 181, pTau 217), each	Investigational	January 1, 2025	January 1, 2025
84394	Tau, total (tTau)	Investigational	January 1, 2025	January 1, 2025
84431	Thromboxane metabolite(s), including thromboxane if performed, urine	Investigational	October 6, 2015	November 21, 2024
86001	Allergen specific IgG quantitative or semiquantitative, each allergen	Investigational	January 1, 2024	January 1, 2024
86005	Allergen specific IgE; qualitative, multiallergen screen (eg, disk, sponge, card)	Investigational	January 1, 2024	January 1, 2024
86152	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); (e.g., CellSearch Circulating Tumor Cell (CTC) Kit for monitoring Metastatic Breast Cancer)	Investigational	January 1, 2013	November 21, 2024
86153	Cell enumeration using immunologic selection and identification in fluid specimen (e.g., circulating tumor cells in blood); physician interpretation and report, when required, (e.g., CellSearch Circulating Tumor Cell (CTC) Kit for monitoring Metastatic Breast Cancer)	Investigational	January 1, 2013	November 21, 2024
86343	Leukocyte histamine release test (LHR)	Investigational	January 1, 2007	May 15, 2024
86581	Streptococcus pneumoniae antibody (IgG), serotypes, multiplex immunoassay, quantitative	Investigational	January 1, 2025	January 1, 2025
86677	Antibody; Helicobacter pylori	Investigational	February 12, 2016	August 30, 2024
86711	Antibody; JC (John Cunningham) virus	Investigational	January 1, 2013	May 15, 2024
87513	Infectious agent detection by nucleic acid (DNA or RNA); Helicobacter pylori (H. pylori), clarithromycin resistance, amplified probe technique	Investigational	January 1, 2025	January 1, 2025
87564	Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique	Investigational	January 1, 2025	January 1, 2025
87594	Infectious agent detection by nucleic acid (DNA or RNA); Pneumocystis jirovecii, amplified probe technique	Investigational	January 1, 2025	January 1, 2025
87626	Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), separately reported high-risk types (eg, 16, 18, 31, 45, 51, 52) and high-risk pooled result(s)	Investigational	January 1, 2025	January 1, 2025

88375	Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session	Investigational	January 1, 2013	August 30, 2024
89329	Sperm evaluation; hamster penetration test	Investigational	November 20, 2006	April 17, 2024
90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management	Covered with PA for <b>ICD-10 diagnosis code(s):</b> F32.2, F33.2. All other diagnoses considered investigational.	January 1, 2013	September 19, 2024
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session	Covered with PA for <b>ICD-10 diagnosis code(s):</b> F32.2, F33.2. All other diagnoses considered investigational.	January 1, 2013	September 19, 2024
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management	Covered with PA for <b>ICD-10 diagnosis code(s):</b> F32.2, F33.2. All other diagnoses considered investigational.	January 1, 2013	September 19, 2024
91065	Breath hydrogen or methane test (e.g., for detection of lactase deficiency, fructose intolerance, bacterial	Investigational; Covered when billed with <b>ICD-10 diagnosis code(s):</b>	April 1, 2014	August 30, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	overgrowth, or oro-cecal gastrointestinal transit)	K90.49, K90.89		
91112	Gastrointestinal transit and pressure measurement, stomach through colon, wireless capsule, with interpretation and report	Investigational	January 1, 2013	August 30, 2024
91113	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), colon, with interpretation and report (Pillcam 2 (medtronic)	Investigational	January 1, 2022	August 30, 2024
92145	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report	Investigational	January 1, 2015	March 20, 2024
92229	Imaging of retina for detection or monitoring of disease; point-of-care autonomous analysis and report, unilateral or bilateral	Investigational	January 1, 2021	March 20, 2024
92512	Nasal function studies	Investigational	October 1, 2009	May 15, 2024
92517	Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP)	Investigational	January 1, 2021	February 21, 2024
92518	Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; ocular (oVEMP)	Investigational	January 1, 2021	February 21, 2024
92519	Vestibular evoked myogenic potential (VEMP) testing, with interpretation and report; cervical (cVEMP) and ocular (oVEMP)	Investigational	January 1, 2021	February 21, 2024
92548	Computerized dynamic posturography	Investigational	October 1, 2010	October 17, 2024
92549	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)	Investigational	December 18, 2019	October 17, 2024
92972	Percutaneous transluminal coronary lithotripsy (List separately in addition to code for primary procedure)	Investigational	January 1, 2024	January 1, 2024
93050	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive, (e.g., SphygmoCor System)	Investigational	January 1, 2016	November 21, 2024
93150	Therapy activation of implanted phrenic nerve stimulator system, including all interrogation and programming	Investigational	January 1, 2024	May 15, 2024

93151	Interrogation and programming (minimum one parameter) of implanted phrenic nerve stimulator system	Investigational	January 1, 2024	May 15, 2024
93152	Interrogation and programming of implanted phrenic nerve stimulator system during polysomnography	Investigational	January 1, 2024	May 15, 2024
93153	Interrogation without programming of implanted phrenic nerve stimulator system	Investigational	January 1, 2024	May 15, 2024
93278	Signal-averaged electrocardiography (SAECG), with or without ECG	Investigational	January 1, 2007	November 21, 2024
93319	3D echocardiographic imaging and postprocessing during transesophageal echocardiography, or during transthoracic echocardiography for congenital cardiac anomalies, for the assessment of cardiac structure(s) (eg, cardiac chambers and valves, left atrial appendage, interatrial septum, interventricular septum) and function, when performed (List separately in	Investigational	January 1, 2022	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	addition to code for echocardiographic imaging)			
93356	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)	Investigational	December 18, 2019	November 21, 2024
93702	Bioimpedance spectroscopy (BIS), extracellular fluid analysis for lymphedema assessment(s)	Investigational	January 1, 2015	November 21, 2024
93740	Temperature gradient studies	Investigational	January 1, 2007	February 21, 2024
93895	Quantitative carotid intima media thickness and carotid atheroma evaluation, bilateral	Investigational	January 1, 2015	November 21, 2024
93896	Vasoreactivity study performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
93897	Emboli detection without intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
93898	Venous-arterial shunt detection with intravenous microbubble injection performed with transcranial Doppler study of intracranial arteries, complete (List separately in addition to code for primary procedure)	Investigational	January 1, 2025	January 1, 2025
94669	Mechanical chest wall oscillation to facilitate lung function, per session	Investigational; Covered when billed with <b>ICD-10 diagnosis code(s):</b> E84.0, E84.11, E84.19, E84.8, E84.9	January 1, 2014	October 17, 2024
95060	Ophthalmic mucous membrane tests	Investigational	November 20,2006	May 15, 2024
95065	Direct nasal mucous membrane test	Investigational	November 20,2006	May 15, 2024
95803	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	Investigational	January 1, 2006	June 20, 2024
95919	Quantitative pupillometry with physician or other qualified health care professional interpretation and report, unilateral or bilateral	Investigational	January 1, 2023	March 20, 2024
95965	Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (e.g., epileptic cerebral cortex localization)	Investigational; Covered when billed with <b>ICD-10 diagnosis code(s):</b> G40.311, G40.319,G40.A11, G40.A19,G40.B11, G40.B19,G40.411, G40.419,G40.803, G40.804,G40.813, G40.814,G40.823, G40.824,G40.911, G40.919	November 20, 2006	June 20, 2024

95966	Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (e.g., sensory, motor, language, or visual cortex localization)	Investigational; Covered when billed with <b>ICD-10 diagnosis code(s)</b> : G40.311, G40.319,G40.A11, G40.A19,G40.B11, G40.B19,G40.411, G40.419,G40.803, G40.804,G40.813, G40.814,G40.823, G40.824,G40.911, G40.919	November 20, 2006	June 20, 2024
95967	Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (e.g., sensory, motor, language, or visual cortex localization)	Investigational; Covered when billed with <b>ICD-10 diagnosis code(s)</b> : G40.311, G40.319,G40.A11, G40.A19,G40.B11, G40.B19,G40.411, G40.419,G40.803, G40.804,G40.813, G40.814,G40.823, G40.824,G40.911, G40.919	November 20, 2006	June 20, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
95976	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with simple cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis codes:</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19	January 1, 2019	June 20, 2024
95977	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with complex cranial nerve neurostimulator pulse generator/transmitter programming by physician or other qualified health care professional	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis codes:</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19	January 1, 2019	June 20, 2024
95983	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, first 15 minutes face-to-face time with physician or other qualified health care professional	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis codes:</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19	January 1, 2019	June 20, 2024
95984	Electronic analysis of implanted neurostimulator pulse generator/transmitter (eg, contact group[s], interleaving, amplitude, pulse width, frequency [Hz], on/off cycling, burst, magnet mode, dose lockout, patient selectable parameters, responsive neurostimulation, detection algorithms, closed loop parameters, and passive parameters) by physician or other qualified health care professional; with brain neurostimulator pulse generator/transmitter programming, each additional 15 minutes face-to-face time with physician or other qualified health care professional (List separately in addition to code for primary procedure)	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis codes:</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19	January 1, 2019	June 20, 2024
96000	Comprehensive computer-based motion analysis by video-taping and 3-	Investigational	July 1, 2007	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	D kinematics			
96001	Comprehensive computer-based motion analysis by video-taping and 3-D kinematics; with dynamic plantar pressure measurements during walking	Investigational	July 1, 2007	October 17, 2024
96002	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles	Investigational	July 1, 2007	October 17, 2024
96004	Physician review and interpretation of comprehensive computer based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report	Investigational	July 1, 2007	October 17, 2024
96567	Photodynamic therapy by external application of light to destroy premalignant and/or malignant lesions of the skin and adjacent mucosa (e.g., lip) by activation of photosensitive drug(s), each phototherapy exposure session	Investigational when billed with the following: <b>ICD-10 diagnosis Code(s):</b> L73.9, L70.0-L70.1; L70.3-L70.9; L73.0	November 20, 2006	October 17, 2024
96904	Whole body integumentary photography, for monitoring of high risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or familial history of melanoma (e.g., MelaFind®)	Investigational	October 1, 2007	October 17, 2024
96931	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, first lesion	Investigational	January 1, 2016	October 17, 2024
96932	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, first lesion	Investigational	January 1, 2016	October 17, 2024
96933	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, first lesion	Investigational	January 1, 2016	October 17, 2024
96934	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition and interpretation and report, each additional lesion (List separately in addition to code for primary procedure)	Investigational	January 1, 2016	October 17, 2024
96935	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; image acquisition only, each additional lesion (List separately in addition to code for primary procedure)	Investigational	January 1, 2016	October 17, 2024
96936	Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin; interpretation and report only, each additional lesion (List separately in addition to code for primary procedure)	Investigational	January 1, 2016	October 17, 2024
97533	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to	Covered with PA for <b>ICD-10 diagnosis code(s):</b> F84.0, F84.2,	November 20, 2006	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	environmental demands, direct (one-on-one) patient contact by the provider, each 15 minutes	F84.3, F84.5, F84.8, F84.9 All other diagnoses considered investigational.		
97610	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	Investigational: Covered without PA for Tufts Health One Care	January 1, 2014	June 20, 2024
98978	Remote therapeutic monitoring (eg, therapy adherence, therapy response); device(s) supply with scheduled (eg, daily) recording(s) and/or programmed alert(s) transmission to monitor cognitive behavioral therapy, each 30 days	Investigational	January 1, 2023	September 19, 2024
A2001	InnovaMatrix AC, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2002	Mirragen Advanced Wound Matrix, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2004	XCelliStem, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2005	Microlyte Matrix, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2006	NovoSorb SynPath dermal matrix, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2007	Restrata, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2008	TheraGenesis, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2009	Symphony, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2010	Apis, per sq cm	Investigational	January 1, 2022	March 20, 2024
A2011	Supra SDRM, per sq cm	Investigational	April 1, 2022	March 20, 2024
A2012	SUPRATHEL, per sq cm	Investigational	April 1, 2022	March 20, 2024
A2013	Innovamatrix fs, per square centimeter	Investigational	January 1, 2024	January 1, 2024
A2014	Omeza Collagen Matrix, per 100 mg	Investigational	October 1, 2022	March 20, 2024
A2015	Phoenix wound matrix, per sq cm	Investigational	October 1, 2022	March 20, 2024
A2016	PermeaDerm B, per sq cm	Investigational	October 1, 2022	March 20, 2024
A2017	PermeaDerm glove, each	Investigational	October 1, 2022	March 20, 2024
A2018	PermeaDerm C, per sq cm	Investigational	October 1, 2022	March 20, 2024
A2019	Kerecis Omega3 MariGen Shield, per sq cm	Investigational	April 1, 2023	March 20, 2024
A2020	AC5 Advanced Wound System (AC5)	Investigational	April 1, 2023	March 20, 2024
A2021	NeoMatriX, per sq cm	Investigational	April 1, 2023	March 20, 2024
A2022	InnovaBurn or InnovaMatrix XL, per sq cm	Investigational	October 1, 2023	March 20, 2024
A2023	InnovaMatrix PD, 1 mg	Investigational	October 1, 2023	March 20, 2024
A2024	Resolve Matrix or XenoPatch, per sq cm	Investigational	October 1, 2023	October 1, 2024
A4100	Skin substitute, FDA cleared as a device, not otherwise specified	Investigational	January 1, 2024	January 1, 2024
A4540	Distal transcutaneous electrical nerve stimulator, stimulates peripheral nerves of the upper arm	Investigational	January 1, 2024	June 20, 2024
A4542	Supplies and accessories for external upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational: Covered without PA for Tufts Health One Care	January 1, 2024	June 20, 2024
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month	Investigational	October 1, 2024	October 1, 2024
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome	Investigational	October 1, 2024	October 1, 2024
A4560	Neuromuscular electrical stimulator (NMES), disposable, replacement only	Investigational	April 1, 2023	October 17, 2024
A4575	Topical hyperbaric oxygen chamber, disposable	Investigational	December 27, 2010	March 20, 2024

A4596	Cranial electrotherapy stimulation (CES) system supplies and accessories, per month	Investigational	October 1, 2022	June 20, 2024
A6000	Non-contact wound warming wound cover for use with the non-contact wound warming device and warming card	Investigational	November 20, 2006	March 20, 2024
A6460	Synthetic resorbable wound dressing, sterile, pad size 16 sq in or less, without adhesive border, each dressing	Investigational	January 1, 2019	March 20, 2024
A6461	Synthetic resorbable wound dressing, sterile, pad size more than 16 sq in but less than or equal to 48 sq in, without adhesive border, each dressing	Investigational	January 1, 2019	March 20, 2024
A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation, and nebulization device (e.g., handset, nebulizer kit, biofilter)	Investigational	October 1, 2024	October 1, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
A7049	Expiratory positive airway pressure intranasal resistance valve	Investigational	April 1, 2023	May 15, 2024
A9268	Programmer for transient, orally ingested capsule	Investigational	October 1, 2023	October 17, 2024
A9269	Programmable, transient, orally ingested capsule, for use with external programmer, per month	Investigational	October 1, 2023	October 17, 2024
A9272	Wound suction, disposable, includes dressing, all accessories and components, any type, each, (e.g., PICO™ Single Use Negative Pressure Wound Therapy System) (NPWT)	Investigational	March 12, 2014	March 20, 2024
A9291	Prescription digital cognitive and/or behavioral therapy, FDA-cleared, per course of treatment	Investigational	April 1, 2022	September 19, 2024
A9292	Prescription digital visual therapy, software-only, FDA cleared, per course of treatment	Investigational	October 1, 2023	March 20, 2024
A9601	Flortaucipir F 18 injection, diagnostic, 1 mCi	Investigational	July 1, 2022	February 21, 2024
C1062	Intravertebral body fracture augmentation with implant (e.g., metal, polymer)	Investigational	January 1, 2021	November 21, 2024
C1735	Catheter(s), intravascular for renal denervation, radiofrequency, including all single-use system components	Investigational	January 1, 2025	January 1, 2025
C1736	Catheter(s), intravascular for renal denervation, ultrasound, including all single-use system components	Investigational	January 1, 2025	January 1, 2025
C1737	Joint fusion and fixation device(s), sacroiliac and pelvis, including all system components (implantable)	Investigational	January 1, 2025	January 1, 2025
C1738	Powered, single-use (i.e., disposable) endoscopic ultrasound-guided biopsy device	Investigational	January 1, 2025	January 1, 2025
C1749	Endoscope, retrograde imaging illumination colonoscope device (implantable)	Investigational	October 1, 2010	August 30, 2024
C1761	Catheter, transluminal intravascular lithotripsy, coronary	Investigational	July 1, 2021	November 21, 2024
C1818	Integrated keratoprosthesis	Investigational	January 1, 2007	March 20, 2024
C1821	Interspinous process distraction device (implantable)	Investigational	January 1, 2007	November 21, 2024
C1823	Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads	Investigational	January 1, 2019	June 20, 2024
C1824	Generator, cardiac contractility modulation (implantable)	Investigational	December 18, 2019	November 21, 2024
C1825	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)	Investigational	January 1, 2021	November 21, 2024
C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system	Investigational	January 1, 2023	June 20, 2024
C1827	Generator, neurostimulator (implantable), nonrechargeable, with implantable stimulation lead and external paired stimulation controller	Investigational	January 1, 2023	June 20, 2024

C1832	Autograft suspension, including cell processing and application, and all system components	Investigational	January 1, 2022	March 20, 2024
C1833	Monitor, cardiac, including intracardiac lead and all system components (implantable)	Investigational	January 1, 2022	November 21, 2024
C1839	Iris prosthesis	Investigational	November 1, 2023	March 20, 2024
C1878	Material for vocal cord medialization, synthetic (implantable), (e.g., Radiesse®/Prolaryn™)	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> J38.01, J38.02	January 1, 2016	February 21, 2024
C2614	Probe, percutaneous lumbar discectomy	Investigational	January 1, 2007	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	pressure sensor with delivery catheter, including all system components (e.g., CardioMEMS™ HF System)			
C7537	Insertion of new or replacement of permanent pacemaker with atrial transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)	Investigational	January 1, 2023	November 21, 2024
C7538	Insertion of new or replacement of permanent pacemaker with ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)	Investigational	January 1, 2023	November 21, 2024
C7539	Insertion of new or replacement of permanent pacemaker with atrial and ventricular transvenous electrode(s), with insertion of pacing electrode, cardiac venous system, for left ventricular pacing, at time of insertion of implantable defibrillator or pacemaker pulse generator (e.g., for upgrade to dual chamber system)	Investigational	January 1, 2023	November 21, 2024
C7562	Catheter placement in coronary artery(ies) for coronary angiography, including intraprocedural injection(s) for coronary angiography, imaging supervision and interpretation; with right and left heart catheterization including intraprocedural injection(s) for left ventriculography, when performed with intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention	Investigational	January 1, 2025	January 1, 2025
C7563	Transluminal balloon angioplasty (except lower extremity artery(ies) for occlusive disease, intracranial, coronary, pulmonary, or dialysis circuit), open or percutaneous, including all imaging and radiological supervision and interpretation necessary to perform the angioplasty within the same artery, initial artery and all additional arteries	Investigational	January 1, 2025	January 1, 2025
C7564	Percutaneous transluminal mechanical thrombectomy, vein(s), including intraprocedural pharmacological thrombolytic injections and fluoroscopic guidance with intravascular ultrasound (noncoronary vessel(s)) during diagnostic evaluation and/or therapeutic intervention, including radiological supervision and interpretation	Investigational	January 1, 2025	January 1, 2025

C8002	Preparation of skin cell suspension autograft, automated, including all enzymatic processing and device components (do not report with manual suspension preparation)	Investigational	January 1, 2025	January 1, 2025
C8003	Implantation of medial knee extraarticular implantable shock absorber spanning the knee joint from distal femur to proximal tibia, open, includes measurements, positioning and adjustments, with imaging guidance (e.g., fluoroscopy)	Investigational	January 1, 2025	January 1, 2025
C9358	Dermal substitute, native, non-denatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 square centimeters	Investigational	July 24, 2015	March 20, 2024
C9727	Insertion of implants into the soft palate; minimum of three implants (Pillar Procedure)	Investigational	January 1, 2007	February 21, 2024
C9733	Nonophthalmic fluorescent vascular angiography, (e.g. SPY Portable Handheld Imaging System (SPY-PHI) (Stryker)	Investigational	April 1, 2012	June 20, 2024
C9751	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3-D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)	Investigational	January 1, 2019	October 17, 2024
C9755	Creation of arteriovenous fistula, percutaneous using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, when performed) and fistulogram(s),	Investigational	January 1, 2019	October 17, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	angiography, venography, and/or ultrasound, with radiologic supervision and interpretation, when performed			
C9757	Laminotomy (hemilaminectomy), with decompression of nerve root(s), including partial facetectomy, foraminotomy and excision of herniated intervertebral disc, and repair of annular defect with implantation of bone anchored annular closure device, including annular defect measurement, alignment and sizing assessment, and image guidance; 1 interspace, lumbar	Investigational	April 1, 2022	November 21, 2024
C9758	Blinded procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt or placebo control, including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational	December 18, 2019	November 21, 2024
C9759	Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed	Investigational	July 1, 2020	November 21, 2024
C9760	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure, transcatheter implantation of interatrial shunt or placebo control, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational	July 1, 2020	November 21, 2024
C9764	Revascularization, endovascular, open or percutaneous, any vessel(s); with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational	July 1, 2020	November 21, 2024
C9765	Revascularization, endovascular, open or percutaneous, any vessel(s), with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Investigational	July 1, 2020	November 21, 2024
C9766	Revascularization, endovascular, open or percutaneous, any vessel(s), with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational	July 1, 2020	November 21, 2024
C9767	Revascularization, endovascular, open or percutaneous, any vessel(s), with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational	July 1, 2020	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	approach, with subretinal injection of pharmacologic/biologic agent			
C9782	Blinded procedure for New York Heart Association (NYHA) Class II or III heart failure, or Canadian Cardiovascular Society (CCS) Class III or IV chronic refractory angina; transcatheter intramyocardial transplantation of autologous bone marrow cells (e.g., mononuclear) or placebo control, autologous bone marrow harvesting and preparation for transplantation, left heart catheterization including ventriculography, all laboratory services, and all imaging with or without guidance (e.g., transthoracic echocardiography, ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational	April 1, 2022	November 21, 2024
C9783	Blinded procedure for transcatheter implantation of coronary sinus reduction device or placebo control, including vascular access and closure, right heart catheterization, venous and coronary sinus angiography, imaging guidance and supervision and interpretation when performed in an approved investigational device exemption (IDE) study	Investigational	April 1, 2022	November 21, 2024
C9784	Gastric restrictive procedure, endoscopic sleeve gastropasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational	July 1, 2023	August 30, 2024
C9785	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational	July 1, 2023	August 30, 2024
C9804	Elastomeric infusion pump (e.g., On-Q* pump with bolus), including catheter and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)	Investigational	January 1, 2025	January 1, 2025
C9806	Rotary peristaltic infusion pump (e.g., ambIT pump), including catheter and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)	Investigational	January 1, 2025	January 1, 2025
C9807	Nerve stimulator, percutaneous, peripheral (e.g., sprint peripheral nerve stimulation system), including electrode and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)	Investigational	January 1, 2025	January 1, 2025

C9808	Nerve cryoablation probe (e.g., cryoICE, cryoSPHERE, cryoSPHERE MAX, cryo2), including probe and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)	Investigational	January 1, 2025	January 1, 2025
C9809	Cryoablation needle (e.g., iovera system), including needle/tip and all disposable system components, nonopioid medical device (must be a qualifying Medicare nonopioid medical device for postsurgical pain relief in accordance with Section 4135 of the CAA, 2023)	Investigational	January 1, 2025	January 1, 2025
E0217	Water circulating heat pad with pump	Investigational	January 1, 2024	January 1, 2024
E0218	Water circulating cold pad with pump	Investigational	November 20, 2006	November 21, 2024
E0221	Infrared heating pad system	Investigational	October 1, 2008	November 21, 2024
E0231	Non-contact wound warming device (temperature control unit, AC adapter and power cord) for use with warming card and wound cover	Investigational	October 1, 2008	March 20, 2024
E0232	Warming card for use with the non-contact wound warming device and non-contact wound warming wound cover	Investigational	October 1, 2008	March 20, 2024
E0236	Pump for water circulating pad	Investigational	November 20, 2006	November 21, 2024
E0446	Topical oxygen delivery system, not otherwise specified, includes all supplies	Not a covered benefit	January 1, 2011	March 20, 2024
E0466	Home ventilator, any type, used with noninvasive interface, (e.g., mask, chest shell)	Investigational when billed with the following ICD-10 diagnosis code: G47.33	January 1, 2016	June 20, 2024
E0469	Lung expansion airway clearance, continuous high frequency oscillation, and nebulization device	Investigational	October 1, 2024	October 1, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	noninvasive interface, (e.g., mask, chest shell)	billed with the following <b>ICD-10 diagnosis code (s):</b> G47.33  Investigational: Covered without PA for Tufts Health One Care		
E0480	Percussor, electric or pneumatic, home model, (The Frequencer™)	Investigational	April 1, 2010	October 17, 2024
E0481	Intrapulmonary percussive ventilation system and related accessories	Investigational: Covered without PA for Tufts Health One Care	January 1, 2017	October 17, 2024
E0485	Oral device/appliance used to reduce upper airway collapsibility, adjustable or nonadjustable, prefabricated, includes fitting and adjustment	Investigational	January 1, 2024	January 1, 2024
E0490	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote	Investigational	October 1, 2023	October 17, 2024
E0491	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply	Investigational	October 1, 2023	October 17, 2024
E0492	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application	Investigational	January 1, 2024	May 15, 2024
E0493	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	Investigational	January 1, 2024	May 15, 2024
E0677	Nonpneumatic sequential compression garment, trunk	Investigational	April 1, 2023	March 20, 2024
E0683	Nonpneumatic, nonsequential, peristaltic wave compression pump	Investigational	October 1, 2024	October 1, 2024
E0711	Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion	Investigational	April 1, 2023	October 17, 2024
E0721	Transcutaneous electrical nerve stimulator, stimulates nerves in the auricular region	Investigational	October 1, 2024	October 1, 2024
E0733	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	Investigational	January 1, 2024	June 20, 2024
E0734	External upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational	January 1, 2024	June 20, 2024
E0735	Noninvasive vagus nerve stimulator	Investigational	January 1, 2024	June 20, 2024
E0738	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, includes microprocessor, all components and accessories	Investigational	April 1, 2024	October 17, 2024
E0739	Rehabilitation system with interactive interface providing active assistance in rehabilitation therapy, includes all	Investigational	April 1, 2024	October 17, 2024

	components and accessories, motors, microprocessors, sensors			
E0740	Non-implanted pelvic floor electrical stimulator, complete system	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	August 30, 2024
E0743	External lower extremity nerve stimulator for restless legs syndrome, each	Investigational	October 1, 2024	October 1, 2024
E0744	Neuromuscular stimulator for scoliosis	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0745	Neuromuscular stimulator, electronic shock unit	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0746	Electromyography (EMG), biofeedback device	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0749	Osteogenesis stimulator, electrical, surgically implanted	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	November 21, 2024
E0755	Electronic salivary reflex stimulator (intraoral/noninvasive)	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0761	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	March 20, 2024
E0762	Transcutaneous electrical joint stimulation device system, includes all accessories	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0764	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control,	Investigational. applicable to Tufts Health Plan Together	January 1, 2019	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	used for walking by spinal cord injured, entire system, after completion of training program	and Rhode Island Together products only		
E0765	FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0767	Intrabuccal, systemic delivery of amplitude-modulated, radiofrequency electromagnetic field device, for cancer treatment, includes all accessories	Investigational	October 1, 2024	October 1, 2024
E0769	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	March 20, 2024
E0770	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	Investigational. applicable to Tufts Health Plan Together and Rhode Island Together products only	January 1, 2019	October 17, 2024
E0782	Terbutaline therapy via subcutaneous infusion pump for pre-term labor	Investigational: Covered without PA for Tufts Health One Care	July 1, 2009	October 17, 2024
E0783	Terbutaline therapy via subcutaneous infusion pump for pre-term labor	Investigational	July 1, 2009	October 17, 2024
E1629	Tablo hemodialysis system for the billable dialysis service	Investigational	January 1, 2022	October 17, 2024
E1700	Jaw motion rehabilitation system	Investigational EXCEPT when billed with : <b>trismus diagnosis, ICD-10 code: R25.2</b>	January 1, 2017	November 21, 2024
E1701	Replacement cushions for jaw motion rehabilitation system	Investigational EXCEPT when billed with : <b>trismus diagnosis, ICD-10 code: R25.2</b>	January 1, 2017	November 21, 2024
E1702	Replacement measuring scales for jaw motion rehabilitation system	Investigational EXCEPT when billed with : <b>trismus diagnosis, ICD-10 code: R25.2</b>	January 1, 2017	November 21, 2024
E1800	Dynamic adjustable elbow extension/flexion device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1802	Dynamic adjustable forearm pronation/supination device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1803	Dynamic adjustable elbow extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1804	Dynamic adjustable elbow flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1805	Dynamic adjustable wrist extension/flexion device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1807	Dynamic adjustable wrist extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1808	Dynamic adjustable wrist flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025

E1810	Dynamic adjustable knee extension/flexion device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1812	Dynamic knee, extension/flexion device with active resistance control	Investigational	February 1, 2022	October 17, 2024
E1813	Dynamic adjustable knee extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1814	Dynamic adjustable knee flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1815	Dynamic adjustable ankle extension/flexion device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1820	Replacement soft interface material, dynamic adjustable extension/flexion device	Investigational	February 1, 2022	October 17, 2024
E1822	Dynamic adjustable ankle extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1823	Dynamic adjustable ankle flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1826	Dynamic adjustable finger extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1827	Dynamic adjustable finger flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1828	Dynamic adjustable toe extension only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1829	Dynamic adjustable toe flexion only device, includes soft interface material	Investigational	January 1, 2025	January 1, 2025
E1830	Dynamic adjustable toe extension/flexion device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1840	Dynamic adjustable shoulder flexion/abduction/rotation device, includes soft interface material	Investigational	February 1, 2022	October 17, 2024
E1905	Virtual reality cognitive behavioral therapy device (CBT), including preprogrammed therapy software	Investigational	April 1, 2023	October 17, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
E2120	Pulse generator system for tympanic treatment of inner ear endolymphatic fluid	Investigational	July 1, 2008	February 21, 2024
E2301	Wheelchair accessory, power standing system, any type	Investigational	January 1, 2024	January 1, 2024
E2610	Wheelchair seat cushion, powered	Investigational	January 1, 2024	January 1, 2024
E3200	Gait modulation system, rhythmic auditory stimulation, including restricted therapy software, all components and accessories, prescription only	Investigational	October 1, 2024	October 1, 2024
G0176	Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more)	Investigational	November 1, 2011	September 19, 2024
G0186	Destruction of localized lesion of choroid (for example, choroidal neovascularization); photocoagulation, feeder vessel technique (one or more sessions)	Investigational	June 8, 2016	March 20, 2024
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	Investigational	January 1, 2007	June 20, 2024
G0282	Electrical stimulation, (unattended), to one or more areas, for wound care	Investigational	November 20, 2006	March 20, 2024
G0295	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	Investigational	November 20, 2006	March 20, 2024
G0327	Colorectal cancer screening, blood-based biomarker	Investigational	July 1, 2021	August 30, 2024
G0329	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care	Investigational: Covered without PA for Tufts Health One Care	November 20, 2006	June 20, 2024
G0428	Collagen meniscus implant procedure for filling meniscal defects (e.g., CMI, collagen scaffold, Menaflex)	Investigational	January 1, 2011	November 21, 2024
G0455	Preparation with Instillation of fecal microbiota by any method, including assessment of donor specimen	Investigational <b>EXCEPT</b> when billed with any of the following <b>ICD-10 diagnosis code(s)</b> : A04.71, A04.72	January 1, 2013	August 30, 2024
G0460	Autologous platelet rich plasma for chronic wounds/ulcers, including phlebotomy, centrifugation, and all other preparatory procedures, administration and dressings, per treatment	Investigational	July 1, 2013	March 20, 2024
G0465	Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)	Investigational	January 1, 2022	March 20, 2024



G2000	Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, non-covered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session	Investigational	January 1, 2019	September 19, 2024
J0172	Injection, Aducanumab-AVWA, 2 MG	Investigational	January 1, 2022	June 20, 2024
J2787	Riboflavin 5'-phosphate, ophthalmic solution, up to 3 mL	Investigational EXCEPT when billed with any of the following ICD-10 diagnosis codes:	January 1, 2019	March 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
		H18.621- H18.623 for ages 14 through age 64		
J7313	Injection, fluocinolone acetonide, intravitreal implant, 0.01 mg	Investigational <b>EXCEPT</b> when submitted with diabetic macular edema diagnosis. Refer to MNG: ILUVIEN® (Fluocinolone Acetonide Intravitreal Implant) for Treatment of Diabetic Macular Edema.	June 19, 2019	March 20, 2024
J7402	Mometasone furoate sinus implant, (Sinuva), 10 mcg	Investigational	April 1, 2021	February 21, 2024
K1007	Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors	Investigational	October 1, 2020	October 17, 2024
K1027	Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting and adjustment	Investigational	October 1, 2021	November 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
K1030	External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only	Investigational	April 1, 2022	November 21, 2024
K1035	Molecular diagnostic test reader, nonprescription self-administered and self-collected use, FDA approved, authorized or cleared	Investigational	April 1, 2023	November 21, 2024
L1945** **Will deny investigational when submitted for IDEO and ExoSym Energy Storing AFO and other exoskeletal devices	IDEO and ExoSym Energy Storing AFO	Investigational	June 8, 2016	October 17, 2024
L2006	Knee-ankle-foot (KAF) device, any material, single or double upright, swing and/or stance phase microprocessor control with adjustability, includes all components (e.g., sensors, batteries, charger), any type activation, with or without ankle joint(s), custom fabricated	Investigational	December 18, 2019	October 17, 2024
L2755** **Will deny investigational when submitted for IDEO and ExoSym Energy Storing AFO and other exoskeletal devices	IDEO and ExoSym Energy Storing AFO	Investigational	June 8, 2016	October 17, 2024
L3904	Wrist hand finger orthosis, external powered, electric, custom fabricated	Investigational	December 10, 2014	October 17, 2024
L5615	Addition, endoskeletal knee-shin system, 4 bar linkage or multiaxial, fluid swing and stance phase control	Investigational	January 1, 2024	October 17, 2024
L5783	Addition to lower extremity, user adjustable, mechanical, residual limb volume management system	Investigational	April 1, 2024	October 17, 2024
L5859	Addition to lower extremity prosthesis, endoskeletal knee-shin system, powered and programmable flexion/extension assist control, includes any type motor(s)	Investigational	October 1, 2019	October 17, 2024
L5926	Addition to lower extremity prosthesis, endoskeletal, knee disarticulation, above knee, hip disarticulation, positional rotation unit, any type	Investigational	January 1, 2024	October 17, 2024
L5969	Addition, endoskeletal ankle-foot or ankle system, power assist, includes any type motor(s)	Investigational	October 1, 2019	October 17, 2024
L5991	Addition to lower extremity prostheses, osseointegrated external prosthetic connector	Investigational	October 1, 2023	October 17, 2024
L6715	Terminal device, multiple articulating digit, includes motor(s), initial issue or replacement	Investigational	January 1, 2012	October 17, 2024
L8605	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies, e.g., SOLESTA® (hyaluronic acid/dextranomer)	Investigational	November 28, 2012	August 30, 2024
L8607	Injectable bulking agent for vocal cord medialization, 0.1 ml, includes shipping and necessary supplies	Investigational	January 1, 2016	February 21, 2024

L8608	Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System	Investigational	January 1, 2019	March 20, 2024
L8658	Interphalangeal joint spacer, silicone or equal, each	Investigational	July 1, 2007	November 21, 2024
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month	Investigational	April 1, 2023	October 17, 2024
L8679	Implantable neurostimulator, 9'; p-pulse generator, any type	Investigational EXCEPT when billed with any of the following <b>ICD-10</b>	January 1, 2014	June 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
		<b>diagnosis code(s):</b> G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9		
L8680	Implantable neurostimulator electrode, each	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G21.4, G24.1, G25.0-G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9	November 20, 2006	June 20, 2024
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G21.4, G24.1, G25.0-G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9	November 20, 2006	June 20, 2024
L8682	Implantable neurostimulator radiofrequency receiver	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9	April 1, 2012	June 20, 2024
L8683	Radiofrequency transmitter (external) for use with implantable	Investigational EXCEPT when billed with any of	April 1, 2012	June 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	neurostimulator radiofrequency receiver	the following <b>ICD-10 diagnosis code(s):</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9		
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9	April 1, 2012	June 20, 2024
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519 G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9	April 1, 2012	June 20, 2024
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s):</b> G20, G21.4, G24.1, G25.0- G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19, G89.28-G89.29 G90.511-G90.519	April 1, 2012	June 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
		G90.521-G90.529 G90.59 G57.70-G57.73 G56.40-G56.43 I20.8-I20.9		
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s)</b> : G20, G21.4, G24.1, G25.0-G25.2, G40.011-G40.019; G40.111-G40.119; G40.211-G40.219, G40.311-G40.319, G40.813, G40.814, G40.A11, G40.A19	April 1, 2012	June 20, 2024
L8698	Miscellaneous component, supply or accessory for use with total artificial heart system	Investigational	January 1, 2019	November 21, 2024
L8701	Powered upper extremity range of motion assist device, elbow, wrist, hand with single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated	Investigational	January 1, 2019	October 17, 2024
L8702	Powered upper extremity range of motion assist device, elbow, wrist, hand, finger, single or double upright(s), includes microprocessor, sensors, all components and accessories, custom fabricated	Investigational	January 1, 2019	October 17, 2024
L8720	External lower extremity sensory prosthesis, cutaneous stimulation of mechanoreceptors proximal to the ankle, per leg	Investigational	October 1, 2024	October 1, 2024
L8721	Receptor sole for use with L8720, replacement, each	Investigational	October 1, 2024	October 1, 2024
M0076	Prolotherapy	Investigational	November 20, 2006	November 21, 2024
M0300	IV chelation therapy (chemical endarterectomy)	Investigational	January 1, 2007	October 17, 2024
P2031	Hair analysis (excluding arsenic)	Investigational	January 1, 2007	October 17, 2024
Q2026	Injection, Radiesse, 0.1 ml (Radiesse® for glottic insufficiency)	Investigational EXCEPT when billed with any of the following <b>ICD-10 diagnosis code(s)</b> : J38.01, J38.02  Investigational: Covered without PA for Tufts Health One Care	October 1, 2014	June 20, 2024
Q4121	Theraskin, per square centimeter	Investigational	July 24, 2015	March 20, 2024
Q4134	hMatrix, per sq cm	Investigational	January 1, 2013	March 20, 2024
Q4135	Mediskin, per sq cm	Investigational	January 1, 2013	March 20, 2024
Q4136	E-Z Derm, per sq cm	Investigational	January 1, 2013	March 20, 2024
Q4140	BioDFence® and BioDFence® G3 human amniotic allograft products	Investigational	August 22, 2018	March 20, 2024
Q4148	NEOX 1k, per square centimeter	Investigational	February 1, 2015	March 20, 2024
Q4150	Allowrap DS or dry, per sq cm	Investigational	January 1, 2015	March 20, 2024

Q4152	Dermapure, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4153	Dermavest, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4154	Biovance, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4155	Neoxflo or clariflo 1 mg	Investigational	January 1, 2015	March 20, 2024
Q4156	Neox 100, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4157	Revitalon, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4158	Kerecis Omega3, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4159	Affinity, per sq cm	Investigational	January 1, 2015	March 20, 2024
Q4160	Nushield, per square centimeter	Investigational	January 1, 2015	March 20, 2024
Q4161	Bio-ConneKt wound matrix, per sq cm	Investigational	January 1, 2016	March 20, 2024
Q4162	AmnioPro Flow, BioSkin Flow, BioRenew Flow, WoundEx Flow, Amniogen-A, Amniogen-C, 0.5 cc	Investigational	January 1, 2016	March 20, 2024



Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Q4163	AmnioPro, BioSkin, BioRenew, WoundEx, Amniogen-45, Amniogen-200, per sq cm	Investigational	January 1, 2016	March 20, 2024
Q4164	Helicoll, per sq cm	Investigational	January 1, 2016	March 20, 2024
Q4165	Keramatrix, per sq cm	Investigational	January 1, 2016	March 20, 2024
Q4166	Cytal, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4167	Truskin, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4169	Artacent wound, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4170	Cygnus, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4171	Interfyl, 1 mg	Investigational	January 1, 2017	March 20, 2024
Q4173	Palingen or palingen xplus, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4174	Palingen or promatrx, 0.36 mg per 0.25 cc	Investigational	January 1, 2017	March 20, 2024
Q4175	Miroderm, per square centimeter	Investigational	January 1, 2017	March 20, 2024
Q4176	NeoPatch, per sq cm	Investigational	January 1, 2018	March 20, 2024
Q4177	FlowerAmnioFlo, 0.1 cc	Investigational	January 1, 2018	March 20, 2024
Q4178	FlowerAmnioPatch, per sq cm	Investigational	January 1, 2018	March 20, 2024
Q4179	FlowerDerm, per sq cm	Investigational	January 1, 2018	March 20, 2024
Q4180	Revita, per sq cm	Investigational	January 1, 2018	March 20, 2024
Q4181	Amnio Wound, per sq cm	Investigational	January 1, 2018	March 20, 2024
Q4183	Surgigraft, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4184	Cellesta, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4185	Cellesta Flowable Amnion (25 mg per cc); per 0.5 cc	Investigational	January 1, 2019	March 20, 2024
Q4188	AmnioArmor, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4189	Artacent AC, 1 mg	Investigational	January 1, 2019	March 20, 2024
Q4190	Artacent AC, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4191	Restorigin, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4192	Restorigin, 1 cc	Investigational	January 1, 2019	March 20, 2024
Q4193	Coll-e-Derm, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4194	Novachor, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4195	PuraPly, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4196	PuraPly AM, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4197	PuraPly XT, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4198	Genesis Amniotic Membrane, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4199	Cygnus matrix, per sq cm	Investigational	January 1, 2022	March 20, 2024
Q4200	SkinTE, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4201	Matrion, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4202	Keroxx (2.5 g/cc), 1 cc	Investigational	January 1, 2019	March 20, 2024
Q4203	Derma-Gide, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4204	XWRAP, per sq cm	Investigational	January 1, 2019	March 20, 2024
Q4205	Membrane Graft or Membrane Wrap, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4206	Fluid Flow or Fluid GF, 1 cc	Investigational	October 1, 2019	March 20, 2024
Q4208	Novafix, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4209	SurGraft, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4211	Amnion Bio or AxoBioMembrane, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4212	AlloGen, per cc	Investigational	October 1, 2019	March 20, 2024
Q4213	Ascent, 0.5 mg	Investigational	October 1, 2019	March 20, 2024
Q4214	Cellesta Cord, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4215	Axolotl Ambient or Axolotl Cryo, 0.1 mg	Investigational	October 1, 2019	March 20, 2024
Q4216	Artacent Cord, per sq cm	Investigational	October 1, 2019	March 20, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Q4217	WoundFix, BioWound, WoundFix Plus, BioWound Plus, WoundFix Xplus or BioWound Xplus, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4218	SurgiCORD, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4219	SurgiGRAFT-DUAL, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4220	BellaCell HD or Surederm, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4221	Amnio Wrap2, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4222	ProgenaMatrix, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4224	Human Health Factor 10 Amniotic Patch (HHF10-P), per sq cm	Investigational	April 1, 2022	March 20, 2024
Q4225	AmnioBind, per sq cm	Investigational	April 1, 2022	March 20, 2024
Q4226	MyOwn Skin, includes harvesting and preparation procedures, per sq cm	Investigational	October 1, 2019	March 20, 2024
Q4227	AmnioCoreTM, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4229	Cogenex Amniotic Membrane, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4230	Cogenex Flowable Amnion, per 0.5 cc	Investigational	July 1, 2020	March 20, 2024
Q4231	Corplex P, per cc	Investigational	July 1, 2020	March 20, 2024
Q4232	Corplex, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4233	SurFactor or NuDyn, per 0.5 cc	Investigational	July 1, 2020	March 20, 2024
Q4234	XCellerate, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4235	AMNIOREPAIR or AltiPly, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4237	Cryo-Cord, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4238	Derm-Maxx, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4239	Amnio-Maxx or Amnio-Maxx Lite, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4240	CoreCyte, for topical use only, per 0.5 cc	Investigational	July 1, 2020	March 20, 2024
Q4241	PolyCyte, for topical use only, per 0.5 cc	Investigational	July 1, 2020	March 20, 2024
Q4242	AmnioCyte Plus, per 0.5 cc	Investigational	July 1, 2020	March 20, 2024
Q4245	AmnioText, per cc	Investigational	July 1, 2020	March 20, 2024
Q4246	CoreText or ProText, per cc	Investigational	July 1, 2020	March 20, 2024
Q4247	Amniotext patch, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4248	Dermacyte Amniotic Membrane Allograft, per sq cm	Investigational	July 1, 2020	March 20, 2024
Q4249	AMNIPLY, for topical use only, per sq cm	Investigational	October 1, 2020	March 20, 2024
Q4250	AmnioAmp-MP, per sq cm	Investigational	October 1, 2020	March 20, 2024
Q4251	Vim, per sq cm	Investigational	October 1, 2021	March 20, 2024
Q4252	Vendaje, per sq cm	Investigational	October 1, 2021	March 20, 2024
Q4253	Zenith Amniotic Membrane, per sq cm	Investigational	October 1, 2021	March 20, 2024
Q4254	Novafix DL, per sq cm	Investigational	October 1, 2020	March 20, 2024
Q4255	REGUaRD, for topical use only, per sq cm	Investigational	October 1, 2020	March 20, 2024
Q4256	MLG-Complete, per sq cm	Investigational	April 1, 2022	March 20, 2024
Q4257	Relese, per sq cm	Investigational	April 1, 2022	March 20, 2024
Q4258	Enverse, per sq cm	Investigational	April 1, 2022	March 20, 2024
Q4259	Celera Dual Layer or Celera Dual Membrane, per sq cm	Investigational	July 1, 2022	March 20, 2024
Q4260	Signature APatch, per sq cm	Investigational	July 1, 2022	March 20, 2024
Q4261	TAG, per sq cm	Investigational	July 1, 2022	March 20, 2024
Q4262	Dual Layer Impax Membrane, per sq cm	Investigational	January 1, 2023	March 20, 2024
Q4263	SurGraft TL, per sq cm	Investigational	January 1, 2023	March 20, 2024
Q4264	Cocoon Membrane, per sq cm	Investigational	January 1, 2023	March 20, 2024
Q4265	NeoStim TL, per sq cm	Investigational	April 1, 2023	March 20, 2024
Q4266	NeoStim Membrane, per sq cm	Investigational	April 1, 2023	March 20, 2024
Q4267	NeoStim DL, per sq cm	Investigational	April 1, 2023	March 20, 2024
Q4268	SurGraft FT, per sq cm	Investigational	April 1, 2023	March 20, 2024

Q4269	SurGraft XT, per sq cm	Investigational	April 1, 2023	March 20, 2024
-------	------------------------	-----------------	---------------	----------------

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
Q4270	Complete SL, per sq cm	Investigational	April 1, 2023	March 20, 2024
Q4271	Complete FT, per sq cm	Investigational	April 1, 2023	March 20, 2024
Q4272	Esano A, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4273	Esano AAA, per sq cm			March 20, 2024
Q4274	Esano AC, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4275	Esano ACA, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4276	ORION, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4278	EPIEFFECT, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4279	Vendaje AC, per sq cm	Investigational	January 1, 2024	March 20, 2024
Q4280	Xcell Amnio Matrix, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4281	Barrera SL or Barrera DL, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4282	Cygnus Dual, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4283	Biovance Tri-Layer or Biovance 3L, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4284	DermaBind SL, per sq cm	Investigational	July 1, 2023	March 20, 2024
Q4285	NuDYN DL or NuDYN DL MESH, per sq cm	Investigational	October 1, 2023	March 20, 2024
Q4286	NuDYN SL or NuDYN SLW, per sq cm	Investigational	October 1, 2023	March 20, 2024
Q4288	DermaBind CH, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4289	RevoShield+ Amniotic Barrier, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4290	Membrane Wrap-Hydro TM, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4291	Lamellas XT, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4292	Lamellas, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4294	Amnio Quad-Core, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4295	Amnio Tri-Core Amniotic, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4296	Rebound Matrix, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4297	Emerge Matrix, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4298	AmniCore Pro, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4299	AmniCore Pro+, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4300	Acesso TL, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4301	Activate Matrix, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4302	Complete ACA, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4303	Complete AA, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4304	GRAFIX PLUS, per sq cm	Investigational	January 1,2024	March 20, 2024
Q4305	American Amnion AC Tri-Layer, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4306	American Amnion AC, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4307	American Amnion, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4308	Sanopellis, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4309	VIA Matrix, per sq cm	Investigational	April 1, 2024	April 1, 2024
Q4310	Procenta, per 100 mg	Investigational	April 1, 2024	April 1, 2024
Q4311	Acesso, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4312	Acesso AC, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4313	DermaBind FM, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4314	Reeva FT, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4315	RegeneLink Amniotic Membrane Allograft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4316	AmchoPlast, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4317	VitoGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4318	E-Graft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4319	SanoGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4320	PelloGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4321	RenoGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4322	CaregraFT, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4323	alloPLY, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4324	AmnioTX, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4325	ACApatch, per sq cm	Investigational	July 1, 2024	July 1, 2024

Q4326	WoundPlus, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4327	DuoAmnion, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4328	MOST, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4329	Singlay, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4330	TOTAL, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4331	Axolotl Graft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4332	Axolotl DualGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4333	ArdeoGraft, per sq cm	Investigational	July 1, 2024	July 1, 2024
Q4334	AmnioPlast 1, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4335	AmnioPlast 2, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4336	Artacent C, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4337	Artacent Trident, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4338	Artacent Velos, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4339	Artacent Vericlen, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4340	SimpliGraft, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4341	SimpliMax, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4342	TheraMend, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4343	Dermacyte AC Matrix Amniotic Membrane Allograft, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4344	Tri-Membrane Wrap, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4345	Matrix HD Allograft Dermis, per sq cm	Investigational	October 1, 2024	October 1, 2024
Q4346	Shelter DM Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4347	Rampart DL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4348	Sentry SL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4349	Mantle DL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4350	Palisade DM Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4351	Enclose TL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4352	Overlay SL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
Q4353	Xceed TL Matrix, per sq cm	Investigational	January 1, 2025	January 1, 2025
S0596	Phakic intraocular lens for correction of refractive error	Investigational	April 1, 2012	March 20, 2024
S1030	Continuous noninvasive glucose monitoring device, purchase (for physician interpretation of data, use CPT code)	Investigational	October 1, 2017	June 20, 2024
S1031	Continuous noninvasive glucose monitoring device, rental, including sensor, sensor replacement, and download to monitor (for physician interpretation of data, use CPT code)	Investigational	October 1, 2017	June 20, 2024
S1091	Stent, noncoronary, temporary, with delivery system (Propel)	Investigational	April 1, 2021	February 21, 2024
S2080	Laser-assisted uvulopalatoplasty (LAUP)	Investigational	January 1, 2008	February 21, 2024
S2117	Arthroereisis, subtalar	Investigational	November 1, 2023	October 17, 2024
S2225	Myringotomy, laser-assisted	Investigational	January 1, 2007	February 21, 2024
S2300	Arthroscopy, shoulder, surgical; with thermally-induced capsulorrhaphy	Investigational	July 1, 2007	November 21, 2024
S2348	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	Investigational	November 20, 2006	November 21, 2024
S3650	Saliva test, hormone level; during menopause	Investigational	January 1, 2007	August 30, 2024
S3652	Saliva test, hormone level; to assess preterm labor risk	Investigational	November 20, 2006	August 30, 2024
S3800	Genetic testing for amyotrophic lateral sclerosis (ALS)	Investigational	October 1, 2007	June 20, 2024

S3844 **Authorization review for HPHC and THPPs is managed by Carelon Medical Benefits Management	DNA analysis of the connexin 26 gene (GJB2) for susceptibility to congenital, profound deafness	Investigational	May 25, 2016	February 21, 2024
S3852	DNA analysis for APOE epsilon 4 allele for susceptibility to Alzheimer's disease	Investigational	November 20, 2006	November 21, 2024
S3900	Surface electromyography (EMG)	Investigational	July 1, 2007	November 21, 2024
S4988	Penile contracture device, manual, greater than 3 lbs traction force	Investigational	April 1, 2024	April 1, 2024
S8080	Scintimammography (radioimmunosintigraphy of the	Investigational	November 20, 2006	February 21, 2024

Procedure Code	Description	Exclusion Category	Origination Date	Last Review Date
	breast), unilateral, including supply of radiopharmaceutical			
S8092	Electron beam computed tomography (also known as ultrafast CT, Cine CT)	Investigational	November 20, 2006	February 21, 2024
S8930	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with patient (e.g., P-STIM™)	Investigational	April 1, 2012	October 17, 2024
S9002	Intravaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device	Investigational	April 1, 2024	April 1, 2024
S9024	Paranasal sinus ultrasound	Investigational	November 20, 2006	February 21, 2024
S9055	Procuren or other growth factor preparation to promote wound healing	Investigational	November 20, 2006	March 20, 2024
S9090	Vertebral axial decompression, per session	Investigational	October 1, 2007	November 21, 2024
S9208	Home management of preterm labor, including administrative services, professional pharmacy services, care coordination, and all necessary supplies or equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)	Investigational	January 1, 2009	August 30, 2024
S9209	Home management of preterm premature rupture of membranes (PPROM), including administrative services, professional pharmacy services, care coordination, and all necessary supplies or equipment (drugs and nursing visits coded separately), per diem (do not use this code with any home infusion per diem code)	Investigational	January 1, 2009	August 30, 2024
T1505	Electronic medication compliance device, includes all components	Investigational	January 1, 2011	October 17, 2024
T2050	Financial management, self-directed, waiver; per diem	Investigational	January 1, 2024	January 1, 2024
T2051	Supports brokerage, self-directed, waiver; per diem	Investigational	January 1, 2024	January 1, 2024

## APPROVAL HISTORY

Reviewed by the Medical Affairs Medical Policy Committee on September 24, 2007.

Subsequent endorsement date(s) and changes made:

- January 30, 2020: Investigational item removed
- February 13, 2020: Investigational items removed
- February 17, 2020: Investigational item removed
- February 19, 2020: Reviewed by IMPAC, Investigational items updated/removed/added
- February 28, 2020: Investigational items updated/removed/added
- March 18, 2020: Reviewed by IMPAC, investigational items removed/updated/added
- March 20, 2020: Unify fax number updated
- March 24, 2020: Investigational item removed
- March 27, 2020: Investigational item added
- April 15, 2020: Reviewed by IMPAC, investigational items updated/removed
- May 20, 2020: Reviewed by IMPAC, investigational items updated
- June 17, 2020: Reviewed by IMPAC, investigational items updated/added
- July 15, 2020: Reviewed by IMPAC, investigational items updated/added
- August 5, 2020: Coding updated
- September 16, 2020: Reviewed by IMPAC, investigational items updated/added/removed
- October 8, 2020: Investigational items added
- October 28, 2020: Investigational items added
- October 21, 2020: Reviewed by IMPAC, investigational items updated/added
- November 18, 2020: Reviewed by IMPAC, investigational items updated
- December 16, 2020: Reviewed by IMPAC, investigational items updated/added
- January 12, 2021: Coding updated
- February 11, 2021: Coding updated
- February 16, 2021: Coding updated
- February 17, 2021: Coding updated
- February 17, 2021: Reviewed by IMPAC, investigational items updated/added/removed
- February 19, 2021: Coding removed and updated
- March 17, 2021: Reviewed by IMPAC, investigational items updated
- April 13, 2021: Coding updated
- April 21, 2021: Reviewed by IMPAC, investigational items updated/added
- May 17, 2021: Coding updated
- May 21, 2021: Coding updated
- May 19, 2021: Reviewed by IMPAC, investigational items updated
- June 16, 2021: Reviewed by IMPAC, investigational items updated
- July 19, 2021: Investigational items removed
- July 21, 2021: Reviewed by IMPAC, investigational items updated
- August 18, 2021: Reviewed by IMPAC, investigational items updated/added
- August 24, 2021: Coding added
- September 3, 2021: Coding updated
- September 15, 2021: Reviewed by IMPAC, investigational items updated
- September 29, 2021: Investigational items removed
- October 15, 2021: Investigational items added and removed
- October 20, 2021: Reviewed by IMPAC, investigational items updated
- November 17, 2021: Reviewed by IMPAC, investigational items updated
- November 30, 2021: Investigational items removed
- December 21, 2021: Reviewed by Medical Policy Approval Committee (MPAC), Investigational items updated, added and removed.
- January 19, 2022: Reviewed by MPAC, investigational items updated, added and removed.
- February 9, 2022: Investigational items added/removed
- February 10, 2022: Investigational items added/removed
- February 11, 2022: Investigational item added
- March 2, 2022: Investigational items removed/added
- March 16, 2022: Reviewed by MPAC, investigational items, added/updated
- April 14, 2022: Investigational item removed
- May 18, 2022: Reviewed by MPAC, investigational items, added/updated
- May 23, 2022: Coding updated
- May 26, 2022: Coding updated
- June 15, 2022: Reviewed by MPAC, investigational items, added/updated
- July 20, 2022: Reviewed by MPAC, investigational items removed/updated
- September 21, 2022: Reviewed by MPAC, investigational items updated, added, removed
- October 1, 2022: Effective October 1, 2022, AIM Specialty Health® (AIM) will oversee medical necessity review for Tufts Health Public Plans
- October 7, 2022: Coding updated
- October 19, 2022: Reviewed by MPAC, investigational items updated
- November 16, 2022: Reviewed by MPAC, investigational item removed/updated
- December 1, 2022: Reviewed by MPAC, investigational items updated
- December 21, 2022: Reviewed by MPAC, investigational items removed/updated
- January 18, 2023: Reviewed by MPAC, investigational items updated, added and removed



- February 15, 2023: Reviewed by MPAC investigational items updated
- April 3, 2023: Investigational items added/removed
- April 19, 2023: Reviewed by MPAC, investigational items updated
- May 17, 2023: Reviewed by MPAC, investigational items update/removed
- June 6, 2023: Investigational items updated/removed
- June 21, 2023: Reviewed by MPAC, investigational items updated
- July 1, 2023: Coding updated
- August 16, 2023: Reviewed by MPAC, investigational items updated, effective November 1, 2023
- September 20, 2023: Reviewed by MPAC, investigational items updated,
- October 18, 2023: Reviewed by MPAC, investigational items updated/added or removed. Point32Health integrated policy, effective January 1, 2024
- November 16, 2023: Reviewed by MPAC, investigational items updated/removed/added, effective December 1, 2023
- December 13, 2023: Investigational items updated
- January 17, 2024: Reviewed by MPAC, investigational items updated/removed
- January 19, 2024: Coding updated, per AMA HCPCS<sup>®</sup>, and CPT<sup>®</sup> effective January 1, 2024
- February 9, 2024: Investigational item added
- February 26, 2024: Investigational items updated
- March 29, 2024: Coding updated, per AMA HCPCS<sup>®</sup> and CPT<sup>®</sup>, effective April 1, 2024
- April 24, 2024: Reviewed by MPAC, investigational items updated/removed, effective May 1, 2024
- May 15, 2024: Reviewed by MPAC, investigational item added, effective September 1, 2024
- May 24, 2024: Coding updated
- June 20, 2024: Reviewed by MPAC, investigational items updated, including items for One Care, effective August 1, 2024
- July 18, 2024: Coding updated, per AMA HCPCS<sup>®</sup> and CPT<sup>®</sup>, effective July 1, 2024
- August 30, 2024: Reviewed by MPAC, investigational items updated
- September 26, 2024: Coding updated, per AMA HCPCS<sup>®</sup> and CPT<sup>®</sup>, effective October 1, 2024
- October 17, 2024: Investigational item removed
- November 4, 2024: Reviewed by MPAC, investigational items updated/removed
- November 21, 2024: Reviewed by MPAC, investigational items updated/added, effective January 1, 2025
- December 18, 2024: Reviewed by MPAC, investigational items added/removed, effective January 1, 2025
- January 8, 2025: Investigational items updated
- January 9, 2025: Coding updated per AMA HCPCS<sup>®</sup> and CPT<sup>®</sup>, effective January 1, 2025
- January 14, 2025: Administrative update

---

## Background, Product and Disclaimer Information

Medical Necessity Guidelines are developed to determine coverage for benefits and are published to provide a better understanding of the basis upon which coverage decisions are made. We make coverage decisions using these guidelines, along with the Member's benefit document, and in coordination with the Member's physician(s) on a case-by-case basis considering the individual Member's health care needs.

Medical Necessity Guidelines are developed for selected therapeutic or diagnostic services found to be safe and proven effective in a limited, defined population of patients or clinical circumstances. They include concise clinical coverage criteria based on current literature review, consultation with practicing physicians in our service area who are medical experts in the particular field, FDA and other government agency policies, and standards adopted by national accreditation organizations. We revise and update Medical Necessity Guidelines annually, or more frequently if new evidence becomes available that suggests needed revisions.

For self-insured plans, coverage may vary depending on the terms of the benefit document. If a discrepancy exists between a Medical Necessity Guideline and a self-insured Member's benefit document, the provisions of the benefit document will govern. For Tufts Health Together (Medicaid), coverage may be available beyond these guidelines for pediatric members under age 21 under the Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefits of the plan in accordance with 130 CMR 450.140 and 130 CMR 447.000, and with prior authorization.

Treating providers are solely responsible for the medical advice and treatment of Members. The use of this guideline is not a guarantee of payment or a final prediction of how specific claim(s) will be adjudicated. Claims payment is subject to eligibility and benefits on the date of service, coordination of benefits, referral/authorization, utilization management guidelines when applicable, and adherence to plan policies, plan procedures, and claims editing logic.